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1. INTRODUCTION 
Before entering into the study, let us know the basic concepts like origin of earth, 
origin of life in it, origin of medicine in mankind. Knowing these basics concepts reveals 
us some truths which glorify our great Siddhars that they are the pioneers to all modern 
scientists invariable to the department they belong, and also invariable to the country they 
belong. For many scientific evolutions even for today‟s nano concepts our Siddhar 
thoughts are the basics tools for the modern scientists which help them in their researches. 
The age of earth still is a made of great debate. Some people calculated the age of 
the earth based on Bible that the earth was created in 4000BC. Later on in the middle of 
the nineteenth century, the great scientist, Charles Darwin believed that the earth must be 
extremely old because he recognized that natural, selection and evolution required vast 
amounts of time.  
The history of earth describes the most important events and fundamental stages 
in the development of the planet. Nearly all the branches of natural science contribute in 
understanding the Earth‟s history. Biological and geological changes have been 
constantly occurring on our planet since the time of its formation. Organisms 
continuously evolve, taking on new forms or going extinct in response to an ever 
changing planet. This is quoted by our Siddhars as “khw;wj;jhy; MaJ cyfk;”. Life on 
earth starts as small and microscopic and then into complex multicellular life‟s and 
experienced a rapid diversification into the most major phyla and then into chimpanzees 
to modern humans it was quoted as “Gy;yhfp  G+lhfp”. As soon as the humans 
originated in the earth many dramatic changes occurred in the aspects of knowledge of 
the living things. Sympathy, caring and love all these contribute more to show the 
difference between the mankind and their primitives. These feelings particularly 
sympathy on others pay the way for the origin of medicines. Thus sympathy is the basic 
step to treatment.  
Crystallization of knowledge of early humans about plants and minerals helps to 
invent medicines. As soon as the man moves against the nature the word “disease” 
invades the mankind. According to World Health Organization, the definition of health is 
a state of complete physical, mental and social well being. So any system of medicine 
which fulfills this definition of health is said to be the best system of medicine. In this 
2 
 
way our Siddha systems is found to the best system of medicine as it heals the man in all 
aspects by its many wings like internal medicine, external medicine, varma, yoga and noi 
illa neri (social and preventive measures by holistic way). 
 In Siddha system of medicine all the diseases of human being can be categorized 
into 147 and classified into 4448 diseases. (Uthamarayan, 1953). The Siddha system is 
capable of treating all these types of diseases very effectively. Paandu noi is one among 
the important disease classified in the Siddha system of medicine based on the symptoms 
which literally means the pallor, which can be correlated with modern classification of 
Anaemia. A detailed description of signs, symptoms, aetiological factors and treatment 
have been described in detail by great Saint Yoogi Muni in his „Yoogimuni Vaidhya 
Chinthamani‟. 
Greek word anaemia means without blood. It is defined as a qualitative or 
quantitative deficiency of hemoglobin, a molecule found inside the red blood cells. 
Common causes are usually malnutrition, low intake of iron content food and worm 
infestations. So it is a very common disease in the developing countries like India where 
poverty and poor socio-economic conditions plays a vital role in causes of many diseases. 
 Iron deficiency is the most common and widespread nutritional disorder in the 
world. As well as affecting a large number of children and women in developing 
countries, it is the only nutrient deficiency which is also significantly prevalent in 
industrialized countries. The numbers are staggering: 2 billion people – over 30% of the 
world‟s population – are anaemic, many due to iron deficiency, and in resource-poor 
areas, this is frequently exacerbated by infectious diseases. Malaria, HIV/AIDS, 
hookworm infestation, schistosomiasis, and other infections such as tuberculosis are 
particularly important factors contributing to the high prevalence of anaemia in some 
areas. Iron deficiency affects more people than any other condition, constituting a public 
health condition of epidemic proportions (WHO Global Database on Anaemia, 2013). It 
also remains a problem even in developed countries where other forms of malnutrition 
have already been virtually eliminated. 
Anaemia is characterized by a decrease of the concentration of hemoglobin and 
then the lack of erythrocytes. The anaemia prevalence remains high in India, with an 
overall incidence of 64.6% in children, 55.8% among pregnant women and 44.4% among 
young girls (WHO, 2011). The Ministry of Public Health of India investigated in 
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September 2011 an anaemia frequency of 56.9% among children, 27.3% among women 
of reproductive age and 19.2% among men. Factors contributing to anaemia may be 
related not only to malnutrition and poverty, but also from the free radicals due to the 
excessive consumption of drugs as well as the viral and parasitic infections. 
I have witnessed many patients in the outpatient department during my 
graduation, who are the victims of anaemia and most of them are below the poverty line. 
This spirit made me to carry out a work in anaemia and come out with a most effective 
medicine at low cost effect.  “Only healthy people can make a healthy India”. This is the 
main motivation for the work done. 
I selected Paandu noi, which can be correlated with the clinical condition called 
iron deficiency anaemia for this dissertation work. Any failure to treat Paandu can lead to 
dangerous end often fatal consequences. So I selected Echuramooli ilai chooranam to 
study for its therapeutic efficacy on Paandu noi. 
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2. AIM AND OBJECTIVES 
Aim 
The main aim of this dissertation is to do a scientific review, to validate the safety 
and efficacy of the Echuramooli ilai chooranam for Paandu noi (Anaemia) by pre 
clinical as well as clinical studies. 
 
Objectives 
 Besides the scientific study, basic concepts of Siddha science and treatment 
aspects also our aim. Hence, the following methodology was adopted to evaluate 
the safety and efficacy of the test drug. 
 
 Identification of the herbal drug Echuramooli. 
 Collection of various Siddha and modern scientific literature. 
 Preparation of drug according to the text. 
 Physio-chemical analysis of Echuramooli Ilai. 
 Phyto chemicals analysis test drug. 
 Evaluation of the toxicity of test drug. 
 Evaluation of Haematinic activity of test drug  
 Clinical assessment of Echuramooli Ilai on Anaemia. 
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3. REVIEW OF LITERATURE 
3.1 Gunapadam  aspect 
D”µ‰¼ 
Other names: 
 ö£¸©¸¢x 
 ö£¸[QÇ[S 
 uø»a”¸Î 
 uµõ”U öPõi &Sn£õh® (‰¼øP ÁS¨¦) •¸@PŒ •u¼¯õº                                                                                                                                                                                 
 
Orgonoleptic Characters: 
 ”øÁ  & øP¨¦ 
 ußø© & öÁ¨£® 
 ¤›Ä  & Põº¨¦ 
 öŒ#øP & öÁ¨£•shõUQ 
    Eµ©õUQ 
    ¸x EshõUQ 
 Sn® 
 “£õshPØÖ ö©#°Ø £hºSmh @|õ# Â»UP® 
 }sh Â¸u¯@|õ# }US[Põs & uõshu¨ø£ 
 •ß@Ú ö¯õÈzxÂk ‰Áõz uø»a”¸Î 
 ö¯ß@Ú ²»Q ¼øŒ”     (A.S) 
 
  
 Cuß Cø»US øP¨¦a”øÁ°¸¨£uõÀ Cø»ø¯ E»ºzv¨ ö£õi öŒ#x 2 
Qµõ® Ãu® Põø» ©õø» öPõkUP öŒõÔ, ]µ[S, £hºSmh®, |g”, C¸u¯@|õ#, 
£õsk, @Œõø£, ”µ® }[S®. 
  & ]zu øÁzv¯ £uõºzu Sn ÂÍUP® ‰» ÁºUP® 
 
D”µ‰¼ @Œ¸® ©¸¢xPÒ : 
1. I¢öusøn#z øu»® & öŒõÔ ]µ[SUS 
uõöÚßÓ I¢öusön#z øu»® @PÐ 
Œõ›¯õ® {®ö£sön# C¾¨ø£ Gsön# 
@uöÚßÓ |Àö»sön# @u[Põ# Gsön# 
]Ø@Óµs hzöusön# I¢x[ Tmk 
‰»ö©õk S[Q¼¯® |ÁaŒõ µ¢uõß 
•øÚ¯õÚ BøÚv¨ ¤¼²® @Œµz 
uõ»ªS ]ØÓµzøu @£µ µzøu 
uÛ¯õÚ ö£¸©¸¢x •”Ö •møh 
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@Põ»ªS ©°¼ÓS Ashz @uõk 
SvøµUPõØ SÍ®¦^ÁÀ BPõ ŒzyÒ 
bõ»ªvØ §zvkPõ ÍõÝ®‰h 
|ØPh¼ß ~øµ@¯õk Œ•zµõ¨ £Ç@©. 
£Ó¢x@£õ® EÒSzx ¦ÓÃa @Œõk 
£õskC]Ä ¤µ@©P® ]µ” @µõP® 
CÓ¢x@£õ® ö£¸Á°Ö @ŒõøPPõ ©õø» 
HPõu }ºU@PõøÁ S©µ Psh® 
£Ó¢x@£õ® SvøµÁ¼ •¯ÀÁ ¼¨¦ 
£ÊuõÚ PõUøPÁ¼ |kUS Áõu® 
xÓ¢@uõk® ‹Û¯•® ¤À¼ ]µ[S 
öŒõÔPµ¨£õß Sèh®Ásk G¼²® @£õ@©. 
& @£õPºøÁzv¯® 700 (Page 149) 
 
2. Cµzu Sß©õvUS ©¸¢x 
 
öÁÒøÍa Œõµøn @Áº 
öPõi@Á¼ @Áº 
PÒÎU öPõÊ¢x 
ŒõvUPõ# 
D”Áµ‰¼ 
P¸@ÁÀ Cø» 
G¸UQß @Áº £møh   CøÁPÒ ÁøPUS 1 £»® 
^µP® 
P¸g^µP® 
A›]zv¨¤¼ 
”US 
C¢x¨¦ 
ÁŒ®¦ 
ªÍS 
ö£õ›zu ö£¸[Põ¯® 
PkS   & 1 EÇUS 
öÁÒøÍ¨§sk & 1 £»® 
|À» ¤snõUS & J¸ øP¯ÍÄ 
 CøÁPøÍ JßÔµshõP¨ ö£õizxU PÀÁzv¼mkU S¨ø£@©Ûa 
ŒõØÔÚõÀ |ßS Aøµzx ”søhUPõ#¨ ¤µ©õn® E¸mhÄ®.  Cøu 
|Àö»søn°¿µ øÁzxz vÚ¢@uõÖ® AvPõø»°À Œõ¨¤h Cµzu Sß©® 
w¸®. 
                   & Œµ@£¢vµº øÁzv¯ •øÓPÒ(Page :120) 
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3. ]»¢vUS Gsön# 
 |ßÚõ›, ]ÖSÔgŒõß @Áº, {»@Á®¦@Áº. A¢uµzuõ©øµ @Áº, 
ö|À¼•ÒÎ, D”µ‰¼, öPõÈg]@Áº, £¸zv@Áº, @£#¨¥ºUS @Áº, ©nzuUPõÎ 
@Áº CÁØøÓ KµÍÁõPU Tmi¯øµzx Azxhß öÁÒÍõmk }º Áõºzx¨ ¤øŒ¢x 
ÁiPmhÄ®. AvÀ @Á¨ö£sön#, |Àö»sön#, @u[Põö¯søn, 
¦[öPsön# CøÁ |õßS® KµÍÁõ# Gkzxa @Œºzx •øÓ¨£i ÁizvÓUPÄ®. 
AÍÄ : @uøÁ¯õÚ AÍÄ EÒÐUSU öPõkzx @©@»²® §] öÁ¢}º Âmk 
SÎUPz w¸®. 
    & APzv¯º øÁzv¯ PõÂ¯® 1500(Page: 624) 
 
4. Pµ¨£õÝUS ©¸¢x : 
 |ßÚõ›@Áº  ö|kg]À @Áº 
 Œ[P® @Áº   |zøua‹› @Áº 
 ö£¸©¸¢x @Áº  öÁÒøÍ¨ §sk 
 BÁõøµ@Áº  ÁŒ®¦ 
 CøÁPøÍ ÁøPUS 1 ÁµõPöÚøh Ãuö©kzx yÒ öŒ#x, 
B©nUöPsön# 1 @Œ›À SÇ¨¤ Ak¨¤ß @©@»ØÔ G›zx¨ £uzv¼ÓUPÄ®.  
CvÀ J¸ xmöhøh²® öPõÒÍU Pµ¨£õß w¸®.  Czøu»zøu Pµ¨£õß 
¦sPÎ¾® Ch»õ®. 
 & Œµ@£¢vµº øÁzv¯ •øÓPÒ 
 (Âµn®, Pµ¨£õß @µõP ]QaøŒ) 
 
5. öŒ[Pµ¨£õÝUS ©¸¢x 
 öŒ[Pzuõ›@Áº G¸UP® @Áº 
 ]ÖSÔgŒõß SÓmøh @Áº 
 ö£¸©¸¢x@Áº §sk 
 ÁŒ®¦ 
 CøÁPøÍa Œ©öÚkzx (1 £»®) £”Âß £õÀ Âmk |ßÓõP Aøµzx 
|Àö»sön# 1 ½ @Œ¸hß Tmi Ak¨¤ß @©@»ØÔ G›zx¨ £uzv¼ÓUPÄ®.  
C¢u Gsönø¯ J¸ ì§Ûö»kzx EÒÐUSa Œõ¨¤hÄ®.  Cøu@¯ 
öŒ[Pµ¨£õß ¦sPÎß «x §Œ w¸®. 
 & Œµ@£¢vµº øÁzv¯ •øÓPÒ   (Page: 256) 
 
 
6. KkPµ¨£õÝUS ©¸¢x 
 {»@Á®¦  ö£¸©¸¢x 
 ]ÁÚõº@Á®¦  A¢uµzuõ©øµ 
 ]ÖSÔgŒõß  Ezuõ©o 
 }º •ÒÎ  xÍ] 
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 ©nzuUPõÎ  |ßÚõ› 
 @£#¨ ¥ºUP[Põ# 
  & CøÁPÎß @Áº ÁøPUS 1 ÁµõPöÚøh 
 ÁŒ®¦, §sk CÆÂµsk® ÁøPUS 1 ÁµõPöÚøh²® Gkzx Cizxz 
uspº Âmk |ßÓõP Aøµzx, 
 @u[Põö¯sön#  & 1 EÇUS 
 C¾¨ö£sön#  & 1 EÇUS 
 ¦[öPsön#  & 1 EÇUS 
 |Àö»sön#  & 1 EÇUS 
 •u»õÚøÁPÐhß JßÓ P»¢x Ak¨¤ß @©À HØÔ G›zx¨ 
£uzv¼ÓUPÄ®. C¢u Gsön°À J¸ ÁµõPöÚøhö¯kzx EmöPõsk, 
¦sPÎß @©@»²® @£õh KkPµ¨£õß w¸®. 
   &  Œµ@£¢vµº øÁzv¯ •øÓPÒ .  
 
7. Â¨¦¸vUSz v¸SUPÒÎö¯sön# 
 v¸SUPÒÎ@Áº  A•UQµõQÇ[S 
 öPõi@Á¼@Áº  ö£¸©¸¢x @Áº 
 Busøh @Áº  Ezuõ©o @Áº 
 Œ[P[S¨¤@Áº  ¤µsøh@Áº 
 ö£¸[Põ¯®   ªÍS 
 P¸g^µP®   öÁ[Põ¯® 
 PkUPõ#z@uõÀ  ”zvöŒ#u Põ¢u® 
 §uPµ¨£õß£møh  C¢x¨¦ 
 K©®    ”US 
 •u»õÚ ŒµUSPøÍ ÁøPUS J¸ £õUPÍöÁkzx Cizx ¤ß¦ A®ª°ß 
@©À øÁzxz uspº Âmk Aøµzx @Á¨ö£sön# B©nUöPsön# 
CÆÂµsk® uÛzuÛ@¯ 1¼ @Œº Ãuö©kzx JßÖ Tmi AuÝhß SÇ¨¤ 
Ak¨¤ß @©À øÁzx £u©õPU Põ#a] CÓUPÄ®. 
 C¢u Gsön°À J¸ ì§ß AÍöÁkzxz vÚ¢@uõÖ® AvPõø»°À 
EmöPõÒÍÄ®. 
£zv¯® 
 E¨¦, ¦Î, •u¼¯øÁPøÍ }UPÄ®. Â¨¦¸vPÒ  w¸®.  
  & Œµ@£¢vµº øÁzv¯ •øÓPÒ  (Page: 324) 
 
8. Pµ¨£õÝUS ©¸¢x 
 P¸g^µP®   §uPµ¨£õß £møh 
 £Ø£hõP®   öÁ[Põ¯® 
 ö£¸[Põ¯®   ÁŒ®¦ 
 öPÍ›    Põmk ö©õaøŒ 
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 Œøha]   ªÍPµøn @Áº 
 ]ÖPõgöŒõÔ   ŒzvaŒõµøn 
 ö£õß•”møh   ö£¸[S¸®ø£ 
 ¦Ú¼ usk   ö£¸©¸¢x 
 |ßÚõ› @Áº   öPõi@Á¼ @Áº 
 ]Ö SÓmøh   S¨ø£@©Û @Áº 
 ]ØÓÁøµ QÇ[S   
 CøÁ AøÚzx® ÁøPUS J¸ £»® Ãu® Gkzx PØP©õUQ £”ö|# J¸ 
£i²hß P»¢x Ak¨¤@»ØÔ ÁiUPÄ®. 
 AÍÄ  :  1 PõöŒøh 2 @ÁøÍ 
 AÝ£õÚ® :  £õÀ 
      & Œµ@£¢vµº øÁzv¯ •øÓPÒ Pº¨¤o  
      £õ»@µõP ]QaøŒ (£õP® 4) (Page 235) 
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3.2 Botanical Aspect 
Classification 
1. According to Bentham & Hooker‟s (1876) classification “Aristolochia indica” is 
classified as follows: 
 
Kingdom  :  Plant Kingdom 
Division  :  Angiosperms 
Group   :  Dicotyledons 
Class   :  Monochylamydeae 
Series   :  Multiovulate terrestris 
Family    :  Aristolochiaceae 
Genus   :  Aristolochia linn 
Species  :  indica linn 
 
Vernacular Names 
Tamil   :  Isvaramooli, Karuta kodi, Garudakkodi, Perumkizhangu 
English:  Indian Birth wort 
As the name Iswari indicates the plant is believed to have the power to neutralize 
or resist snake poison. 
 
Habitat  
 The plant is distributed in all the provinces of India and in Srilanka, Nepal and 
Bangladesh. 
 It is usually found scrambling over hedges and bushes. 
 It can be propagated by seeds, which generates in and about two weeks. 
 
Habit and General Features 
Aristolochia indica linn is a glabrous perennial twiner with a long slightly 
tuberous or stout root that penetrates deep into the soil. The younger branches and tender 
shoots are slender striated and smooth while stems and older branches are woody strong 
and flexure and covered with corky bark. The former bear simple alternate short-petioled 
entire, membranous very variable three nerved leaves, the shape varying from linear to 
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obovate or sub-panduri form and from 10 x 1.2 or 1.8 cm to 18 x 8 cm in size. The 
flowers are irregular, greenish-white to light Purplish and 2.5 cm or more long. These 
have a tubular perianth with a swollen base a long narrow neck and an obliquely trumpet-
shaped mouth or lip. The fruits are septicidally dehiscent pendent capsules tightly packed 
with numerous flat triangular broadly winged or very thin seeds. All parts of the plant 
have a bitter taste and emit when crushed a characteristic sharp nauseous odour. 
 
External Morphology 
Leaves 
Simple, alternate, short-petioled, the petiole- from 6 to 8 mm long, very slender 
with its base dilated and often with a stipule like prophyll or reduced leaf of the 
undeveloped auxiliary bud; blade somewhat wedge-shaped or obovate, very variable in 
shape and size. The shape varies from linear to obovate, oblong or sub-panduri form and 
the size in the narrowest forms are about 10 cm by 1.2 or 1.8cms and in the larger and 
broader forms from 10 to 18 cm by 7.5 cm at the broadest part which may be at the base, 
middle or above the middle, entire membranous or thin, smooth, the base cuneate rounded 
or shallowly or slightly cordate and mostly three or occasionally five-nerved and the tip 
obtuse or abruptly or gradually obtusely acuminate or even apiculate tender leaves are 
light purplish. 
 
Ethno Medical Information: 
Extracts or Isolates of   Aristolochia indica containing aristolochic acid.  
The chief active principle of the drug is aristolochic acid, though aristolic acid and p-
coumaric acids also appear to contribute to the activities of the drug.  
Aristolochic acid is 8-methoxy-3; 4-methylene – dioxy – 10 – nitrophenanthene – 
1 – carboxylic acid. 
It is intensely bitter and is optically inactive. It is the same as isoaristolochic acid, 
aristolochia yellow, aristinic and aristolochic acids, but is different from aristolochine 
now identified as 1-curine. 
Isolation of the acid by column chromatography and crystallization from the 
mixture of dimethyl formamide and ethanol resulted in yellow-orange crystals with mp 
275-78
0 
Aristolochic acid can also be isolated by extracting the plant material with alcohol 
(95%) or ammonium hydroxide (5%) and chromatographing the extract. 
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Aristolochic acid possess anti cancer activity. 
It is the active against adeno carcinoma and ascetic hepatoma in rats. 
It is also active against Ehrlich ascities carcinoma in mice but is inactive against a 
wide spectrum of experimental neoplasms. 
It stimulates phagocytic activity in guinea pigs administered chloromphenicol, 
cyclophosphamide and to a limited extent prednisone. 
Aristolochic acid increased the defense mechanism of the eye against virus 
infections. The application of Aristolochic acid leads to a more rapid healing of the 
lesions. The animals treated with aristolochic acid show increased number of micro and 
macrophages in the cornea and in the vitreous body respectively. 
Aristolochic acid is used for stimulating phagocytosis in infectious diseases in 
formulation with antibiotics. 
Aristolochic acid stimulates phagocytic function of reticulo – endothelial system 
in rats. 
 
Phytochemical studies: 
 
 
 
 
 
Constituents Mol. Formula mpoC 
Aristolochic acid 1a, 2, 3a, 4a C17H11NO7 275-78 
Aristolochic acid – D 3a – 4 C17H11NO8 269-72 
Aristolochic acid – D Me either lactam 4 C18H11NO5 350-55 
Aristololactam3 C17H11NO5 315-17 
Aristolochic b-D-glucoside 3a,4 C23H21NO9 330-33 
Aristolic acid C17H12O5 292 
Aristoloamide 3a C18H14O5 172 
Aristoloamide3a C17H13NO4 293-94 
Methyl aristolochate C18H13NO7 285-86 
6-Methoxy Me-aristolate C19H16O6 206-07 
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Alkaloids: 
 
 
 
Steroids 
 
 
Others 
 
 
 
 
 
Constituents Mol. Formula mpoC 
1 – Curine (aristolochine) 5a, 1c, * C36H38N2O6 215 (MeOH) 
Unidentified Sesquiterpenoids (Mol wts, 608; 622, 636) Bp oC 
Ishwarane6a C15H24 80-82/1 mm 
Ishwarane1b C15H24 104-05/1 mm 
Aristolochane 6a C15H24 85/0.5 mm 
Selina-4(14), 11-diene 5b+ C15H24 80-85/0.3 mm 
Sesquiterpene A7 C15H24 112-12.5/6 mm 
Sesquiterpene B7 C15H24 113/6 mm 
Ishwarol 1c 5c C15H24O 110/1 mm 
Ledol 7,5d, 3a C15H26O mp 103-04 
Isomer of ledol 3a C15H26O mp 150 
Ishwarone 1c, 6b, 8 C15H26O mp 57 
Constituents Mol. Formula mpoC 
b-Sitosterol-1a C29H50O 134-35 
Strerol glycoside 1a C29H50O 285-90 
Stigmast-4-en-3-ojne3a,b C29H47O 80-81 
Constituents Mol. Formula mpoC 
Ceryl alcohol-1a C26H54O 79 
Allantoin-1a C4H6N4O3 232 (decomp) 
p-Coumaric acid 3a C9H8O3 210-13 (206) 
d-Camphor 1b, 7 C9H8O3 177 
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Structure elucidation of Phytochemicals in Aristolochia indica 
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3.3. Siddha aspect of the disease 
£õsk 
@ÁÖ ö£¯º 
 öÁsø© @|õ# 
 öÁÐ¨¦ @|õ# 
C¯À 
 “PÈÁõS¢u @uP©¨£õ PõnzuŒ Ázuõ# 
 ÁØÔÂk ©ßÚÁõŒÀ @PmQÀ 
 £ÈPõµº •PzvÚõÀ •›¯õº @£õ» £õsöhÀ»õ® 
 öÁÐzx Sizux µzu®” 
     & APzv¯º øÁzv¯ PõÂ¯® 
 “@uPzv@» Cµzu® ÁØÔ 
 w[PõÚ Â¢u @|õ# Põq©¨£õ” 
     & APzv¯º SnÁõPh® 
C¯ØøP {Ó® ©õÔ, EhÀ öÁÐzx Ps, |PUPs CøÁPøÍ }UQ¨ 
£õºzuõÀ S¸v°ßÔ öÁÐzv¸US® @|õ¯õS®. 
@|õ# Á¸® ÁÈ 
AÔ¢x@© EØ£zv öŒõÀ»U @PÍõ# 
  AvŒõµ©»ªÍQ ö¯¢@|µ¢uõß 
¤Ô¢x@© ¦Î²¨¦ ö£¸zu»õ¾® 
  ö£zu©õ©UQÛ °¸zu»õ¾® 
ªÔ¢x uõ® §»ªP A¸¢u»õ¾® 
  «Ôö¯©xU PøÍzuõß ¦]zu»õ¾® 
£Ô¢x@© £PÀ {zvøµ öŒ#u»õÝ® 
  £õskÁ¢x £õ›¾Ò@Íõº £k® £õhõ@© 
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£õhõÚ £g” uøÚzuõ¸i@ÚõºUS® 
  £õ[PõÚ ]ÁxQø»¨ £ØÔ@ÚõºUS® 
©õhõÚ £”Áøu¨ £miÛ¯uõP 
  øÁUQß@Óõº ©øÓÁÈ@¯ |hzvhõuõº 
PõhõÚ Áõµo¯¢uÛØÁÈ £ÔzxU 
  PkÁøuPÒ öŒ#Qß@ÓõºPs Põnõu 
@PõhõÚ £È öŒõÀ¼U SiöPkUS[ 
  öPõk®£õÂ £õskÂÚõØ SvöPõÒÁõ@µ 
      & ³Q øÁzv¯ ]¢uõ©o 
SÔSn[PÒ 
 EnÄ •u¼¯ @ÁÖ£õkPÍõÀ, wUSØÓ® ªS¢x S¸v°ß {Ózøu²® 
Gøhø¯²® öPkzx, EhØUS @Ási¯ Fmhzøu²® öPõhõ©À, Ehø» 
öÁÐUPa öŒ#²®. 
 ]Ôx öuõø»Ä |hUQÝ® PõÀ K#¢x @£õuÀ, ö£¸‰a” Áõ[PÀ EnÂÀ 
Â¸¨£ªßø©, Áõ#S©mhÀ, uø»”ØÓÀ, Ps C¸ÍÀ, AiUPi ©¯UP©õuÀ, ©õº¦ 
xizuÀ, EhÀ CøÍzuÀ BQ¯ SÔSn[PøÍ²® Põmk®. 
@|õ# Gs. 
 SØÓzuõÀ Á¸ÁÚ |õßS®, |gŒõÀ Á¸ÁÚ JßÖ® Ti I¢uõS®. 
1.ÁÎ(Áõu¨ £õsk) 2.(¤zu¨) £õsk 3.I¯(P£¨) £õsk 4.•USØÓ¨ 
(v›@uõå) £õsk 5.|g”(Âh) £õsk GÚ I¢öuÚ ÁSzxÒÍõº.  CßÝ® 
©sqs öÁÐ¨¦ (£õsk @|õ#) JßÖÒÍx. S¸vU SøÓÁõÀ EhØPmkPÒ 
ö©¼¢x EhÀ Ã[Q, {Ó®©õÔ ©gŒÒ AÀ»x }»{Ó® ö£ØÖ®, ªS¢u 
}º@ÁmøP, AiUPi ©¯UP® Á¸uÀ, ©Úa@ŒõºÁøhuÀ, AÔÄ uk©õÓÀ, Bsø© 
SøÓuÀ GßÝ® SÔPøÍ²® Põmk®. 
ö£õxUSÔ Sn[PÒ 
 EhÀ Áßø© |õÐUS |õÒ SøÓ¢x |hUP C¯»õø©, uø»@|õuÀ, ©õº¦ 
xizuÀ, Ps AiUPi C¸ÍÀ, uø»a”ØÓÀ, ©¯UP•shõuÀ, ‰a”z uk©õÓÀ, 
£]zwU öPhÀ, EnÄ @Áshõø©, Esh ]Ö EnÄ® Áõ¢v¯õuÀ BQ¯ SÔPÒ 
@uõßÖ®. 
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CßÝ®, ªPÄ® öÁÐzxz @uõÀ ”¸[PÀ, EhÀ ö©¼¢x £Í£Ízx 
öÁÐ¨£õuÀ, |PU PsPÒ  uizx öÁÐzuÀ, |õöÁizx¨ ¦snõuÀ, öuõsøh 
PmhÀ BQ¯øÁ EshõS®. 
 C¢@|õ# ö£sPÐUSshõ°ß, ‹uPzvÀ öÁÎ¯õS® S¸v,  ußÛÓ®, 
Gøh, AÍÄ •u¼¯Ú SøÓ¢x öÁÎ¯õS®. ]»¸US AÍÄ  Ph¢x  öÁÎ¯õS®. 
 SÇ¢øuPÐUS® ö£›¯ÁºPÐUS® EshõS® Á°ØÖ¨¦Ê @|õ#, 
S¸v¯ÇÀ @|õ# BQ¯ÁØÔØS® xøn@|õ¯õP Aø©²®. 
 AÇÀ Eh@»õºUS C¢@|õ# EshõS©õ°ß, •u¼À £]zwø¯U öPkzx 
Esh EnÄ  öŒ›¯õø©, EhÀ G›aŒÀ, ”µ® EÒÍx @£õßÖ öÁ¨¦z @uõßÓÀ, 
|õöÁÐzxa ]ÁzuÀ, AÀ»x £mkz xo@£õÀ ÁÊÁÊzuÀ,  EnøÁ 
ö©À»Ä® ÂÊ[PÄ® •i¯õø©, ]Ôx ¤zu }ºP»¢x AiUPi Áõ¢v¯õuÀ, Áõ# 
øP¨¦, Á°ØÖ @|õ#, Á°Ö Pkzx ~øµ ~øµ¯õPU PÈuÀ GßÝ[SÔPÒ 
EshõS®. 
|õi |øh 
 “@Œzx© |õi °ÍQÚõÀ £õshõS® 
 
 Pshõ@¯õ ]@»Ø £ÚzvÀ Áõu|õi P»¢vkQÀ 
 ............................................... £õsk 
 
 uõÚ•ÒÍ @Œºzx©¢uõÛÍQÀ £õsk@µõP® 
 
 Ch©õÚ @Œzx©zvØ Áõu|õi 
 GÊ¢uqQÀ £õshõS® 
 
 Eshõ@¯õ @Œzx©zvÀ Áõu|õi 
 P»¢vk@©À £õsk¤ÓUS¢uõ@Ú 
 
 ÁõuzvÀ ^ug@ŒºzuÀ £õskshõ@© 
 
EnÄ 
 @|õ# öuõhUPzvÀ £]ø¯z yshU Ti¯x® Eh¼ß S¸vø¯¨ 
ö£¸UPUTi¯x©õÚ EnÄ ö£õ¸ÒPøÍ¨ ö£›x® öPõkzuÀ @Ásk®. Á°ØÖ¨ 
¦ÊUPÒ öÁÎ¯õ°ß, APzv Røµø¯ AiUPi @Œºzx Á¸Áx |ßÖ. EnÄ 
GÎvÀ öŒ›UP Ti¯uõP@Á C¸zuÀ @Ásk®. 
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RøµÁøPPÎÀ, P›Œõø», ö£õßÚõ[Põo, AÖRøµ, ]ÖRøµ, 
©nzuUPõÎ, uõÎURøµ, CøÁPøÍ öPõkUP @Ásk®. 
 Põ#PÔPÎÀ, Pzu›¨¤g”, •¸[øP¨¤g”, ÁõøÇUPaŒÀ, AÁøµ¨¤g” 
•u¼¯Ú öPõkUP @Ásk®. 
 @|õ#Áßø© ªS¢v¸¨¤ß £]zw SøÓ¢x, EnÂÀ öÁÖ¨¦, Áõ¢v 
CøÁPÒ EshõS©õøP¯õÀ, GÎvÀ öŒ›UPUTi¯ EnÄPÍõQ¯ Pg] 
ÁøPPøÍ²®, FÛß CµŒzøu²® öPõkUP @Ásk®. 
 Bmk Dµø» ]Ö ]Ö xskPÍõPz xsizx, Auß AÍÂØ@PØ£ }ºTmi 
J¸ öPõvÁ¢u¤ß Gkzx |ßÓõP¨ ¤øŒ¢x A¢}øµ Áizx @Ási¯ AÍÄ 
£ÇµŒ[PÐÒ öPõi•¢v›, ŒõzxUSi, B¨¤Ò CÁØÔÀ H@uÝ® JßøÓ @Œºzx 
öPõkUP @Ásk®. 
@©õº AÝ£õÚ©õP öŒ¯À£k® Âu®
 
ÃUP ©@Põuµ•Ò ÃÖ Sß©® £õsk ¤zu¢ 
uõUS©¸¢ vmhuv Œõµö©õk & TUSµ@» 
©õÓõzv›@uõå ©¢u©ÚØuP® @£õ® 
ÃÐÂß @©õºUS ö©#” 
 £”Âß @©õ¸US ÃUP®, ©@Põuµ®, Á°ØÖÁ¼, £õsk, @µõP®, ¤zu 
@Põ£®, Ck©¸¢uõÀ Á¸® @|õ#PÒ, @£v, v›@uõå®, AUQÛ ©¢u®, öÁ¨£® 
uõP® @£õS®. 
 ]Ôx ¦Îzu @©õøµ Es£vÚõÀ Cµzu uõøµPÎß ©õ”UPøÍ }º‰»©õ# 
öÁÎ¯õUQ Cµzu Kmhzøu ^º£kzx®, ©»Œ»PmkPÒ EshõPõ©À ukUS®. Cx 
©@Põuµ®, Á°ØÖÁ¼, £õsk, AUQÛ ©¢u® •u¼¯ÁØÔØS ]Ó¢u £zv¯©õS®. 
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3.4 Modern aspect of the disease 
Anaemia 
Definition: 
 
It is a condition of reduction in the haemoglobin concentration of the peripheral 
blood below the normal level in relation to age and sex. However, it should be 
remembered that anaemia is not a disease by itself but an expression (or) sign of an 
underlying disease. 
Classification: 
Based on, 
I. Etiology 
II. Red Cell Morphology 
I. Etiological Classification: 
1) Due to blood loss 
a) Acute 
b) Chronic 
2) Haemolytic anaemia due to destruction of RBC 
3) Impaired RBC production. 
a) Defective proliferation and differentiation of stem cells. 
i) Aplastic anaemia 
ii) Chronic renal failure 
iii) Endocrinopathy 
b) Defective proliferation and maturation of differentiated erythroblasts. 
i) Defective DNA synthesis vitamin B12, Folic acid deficiency 
ii) Defective haemoglobin synthesis. 
iii) Iron deficiency anaemia and pyridoxine deficiency. 
iv) Sideroblastic anaemia 
v) Anaemia due to chronic infection and inflammation (or) neoplasia. 
c) Myelophthistic anaemia due to infiltration of bone marrow by various agents. 
4) Anaemia of uncertain etiology 
E.g.: Rheumatoid arthritis, Pre-maturity, burns etc. 
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Iron Deficiency Anaemia 
It is a commonest type of anaemia 
Cause: 
 Low intake of iron content food. 
 Defective Absorption 
 Gastrectomy 
 Gastro jejunostomy. 
 Sprue Syndrome 
 Growing worm 
 Bleeding piles 
 Menorrhogia 
 Hamotemesis,  
 Malaena 
 Oesophageal virus 
 Gastro Intestinal malignancy etc, 
 
Based on RBC morphology 
1) Normocytic anaemia 
a. Acute blood loss 
b. Liver disease 
c. Endocrinopathy 
d. Infection 
e. Deficient diet 
f. Less absorption 
g. Increase demand e.g.: Pregnancy, Lactation. 
 
2) Macro anaemia 
a) Megaloplastic 
b) Non megaloplastic 
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3) Microcytic anaemia 
a) Iron deficiency 
b) Thalasaemia 
c) Sideroplastic anaemia 
d) Pyridoxine deficiency 
e) Anaemia of chronic disease 
 
4) Sideroplastic Anaemia 
Haemoglobin Synthesis is low 
Cause: 
1. Hereditary 
2. Acquired sideroplastic anaemia 
i) Drug – Isoniozid Chloro Phenicol 
ii) Lead poisoning 
iii) Haemolytic anaemia 
iv) Chronic alcoholism 
  
5) Megaloplastic Anaemia 
It is characterized by megaloplastic reaction of the bone marrow due to slow DNA 
Synthesis. Megaloplastic macrocytic anaemia is deficiency of vitamin B12 and folic acid. 
6) Haemolytic anaemia 
It happens due to increased breakdown of RBC. Therefore there will be anaemia, 
hyperbilirubinemia, haemolytic jaundice excessive stercobilinogen in the stool. Excessive 
urobilinogen in urine and high reticulocyte count in blood. 
 
7) Sickle – cell Anaemia 
The basic fault is abnormal haemoglobin called HBS in the RBC which makes the 
letter to assume a sickle shape at a lower physiological range of oxygen pressure. 
 
8) A Plastic Anaemia 
 There is a type of anaemia associated with aplasia (or) hypoplasia of the bone 
marrow resulting in reduction of all the formed elements of blood usually. 
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Clinical Features: 
General 
Weakness fatigue, Lassitude, Oedema of the body, pallor, Dry skin, Lusterless 
hair, Spoon shaped nails (Koilonychias). 
Cardio vascular 
Palpitation, breathlessness, Angina pain, Sinus tachycardia etc. 
GI tract 
Anorexia, acidity, heart burn, palpable spleen, tachycardia etc. 
Neurological 
Dizziness, grittiness, numbness, insomnia, diminished vision, Lack of concentration. 
Reproductive 
Amenorrhea, menorrhogia, abortion, infertility. 
Special Investigations 
Blood: 
Hb % and RBC are low 
MCV low, 50-80fl 
MCH low, 15-20pg 
MCHC low, 24-30 gm/dl 
Peripheral Smear study – Hypochromic 
Reticolocyte count – low 
Platelet count – Normal 
Sr. Iron level is below 60mg/dl 
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4. MATERIALS AND METHODS 
4.1 Preparation of the drug 
Drug selection: 
In this dissertation the leaves of Echuramooli (Aristolochia indica) and its 
preparation were taken as a single drug for Paandu noi (Anaemia) from the Siddh 
literature  „Gunapaddam, First Part- Mooligai Vaguppu (Porutpanbu Nool)’ written by 
K.S.Murugesa Mudaliyar, Page no 129& 130. 
 
Collection of the Drug 
 The leaves of Echuramooli were collected from Idappadi, Salem district and 
shade dried. 
Identification and Authentication of the drug: 
The plant Echuramooli was identified and authenticated by Director, Plant 
anatomy research centre (PARC), Tambaram, Chennai-600045 and Gunapadam experts, 
P.G Gunapadam branch, GSMC, Arumbakkam, Chennai-106. The specimen sample of 
the herb has been preserved in PG Gunapadam department for future reference. 
Preparation of the Drug 
The dried leaves were made into a fine powder form (Echuramooli ilai 
chooranam) and sieved through cloth. 
Purification of the Drug: (Pittaviyal  murai) 
The Echuramooli ilai chooranam was purified by pittaviyal method (steam 
cooking in milk) as per Siddha classical literature. The same drug was later dried and 
powdered then sieved again. 
Storage of the drug:   
 The test drug was stored in a clean, dry glass container. 
 The contents were inspected frequently to avoid moisture and insects. 
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Administration of the Drug: 
 Form of the medicine  : Chooranam 
 Route of Administration : Enteral 
 Dose    :  500 mg 
 Anubanam (Vehicle)  :  Butter milk 
 Time of Administration :  twice in a day; before food 
           Duration   :  1-3 months 
 
 
 
Fig no: 1 Echuramooli Plant (Arishtalochia indica) 
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Fig no: 2 Echuramooli Ilai (Leaf of Arishtalochia indica) 
 
 
 
Fig no: 3 Echuramooli ilai chooranam (Powder form of Arishtalochia indica) 
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4.2. Standardization of the drug 
Standardization is the first step for the establishment of a consistent biological 
activity, a consistent chemical profile, standardized herbal products of consistent quality 
and containing well-defined constituents are required for reliable clinical trials and to 
provide consistent beneficial therapeutic effects.  
Pharmacological properties of an herbal formulation depend on phytochemical 
constituents present therein. Development of authentic analytical methods which can 
reliably profile the phytochemical composition, including quantitative analyses of marker 
or bioactive compounds and other major constituents, without consistent quality of a 
phytochemical mixture, a consistent pharmacological effect is not expected 
(M.Mosihuzzaman et.al 2008). 
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4.2.1. Pharmacognosy study of Aristolochia indica - Leaf 
T.S of Leaf: 
The leaf consists of prominent midrib (Fig: 4) and thick lamina. The midrib has 
wide and thick adaxial hump and broad semicircular abaxial part. The midrib is 900µm 
thick and 1mm wide. The adaxial epidermis of the midrib consists of squarish or 
rectangular thick walled cells with thick curticle (Fig: 7). The abaxial epidermis has 
smaller, squarish thick walled cells. The inner layer of the abaxial epidermis includes 
squarish thisk walled cells (Fig: 7). The adaxial hump comprises wide, angular, compact 
collenchymas cells. The remaining part of the midrib has large, thin walled, compact 
polygonalcells. The palisade tissue extends upto the lateral portions of the 
collenchymatous adaxial hump. The vascular bundle is single, broadly arc shaped and 
collateral. The bundle consists of several short, parallel lries of circular thick walled 
xylem elements and thick abaxial zone of phloem elements. The vascular strand of the 
midrib is 200µm and 400µm wide. 
Lamina: 
The surfaces of the lamina are smooth and even. It is 270µm thick. The adaxial 
epidermis is quite thick comprising large, thin walled, elliptical cells with thick cuticle 
(Fig: 5). The cells are 40µm thick. The abaxial epidermis is thin and includes narrow, thin 
rectangular cells. The abaxial epidermis is stomatiferous. The mesophyll tissue consists of 
two horizontal bands of cylindrical, less compact palisade cells. The lower part of the 
lamina has about ten layers of small, lobed, spongy parenchyma cells forming air 
chambers. 
Leaf Margin: 
The Marginal part of lamina is slightly bent down and become conical. It is 
210µm thick. The epidermal layer of the leaf margin consists of squarish, thick walled 
cells with thick cuticle. The mesophyll tissue at the marginal part remains unchanged. 
(Fig: 6). 
Calcium oxalate crystals are fairly common in mesophyll tissue of the leaf, the 
crystals are druses. Each druse has four crystals aggregated to form a four petal of the 
flower. (Fig: 8). The crystal is 10µm in diameter. 
29 
 
Legend for the figures     
Fig: 4. T.S. of leaf through midrib 
Fig no: 5 T.S. of lamina 
 
Fig no: 6 T.S. of lamina through marginal part. 
 
(AbE –Abaxial Epidermis, AdE- Adaxial Epidermis, AdH- Adaxial hump, cu – cuticle, 
La- Lamina, LM – Leaf Margin, MR – Midrib, PM- Palisade Mesophyll, SM- Spongy 
Mesophyll, VB – Vascular bundle). 
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Fig no: 7 T.S of Midrib – Enlarged. 
Fig no: 8 Crystal distribution in the leaf mesophyll as viewed under polarized light. 
 
(AbE –Abaxial Epidermis, AdE- Adaxial Epidermis, AdH- Adaxial hump, col- 
collenchymas, cu – cuticle, GP- Ground Parendryma, Cr-Crystals, MT- Mesophyll 
Tissue, Ph – Phloem, PM- Pallisade Mesophyll, Sc- Sclerenchyma, X- Xylem) 
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4.2.2. Phyto chemical analysis 
 
Medicinal plants are of great importance to the health of individuals and 
communities. The medicinal value of these plants lies in some chemical substances that 
produce a definite physiological action on the human body and these chemical substances 
are phytochemicals. These are non-nutritive chemicals that have protective or disease 
preventive property. The most important of these phytochemicals are alkaloids, 
flavonoids, tannins and phenolic compounds (Hill, 1952). 
Chemical tests were carried out using the aqueous extracts from Plants and or the 
powdered specimens, using standard procedures to identify the constituents as describe by 
Sofowara (1993), Trease and Evans (1989) and Harborne
 
(1973). 
Test for Flavonoids (Shinoda test) 
 
Substance is dissolved in alcohol, added with magnesium bits and concentrated 
hydrochloric acid. On heating over a water bath, the appearance of magenta colour shows 
the presence of flavonoids.  
 
Triterpenoids (Noller’s Test)  
 
To few mg of extract, add tin and thionyl chloride and heat in water bath. Purple 
colour indicates the presence of tritepenoids. 
 
Test for Proteins (Biuret test) 
 
To the sample solution in a test tube, add sodium hydroxide solution and then add 
a few drops of very dilute (1 %) copper II sulphate solution and mix gently.  Appearance 
of purple colour indicates the presence of protein.  
 
Test for Reducing sugar (Fehling’s Test) 
 
To the sample solution, Fehling‟s reagent is added. The appearance of brick red 
precipitate or coloration indicates the presence of reducing sugar. 
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Test for Anthraquinones 
 
Few milligram of crude powder is shaken with 10 ml of benzene and filtered. To 
this filtrate, 0.5 ml of 10 % ammonia solution is added and the mixture is shaken well and 
the presence of the violet colour in the layer phase indicates the presence of the 
anthraquinone.  
 
Test for Alkaloids (Dragendorff’s Test)  
 
Few mg of extract in separate test tube was warmed with 2% Sulphuric acid for 2 
minutes. And it was filtered in separate test tube and few drops of Dragendorff‟s reagent 
were added.  The presence of orange red precipitates indicates the presence of alkaloids. 
 
Test for Saponins 
 
To few mg of extract distilled water is added and shaken well. The formation of 
foam indicates the presence of saponin. 
Results are shown in page no: 47 
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4.2.3. Physio-chemical analysis 
Ash and acid insoluble ash: 
 To the ash add 1:5 Hcl: Distilled water 15 ml boil, cooled and then filtered using 
whatman filter paper (No.41) repeat 3 to 4 times till the yellow colour disappear or 
colourless, then remove the filter paper and add to the filter to the original dish and keep 
it in the muffle furnace at 600
o
 C and take constant weight and calculate the acid 
insoluble ash value. 
     Weight of acid insoluble residue x 100 
Acid insoluble ash (%) =  
                    Weight of the sample 
Acid insoluble residue = Acid insoluble ash value – Empty weight of the dish 
Loss on drying: 
 3gm of the drug is heated in a hot oven at 105
0
 c to constant weight. The % of 
weight was calculated. 
Loss on drying value at 105
0
 c – 9.485 %w/w 
Potential of hydrogen (pH): 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate alkaline or 
base solutions. pH of Echura mooli ilai chooranam – 6.5 
Thin layer chromotography (TLC) 
Solvent system: 
Toluene: Ethyl acetate (6:1.5). 
TLC plate: 
  Aluminium plate precoated with silica gel 60F254 of 0.2 mm thickness (Merck). 
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Developing chamber: 
 Camag‟s  twin trough chamber. 
Visualizing reagent: 
 Vanillin-sulphuric acid reagent. 
Extract Preparation:  
4 g of the chooranam was soaked overnight in chloroform. After that it boiled on 
water bath for 10 min, and then it filtered and concentrated to 10 ml.  
Procedure: 
 The extract was applied on the TLC using capillary and developed in the solvent 
system.  The developed TLC plate was air dried and photograph was taken in white light. 
Then it dipped in vanillin-sulphuric acid reagent, heated in an oven at 105°C until the 
development of coloured spots and photograph taken. 
Results are shown in page no: 48 & 49 
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4.2.4. Chemical Analysis 
Proximate Chemical Analysis of the drug 
Preparation of Extract 
5gm of sample is weighed accurately and placed in a 250ml clean beaker and 
added with 50ml of distilled water. Then it is boiled well for about 20 minutes. Then it is 
cooled and filtered in a 1000ml volumetric flask and made up to 100ml distilled water. 
S.No Experiment Observation Inference 
1. 
 
Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Green / Yellow / 
Red precipitation 
Presence of 
Reducing Sugar 
2. 
 
Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of N/50 
Iodine Solution. 
Blue Colour 
Presence of 
Starch 
3. 
 
Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Violet or Purple 
Colour 
Presence of 
Proteins 
4. 
 
Test for amino Acid : 
Place 2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow drying. 
Violet Colour 
Presence of 
Amino Acid 
5. 
 
Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch‟s reagent. Yellow precipitation 
 
Presence of 
Albumin 
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S.No Experiment Observation Inference 
6. 
 
Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Yellow precipitation 
Presence of 
Phosphate 
7. 
 
Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
White precipitation 
Presence of 
Sulphate 
8. 
 
Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Cloudy White 
precipitation 
Presence of 
Chloride 
9. 
 
Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric Acid. 
Red Colour Presence of Iron 
10. 
 
Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
White precipitation 
Presence of 
Calcium 
11. 
 
Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame.  
Yellow Flame 
Presence of 
Sodium 
12. 
 
Test for Potassium : 
Add a pinch of the sample to 2 ml of 
Sodium Nitrate Solution. Then add 
2ml of Cobalt Nitrate in 20% acetic 
acid. 
 
Yellow precipitation 
Presence of 
Potassium 
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S.No Experiment Observation Inference 
13. 
 
Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
White precipitation Presence of Zinc 
 
14. 
 
Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution. 
White precipitation 
Presence of 
Magnesium 
15. 
 
Test for Alkaloids : 
a. To 2ml of extract, add 2ml of 
Potassium Iodide Solution 
b. To 2ml of extract add 2ml of 
Picric Acid. 
c. To 2 ml of extract add 2ml of 
Phospho tungstic Acid. 
 
Red Colour 
 
Yellow Colour 
 
White precipitation 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. 
 
Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Black precipitation 
Presence of 
Tannic Acid 
 
Results are shown in page no: 50 
 
 
 
 
 
 
 
38 
 
4.2.5. Toxicological study 
Introduction 
Herbal medicines are generally regarded as safe based on their long-standing use 
in various cultures. However, there are case reports of serious adverse events after 
administration of herbal products. In a lot of cases, the toxicity has been traced to 
contaminants and adulteration. However, some of the plants used in herbal medicines can 
also be highly toxic. As a whole, herbal medicines can have a risk of adverse effects and 
drug–drug and drug–food interactions if not properly assessed. Assessment of the safety 
of herbal products, therefore, is the first priority in herbal research. There are various 
approaches to the evaluation of safety of herbal medicines.   
Evaluation of the toxic effects of plant constituents of herbal formulation requires 
detailed phytochemical and pharmacological studies. It is, however, safe to assume that, 
based on human experiences in various cultures, the use of toxic plant ingredients has 
already been largely eliminated and recent reports of toxicity could largely be due to 
misidentification and overdosing of certain constituents  
  According to the literature, many Siddha preparations are effective in curing the 
anaemia with better palatability, as well as cost effectiveness. In our study, the 
Aristolochia Indica leaf Chooranam was evaluated in phenyl hydrazine induced anaemic 
rats to verify the acclaimed haematinic property. 
 
Materials and methods 
Drug and Stock solution 
 The Aristolochia Indica leaf Chooranam was prepared as per the procedure in 
traditional Siddha text recommendation and made into suspension form using CMC as a 
suspending agent and used in this study. The resulting suspension was then grounded and 
filtered. The filtrate was stored in a refrigerator until use. The suspension was further 
diluted with 2% CMC so as to achieve 200mg/ml stock concentration. 
Animals 
 Male albino rats (150-180g) and Mice of either sex weighing 25-30g were used 
for the study. The rats were housed in wire-mesh cages with a 12 h light/dark cycle. They 
had continuous access to food and water during the entire period of experimentation. 
(Approval number: XIII/VELS/PCOL/66/2000/CPCSEA/IAEC/08.08.2012). 
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Acute toxicity study: 
 Acute oral toxicity test for the Aristolochia Indica leaf Chooranam was carried 
out as per OECD Guidelines 425. Animals are observed individually after dosing at least 
once during the first 30 minutes, periodically during the first 24 hours, with special 
attention given during the first 4 hours, and daily thereafter, for a total of 14 days, except 
where they need to be removed from the study and humanely killed for animal welfare 
reasons or are found dead.  
 
 All observations are systematically recorded and Observations include changes in 
skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic 
and central nervous systems, and somatomotor activity and behavior pattern. Attention 
was directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep 
and coma. The principles and criteria summarized in the Humane Endpoints Guidance 
Document taken into consideration. Animals found in a moribund condition and animals 
showing severe pain or enduring signs of severe distress was humanely killed. When 
animals are killed for humane reasons or found dead, the time of death was recorded.  
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4.2.6. Pharmacological study 
Haematinic activity of Aristolochia indica leaf chooranam in Phenylhydrazine 
induced anaemic rats 
Introduction 
  According to the literature, many Siddha preparations are effective in curing the 
anaemia with better palatability, as well as cost effectiveness. In our study, the 
Aristolochia Indica leaf Chooranam was evaluated in phenyl hydrazine induced anemic 
rats to verify the acclaimed haematinic property. 
 
Materials and methods 
Drug and Stock solution 
 The Aristolochia Indica leaf Chooranam was prepared as per the procedure in 
traditional Siddha text recommendation and made into suspension form using CMC as a 
suspending agent and used in this study. The resulting suspension was then grounded and 
filtered. The filtrate was stored in a refrigerator until use. The suspension was further 
diluted with 2% CMC so as to achieve 200mg/ml stock concentration. 
Animals 
 Male albino rats (150-180g) and Mice of either sex weighing 25-30g were used 
for the study. The rats were housed in wire-mesh cages with a 12 h light/dark cycle. They 
had continuous access to food and water during the entire period of experimentation. 
(Approval number: XIII/VELS/PCOL/35/2000/CPCSEA/IAEC/08.08.2012). 
Acute toxicity study 
 Acute oral toxicity test for the Aristolochia Indica leaf Chooranam was carried 
out as per OECD Guidelines 425. Animals are observed individually after dosing at least 
once during the first 30 minutes, periodically during the first 24 hours, with special 
attention given during the first 4 hours, and daily thereafter, for a total of 14 days, except 
where they need to be removed from the study and humanely killed for animal welfare 
reasons or are found dead.  
 All observations are systematically recorded and Observations include changes in 
skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic 
and central nervous systems, and somatomotor activity and behaviour pattern. Attention 
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was directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep 
and coma. The principles and criteria summarized in the Humane Endpoints Guidance 
Document taken into consideration. Animals found in a moribund condition and animals 
showing severe pain or enduring signs of severe distress was humanely killed. When 
animals are killed for humane reasons or found dead, the time of death was recorded.  
 
Evaluation of Haematinic Activity  
 Six rats were kept as normal control group (Group 1), while 24 rats were made 
anaemic by oral intubations of phenyl hydrazine (10 mg/kg body weight) daily for seven 
days. Rats that developed anaemia with haemoglobin concentration <14 g/dl were 
recruited for the study. Anaemic rats were randomly divided into 5 groups (2 to 6) and 
treated as follows: Group 1: received distilled water (1 ml) daily (normal control), Group 
2: received 2% CMC (1 ml) daily (anaemic control), Group 3: received oral single dose of 
the Aristolochia Indica leaf  Chooranam 100 mg/kg body weight/day Group 4: received 
oral single dose of the Aristolochia Indica leaf Chooranam 200 mg/kg, Group 5: received 
oral single dose of the Aristolochia Indica leaf  Chooranam 400 mg/kg Group 6: received 
oral single dose of the haematinic syrup 2ml/kg body weight/day. The treatment was 
continued for 2 weeks.  
Haematological investigation 
 Before and after treatment with drug Aristolochia Indica leaf Chooranam blood 
was collected from the retro orbital vein of experimental animals after an overnight fast 
(T=0) and after 1 and 2 weeks of treatment with Aristolochia Indica leaf Chooranam, was 
used for the determination of red blood cell count (RBC), haemoglobin (Hb) 
concentration and packed cell volume (PCV). The mean cell volume (MCV), mean cell 
haemoglobin (MCH) and the mean cell haemoglobin concentration (MCHC) were 
calculated. 
Statistical analysis 
 Experimental data was analysed using analysis of variance (ANOVA) and 
Dunnet‟s  test to determine significant differences between means. The statistical analysis 
system (INSTAT-V3) package was used for this analysis.  
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4.3. Clinical assessment 
Aim 
A systematic study of pharmaceutical products on human subjects (whether 
patients or non-patient volunteers) in order to discover or verify the clinical, 
pharmacological (including pharmacodynamics / pharmacokinetics), and or adverse 
effects, with the object of determining their safety and or efficacy. 
This study is intended to provide adequate information on the Clinical trial of 
Echuramooli Ilai chooranam with Haemoglobin enhancing potentials. 
Objectives:  
 To evaluate the Haematinic effect of Echuramooli Ilai chooranam  
 To explore the efficacy of Echuramooli Ilai chooranam in patients with 
anaemia. 
 
Design of the Study:  
The Open clinical trial phase-2B 
Study period was 2-3 months 
 
Study Centre:  
Govt. Siddha medical college hospital, Arumbakkam, Chennai – 106.  
 
Study Participants:  
Male and female patients in all races and ethnic groups were eligible for this trial. 
Treatment was administered  both on an inpatient and outpatient basis. The patients will 
be selected from the Outa-patient department of Government Siddha Medical College 
Hospital, Chennai – 106.  
 
Number of Subjects:  
Number of participants were 40-50.  
 
Registration Process:  
To register a patient, the following documents were completed by the investigator.  
 Copy of required laboratory tests  
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 Signed patient consent form  
 Other appropriate forms (e.g., Trial profoma).  
This Clinical trial is an ethical and scientific quality standard for designing, 
conducting and recording trials that involve the participation of human subjects. 
Compliance with this standard provides assurance to public that the rights, safety and well 
being of trial subjects are protected, consistent with the principles enshrined in the 
Declaration of Helsinki and ensures that clinical trial data are credible. 
 
Consent form 
Patients were included in this clinical study only after getting the concern form 
accordance of „Helsinki”. Voluntary written assent of a subject‟s willing to participate in 
this study and in its documentation.  The confirmation is sought only after information 
about the trial including an explanation of its status as research, its objectives, potential 
benefits, risks and inconveniences, alternative treatment that may be available and of the 
subject‟s rights and responsibilities has been provided to the potential subject.  
  
Selection of Patients: 
50 Patients were selected in both malea nd female, the selection of patients were 
carefully examined before treatment for correct diagnosis and ruled out any other co-
existing systemic illness. Selection of patients was based on the following inclusion and 
exclusion criteria. 
 
Inclusion Criteria: 
1. Pallor of skin and conjunctiva 
2. Loss of appetite 
3. Tiredness 
4. Patients having haemoglobin level 7-10 g/dl 
 
Exclusion Criteria: 
i) Iron deficiency Anaemia due to oesophageal varices, hiatus hernia, peptic 
ulcer, Ca of stomach, colon, caecum, ulcerative colitis, haemorrhoids, 
haematuria, haemoptysis, repeated epistaxis 
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ii) Megaloplastic anaemia 
iii) Pernicious anaemia 
iv) Haemolytic anaemia 
v) Sickle cell anaemia 
vi) Bone marrow disorder  
vii) Leukaemia 
viii) Pregnant women 
ix) Lactating women 
 
Withdrawal Criteria: 
 Irregular treatment 
 Patients who followed dual treatment 
 
Line of treatment: 
The patient was orally administrated with Echuramooli Ilai chooranam 500mg 
with buttermilk, twice a day before food. 
 
Criteria for Assessment of Response to Therapy: 
1) Good relief  : 91-100% complete relief in signs and symptoms. 
2) Moderate relief : 76-90%relief in signs and symptoms. 
3) Mild relief  : 51-75% relief in signs and symptoms. 
4) Poor relief  : <50% relief in the signs and symptoms. 
 
Investigation Parameters: 
Before treatment a detailed clinical history was taken by considering the history of 
present and past illness, personal history, family history, menstrual history and associated 
history such as occupational, socio-economical status etc. 
 
The following lab investigations were carried out before and after treatment: 
 Urine routine 
 Blood  - TC, DC, ESR, Hb%, PCV, Sugar, Urea, Cholesterol 
 Motion  - Ova, Cyst 
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Medical Advice and Diet: 
 
 Patients were advised to take cereals, milk, tomatoes, beans, walnuts, vegetable 
leaves, cauliflower, radish and pomegranate regularly. 
 Patients were advised to take mutton, liver, kidney, brain, egg yolk and fishes. 
 Patients were advised to take rich source of Vitamin C like citrus fruits which 
promotes iron absorption. 
 In severe cases with anorexia only Kanji (rice gruel) and soup are advised. 
 Daily consumption of dates supports the therapy. 
 Easily digestible food is preferred. 
 Iron rich greens like Karisalai (Eclipta prostrate), Ponnanganni (Alternanthera 
sessilis), and Manathakaali (Solanum nigrum) also support the therapy. 
Ethical Review:  
 
The protocol and any amendments have been submitted to the Govt. Siddha 
Medical College, Chennai-106. Institutional Ethical Committee (IEC) approval obtained 
to conduct the study. All subjects for this study were provided a consent form describing 
this study and providing sufficient information for subjects to make an informed decision 
about their participation in this study. This consent form was also submitted with the 
protocol for review and it was approved by the IEC. The formal consent of a subject, 
using the IEC-approved consent form, has been obtained before that subject was admitted 
to any study procedure. This consent form was signed by the subject or legally acceptable 
surrogate, and the investigator-designated research professional obtaining the consent. 
 
Statistical analysis:  
 
 The data were subjected to paired student „t‟ test to determine the significance of 
changes followed by comparisons to analyze the significance of difference within the 
before and after treatment. P values of <0.05 were taken as significant. The results are 
shown in page no. 60. 
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5. RESULTS & DISCUSSION:  
Various studies have been carried out in this trial drug Echuramooli ilai 
chooranam. The study includes literary collections, Pharmacognostic study, physico and 
Phyto chemical analysis, toxicological study, pharmacological study and clinical study. 
Echuramooli ilai chooranam was taken for the treatment of Anaemia. The drug has been 
selected for the treatment of Anaemia in reference with Gunapadam-Mooligai vaguppu 
(Porut panbu Nool ) - First part written by K.S.Murugesa Mudaliyar. 
Literary collections about the drug from various text books were done. It indicates 
the efficacy of the drug in the treatment of Anaemia. Botanical aspect deals with the 
identification, description, cultivation and ethno medicinal importance of the plant. 
Gunapadam aspect expressed that the drug possess good Haematinic property. 
Since the trial drug, Echuramooli ilai chooranam is very easy to prepare, the drug 
was prepared according to the classical methods. Then it was purified by pittaviyal 
method. This method helps to vitalize the drug. 
The trial drug was studied for its clinical importance in the management of 
Paandu noi (Anaemia). 
 
Siddha aspect: 
From the literatures, the trial drug has bitter taste, the potency of the drug is hot 
and Bio- transformation of the drug is karppu. As per the Siddha concept, this disease 
occurs due to the derangement of the pitha humor. 
   “gpj;j kjpfhpg;gpd; NgRk; ghpfhuk; 
   Rj;jj; JtNuhL nrhy;ypdpg;Gr;- rj;jhFk; 
   ifg;Gr; RitNa fUjtjd; tPW “              - fz;Zrhkpak; 
The properties of bitter taste are decreases the Iyam and Pitha humour, increases 
the Vatha humour. Bitter taste has the property to kills the worms which seems to be the 
main causes for anaemia and also purifies the blood. By giving this drug it normalise the 
deranged humours, reduces the signs and symptoms. 
Therefore the drug Echuramooli ilai Chooranam with butter milk acts on the basis 
of Ethirurai way and is very effective in treating Paandu noi. 
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Modern aspect of Aristolochia indica ilai chooranam: 
Table No. 1 : Phyto Chemical Constituents of Aristolochia indica ilai chooranam 
  
 
 
     
   
  
 
             
 
 
 
 
From the above results alkaloids, triterpines, saponin, steroids, protein and 
coumarin are present in the Echura mooli ilai chooranam. 
By the available phytochemicals, the trial drug has the therapeutic potency of 
increasing haemoglobin level in the blood.  
 
 
 
 
 
 
Phyto Chemical Constituents Results 
1.Alkaloids Present 
2.Triterpines Present 
3.Flavanoids Absent 
4.Saponin Present 
5.Steroids Present 
6.Protein Present 
7.Anthraquinones Absent 
8.Coumarin Present 
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Physio chemical analysis  
 
Table: 2 Physio chemical results of Aristolochia indica ilai chooranam 
S.No Parameter Mean 
1. Loss on Drying at 105°C 9.485% 
2. Total Ash 17.725% 
3. Acid insoluble Ash 9.172% 
4. Water Soluble Extractive 21.45% 
5. Alcohol Soluble Extractive 16.75% 
6. pH 6.5 
7. TLC Enclosed 
 
 
Fig. No: 9 TLC of Aristolochia indica ilai chooranam  
After spray with visualizing agent 
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Table No: 3 TLC result of Aristolochia indica ilai chooranam 
 
By the above results, the trial drug has very low foreign matter and acid insoluble 
ash, indicates that trial drug will digest completely in human GI tract. The analytical 
parameters like total Ash value, Acid insoluble ash value, Loss on drying values are 
helping us to interpret the digestion and solubility capacity of the crude extract. As per the 
result the tested sample contains good percentage of solubility as well as digestive 
capacity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl.No 
After Dipping in Vanillin-Sulphuric acid 
Rf value Colour of the spot 
1 0.14 Grey 
2 0.28 Blue 
3 0.34 Grayish green 
4 0.46 Purple 
5 0.51 Purple 
6 0.67 Purple 
7 0.70 Greyish green 
8 0.80 Violet 
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Table No.4 Chemical analysis result of Aristolochia indica leaf chooranam 
S.No Experiment Observation Inference 
1. Test for reducing Sugar : Green  precipitation 
Presence of Reducing 
Sugar 
2. Test for Starch : Absence of Blue Colour Absence of Starch 
3. Test for Proteins : 
Absence of Violet or Purple 
Colour 
Absence of Proteins 
4. Test for amino Acid : Absence of Violet Colour 
Absence of Amino 
Acid 
5. Test for Albumin : Absence of Yellow precipitation Absence of Albumin 
6. Test for Phosphate : Absence of Yellow precipitation Absence of Phosphate 
7. Test for Sulphate : White precipitation Presence of Sulphate 
8. Test for Chloride :  Cloudy White precipitation Presence of Chloride 
9. Test for Iron : Red Colour Presence of Iron 
10. Test for Calcium : White precipitation Presence of Calcium 
11. Test for Sodium : Absence of Yellow Flame Absence of Sodium 
12. Test for Potassium : Absence of Yellow precipitation Absence of Potassium 
13. Test for Zinc : Absence of White precipitation Absence of Zinc 
14. Test for Magnesium : Absence of White precipitation Absence of Magnesium 
15. Test for Alkaloids : 
Absence of Red Colour 
Absence of Yellow Colour 
Absence of White precipitation 
Absence of Alkaloids 
Absence of Alkaloids 
Absence of Alkaloids 
16. Test for Tannic Acid : Black precipitation 
Presence of Tannic 
Acid 
 
Results 
From the preliminary chemical analysis of Echura mooli ilai chooranam   have an 
idea that the trial drug has reducing sugar, Sulphate, Chloride, Iron, Calcium and Tannic 
acid. 
 The above result, the major ions are performing an important role in the blood and 
promotes haemoglobin level. They decrease the symptoms and signs.   
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Scanning Electron Microscope images 
Fig. No: 10 SEM image of Aristolochia indica ilai chooranam at 10.0um      
Fig. No: 11 SEM image of Aristolochia indica ilai chooranam at 2.0um 
Result: 
The nano particle size of the Aristolochia indica ilai chooranam is 11.1nm, 
14.9nm, 19.8nm, 26.7nm and 51.8nm. Because of these smaller particle sizes the 
Aristolochia indica ilai chooranam, is easily absorbed in the digestive system. 
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Table 5:  Effect of Phenylhydrazine (10mg/kg, p.o. daily for 7 days) alone on 
Haematological parameters. 
 
Values are mean  S.E.M. (Dunnet‟t' test). **P<0.01 Vs Control N=6. 
 
Graph No.1 Effect of Phenylhydrazine alone on Haematological parameters 
 
 
 
 
Parameters 
 
Group 1 
(Normal) 
Group 2 
(Anaemic) 
Group 3 
(Anaemic) 
Group 4 
(Anaemic) 
Group 5 
(Anaemic) 
Group 6 
(Anaemic) 
Hb (g/dl) 18.64 ± 0.46 13.85±0.32** 13.76±0.30** 13.64±0.34** 11.75±0.32** 12.56 ± 0.30** 
PCV (%) 52.32 ±1.44 40.41 ± 2.21** 41.52 ± 2.11** 41.20 ± 2.79** 40.31 ± 2.02** 40.34 ± 2.55** 
RBC (x106/ml) 6.88 ± 0.14 4.42 ± 0.30** 4.28 ± 0.20** 4.46 ± 0.22** 4.57 ± 0.28** 4.39 ± 0.31** 
MCV (fl) 74.62 ± 2.74 85.23±4.18 86.99±4.36 85.20±3.12 85.48±4.19 88.14± 3.12 
MCH (pg) 25.10 ± 1.56 27.18±1.31 27.40±1.51 29.30±1.32 30.40±1.20 30.18 ± 2.34 
MCHC (g/dl) 32.55 ± 0.40 34.12±0.6 34.22±0.92 34.11±1.18 34.45±3.24 30.42 ± 1.74 
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Table No. 6 Hematological parameter of rats after Seven days treatment with 
Aristolochia indica Chooranam. 
Values are mean  S.E.M. (Dunnet‟t' test). *P<0.05; **P<0.01 Vs Control N=6. 
 
 
Graph No. 2 Changes in Hematological parameters after 7 days treatment with 
Aristolochia indica  leaf Chooranam 
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Group 1 
(Normal) 
Group 2 
(Anemic 
Control) 
Group 3 
(50 mg/kg) 
Group 4 
(100 mg/kg) 
Group 5 
(200 mg/kg) 
Group 6 
(Heamatinic 
syrup) 
Hb (g/dl) 18.98 ±1.45 14.20±1.32 17.26±0.43 16.78±0.48 17.04 ± 0.77 22.15 ±2.32** 
PCV (%) 54.20 ±1.98* 45.27±2.11 46.24±2.20 48.64±2.26 46.45±3.00 55.48 ±2.24* 
RBC (x106/ml) 7.18±0.24** 5.12±0.22 6.47±0.28** 7.26±0.25** 7.88±0.23** 8.00±0.22** 
MCV (fl) 78.56±2.13  75.21±2.12 80.10±2.11 77.45±2.02 75.74±3.12 72.52±2.32  
MCH (pg) 25.15±1.44  26.78±1.28 25.80±1.67 28.02±1.22 30.00±2.00 24.36±1.28  
MCHC (g/dl) 32.02±1.30  29.33±1.20  26.32±1.05 26.17±1.28 27.2±1.47 32.41±2.00 
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Table 7:Hematological parameters of rats after 14 days treatment with Aristolochia  
indica     leaf Chooranam. 
 
Values are mean  S.E.M. (Dunnet‟t' test). *P<0.05; **P<0.01 Vs Control N=6. 
 
Graph No. 3 Hematological parameters after 14 days treatment with Aristolochia 
indica leaf Chooranam 
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Normal Control AIC50 mg/kg) AIC100 mg/kg AIC200 mg/kg Standard
Hb (g/dl) PCV (%) RBC (x106/ml) MCV (fl) MCH (pg) MCHC (g/dl)
Parameters  
 
Group 1 
(Normal) 
Group 2 
(Anemic 
Control) 
Group 3 
(50 mg/kg) 
Group 4 
(100 mg/kg) 
Group 5 
(200 mg/kg) 
Group 6 
(Heamatinic 
syrup) 
Hb (g/dl) 18.45 ±1.32** 9.00 ± 1.12 20.01 ± 0.74** 20.18 ± 0.80** 20.45 ± 1.95** 22.10 ±1.88** 
PCV (%) 47.38 ± 1.10 44.11±1.30 44.08±2.4 42.10±2.2 45.00±1.2 52.02 ± 1.46* 
RBC (x10
6
/ml) 4.22±0.24 4.84±0.30 4.86±0.33 4.78±0.28 4.84±0.29 5.10±0.28 
MCV (fl) 78.38±2.12** 90.56±2.42 82.26±2.21* 78.31±1.72** 81.46±2.23* 74.52±2.21** 
MCH (pg) 25.78±2.64 33.12±2.17 31.24±1.96 29.86±1.82 28.14±1.70 28.10±2.53 
MCHC (g/dl) 32.26±1.11 33.15±1.20 33.19±1.23 33.52±0.65 33.28±2.30 34.17±2.20 
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 Toxic compounds like phenylhydrazine could also destroy red blood cell and 
generate anaemia. The mechanism of oxidative hemolysis Produced by Phenylhydrazine 
is known. Phenyldiazene is a phenyl free radical produced via the 2-electron oxidation of 
phenylhydrazine by oxyhemoglobin. This free radical was found to hemolyze red cells 
rapidly and convert oxyhemoglobin into methemoglobin. Then it is the active hemolytic 
agent in red blood cells which could lead to anaemia. The RBC, Hb, and PCV of rats 
administered Phenylhydrazine decreased significantly (P<0.01) while the MCV and MCH 
increased giving rise to macrocytic anaemia (P<0.05). Aristolochia Indica ilai 
Chooranam at the dose of 100-400 mg/kg showed good percentage of improving in 
haemoglobin level, which was almost equivalent to standard treated group indicating 
correction of anaemia induced by Phenyl hydrazine after 14 days treatment.  
 
 Treatment with Aristolochia Indica leaf Chooranam at the dose levels 200 and 
400mg/kg for 14 day showed significant increase in Hb (p<0.01) compared to positive 
control and it was comparable to standard drug used in this study. Phenylhydrazine 
altered the haematological parameters by haemolysis characterized by decrease in 
haemoglobin concentration, total RBC counts and PCV on day 7. However, the 
haematological parameters were restored to normal range after treatment with 
Aristolochia Indica leaf Chooranam for 14 days.  Effective changes was observed after 
one week of treatment of anaemic rats with Aristolochia Indica leaf Chooranam reversed 
the influence of Phenylhydrazine resulting to a significant (P<0.05) increase in RBC, Hb, 
and PCV. The Hb, RBC and PCV reached near normal at the second week of the 
treatment.  
 
  Rats treated with Phenylhydrazine (10mg/kg/day for 7 days) resulted in a marked 
haemolytic anaemia characterised by decreased RBC, Hb and PCV. The main function of 
the RBC is the transportation of oxygen in to the tissues of the body. At such, any 
pathological or physiological condition that affects the RBC alters its function and this 
may be detrimental to the body. In this study Phenylhydrazine altered the function of 
RBC by haemolysis characterised by decreased levels of RBC, Hb and PCV. However, 
this effect was restored after one week of Aristolochia Indica ilai Chooranam treatment. 
Also the recovery was progressive such that after 1week of continuous treatment, the Hb 
concentration and PCV were higher in the treated groups than in the normal control 
group.  
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Clinical results of Aristolochia indica ilai chooranam on anaemic patients 
 
 
Inference 
Among 50 patients, 4 patients(8%) belongs to the age group 11-20 and 8 patients 
(16%) belongs to the age group 21-30 and 16 patients (32%) belongs to the age group of 
31-40 and 12 patients (24%) belongs to the age group of 41-50 and 10 patients (20%) 
belongs to the age group of 51-60. 
 
Sl. 
No 
Age in 
Years 
No. of 
Patients/50 
Percentage 
(%) 
1. 11-20 4 8 
2. 21-30 8 16 
3. 31-40 16 32 
4. 41-50 12 24 
5. 51-60 10 20 
Sl. 
No 
Sex 
No. of 
Patients/50 
Percentage 
(%) 
1. Male 20 40 
2. Female 30 60 
40%
60%
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11-20 21-30 31-40 41-50 51-60
8%
16%
32%
24%
20%
Graph No. 4 Age distribution Table No: 8 Age distribution 
Graph No. 5 Sex distribution Table No: 9 Sex distribution 
Inference 
Among 50 patients, 20 patients (40%) were male and 30 patients (60%) were female. 
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Inference 
Among 50 patients, 16 patients (32%) were labour and 15 patients (30%) were housewife, 
9 patients (18%) were office workers and 10 patients (20%) were computer operator. 
 
 
Inference 
Among 50 patients, 27 patients (54%) were poor and 16 patients (32%) were middle and 
7patients (14%) were rich. 
 
 
Sl. 
No 
Occupation 
No. of 
Patients/50 
Percentage 
(%) 
1. Labour 16 32 
2. Housewife 15 30 
3. 
Office 
worker 
9 18 
4. 
Computer 
Operator 
10 20 
Sl. 
No 
Socioeconomic 
Status 
No. of 
Patients/50 
Percentage 
(%) 
1. Poor 27 54 
2. Middle 16 32 
3. Rich 7 14 
0%
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15%
20%
25%
30%
35%
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worker
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Operator
32%
30%
18%
20%
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54%
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Graph No. 6 Occupational distribution Table No: 10 Occupational distribution 
Graph No. 7 Socio economic status Table No: 11 Socio economic status 
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Table No. 12 Improvement of Signs & Symptoms 
Sl.No Symptoms 
No. of Patients/50 
% of 
improvement 
Before 
Treatment 
After 
Treatment 
Improved 
1. Pallor of skin & conjunctiva 50 10 40 80 
2. Loss of appetite 45 10 35 77 
3. Tiredness 40 12 28 70 
4. Dyspnoea 30 10 20 66 
5. Palpitation 25 7 18 72 
6. Swelling of the body 20 8 12 60 
7. Malaise 20 10 10 50 
 
 
Inference – The improvement %  are 
Pallor skin & conjunctiva - 80% Loss of Appetite - 77% Tiredness - 70% 
Dyspnoea - 66%   Palpitation - 72%  Malaise - 50% 
Swelling of the body - 60%     
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Graph No. 8 Improvement of signs & symptoms 
59 
 
 
 
Inference 
Among 50 patients, 50% have good relief, 26% have moderate relief, 14% have 
mild relief and 10% poor relief. 
The Aristolochia indica ilai chooranam was studied for its clinical importance in 
the management of Paandu noi (Anaemia). 
It was administered in 50 patients at a dose of 500-1gm, twice a day with butter 
milk. After 3 weeks of administration most of the patients showed good result apart from 
their immune system. 
Among the 50 patients, 25 showed good results (50%), 13 showed moderate 
reliefs (26%), only 7 patients took partial clinical response (14%) and other 5 patients did 
not respond even after 4 weeks of administration (10%). 
 
 
 
 
 
 
 
Sl. 
No 
Total 
No. of 
Patients 
Extent of Relief in Percentage 
Good Moderate Mild Poor 
1. 50 50 26 14 10 
50
26
14
10 Good
Moderate
Mild
Poor
Graph No. 9 Extent of relief in % Table No: 13 Extent of relief in % 
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Biostatistical Analysis 
Effect of Aristolochia indica ilai chooranam on Hb level (gm %) in human subjects 
Sl.No 
Hb level (gm %) 
 
Sl.No 
Hb level (gm %) 
Before 
Treatment 
After 
Treatment  
Before 
Treatment 
After 
Treatment 
1 10.00 14.20 
 
26 10.20 12.70 
2 11.20 13.70 
 
27 10.90 13.20 
3 12.00 9.20 
 
28 10.80 12.20 
4 13.10 16.20 
 
29 12.00 14.20 
5 9.50 11.50 
 
30 10.40 11.70 
6 10.00 11.60 
 
31 12.00 14.10 
7 11.50 12.50 
 
32 12.30 14.50 
8 14.00 15.20 
 
33 11.00 12.60 
9 13.30 14.80 
 
34 12.00 12.80 
10 7.50 10.00 
 
35 11.80 14.00 
11 13.00 14.50 
 
36 12.10 14.70 
12 7.50 10.80 
 
37 12.40 15.10 
13 11.00 12.70 
 
38 13.00 14.70 
14 8.00 11.10 
 
39 10.00 12.40 
15 10.00 11.90 
 
40 13.70 16.10 
16 14.40 15.20 
 
41 11.00 13.20 
17 14.50 15.90 
 
42 10.20 12.70 
18 12.00 15.40 
 
43 8.60 9.20 
19 9.00 11.40 
 
44 13.10 16.20 
20 12.60 14.30 
 
45 9.00 11.50 
21 10.20 12.10 
 
46 9.00 10.60 
22 11.30 12.50 
 
47 11.30 14.80 
23 11.60 13.70 
 
48 13.00 14.20 
24 13.00 15.10 
 
49 13.00 16.50 
25 10.50 11.90 
 
50 7.40 8.00 
 
Software: spss17 version 
Variables: Hb level (gm %) – before treatment, after treatment 
Number of cases: 50 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.847 
Before and after treatment mean difference: 1.97±1.06 (gm%). 
P Value (2 tailed): p<0.01. 
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Inference:  
The p value is significant (p<0.01).  So the treatment was significantly improving 
the Hb level (gm %). 
By knowing the above clinical studies, administrating the Aristolochia indica ilai 
chooranam increases the haemoglobin level in blood and showed promising result in 
anaemia.  
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6. CONCLUSION 
 
The trial drug Echuramooli ilai chooranam (Arishtolochia indica) is selected from 
the classical Siddha text Gunapadam- Mooligai vaguppu( porut panbu nool)-First part 
written by K.S.Murugesa mudhaliyar for the evaluation of safety and efficacy in the 
management of Haematinic action. 
 The trial drug was duly identified and authenticated by the botanist and 
Gunapadam experts. 
Since the trial drug, Echuramooli ilai chooranam is very easy to prepare and the 
drug was prepared according to the classical methods. Then it was purified by pittaviyal 
method. This method helps to vitalize the drug. 
 Though the drug has bitter taste, the hot potency and bio-transformation into 
pungent clearly indicates its activity on red blood cells. 
The presence of ferrous ions indicated that they help in maintaining the hemoglobin 
level. The other components Calcium, Chloride, Sulphate, Reducing sugar, Zinc and 
Magnesium are also responsible for its haematinic property. 
 In order to provide effective, safe and cheap drug and to prove the traditional 
claim for the treatment of anemic conditions the Aristolochia Indica Chooranam at a dose 
of 100, 200 and 400 mg/kg (p.o.), was evaluated and found significantly increased the 
haemoglobin, haematocrit value and RBC count in anaemic rats indicating the haematinic 
effect. The rapid and progressive recovery of anaemic rats responding to treatment of 
Aristolochia indica Chooranam may be due to its erythropoietic activity. However, the 
mechanism of action by which Aristolochia indica Chooranam produced its effect on 
increasing RBC, Hb and PCV in experimental animals need to be evaluated in a scientific 
manner using specific experimental animal models and also multi centre clinical trials are 
required to understand the exact molecular mechanisms of action. Based on the results it 
can be concluded that the Aristolochia Indica Chooranam is a good drug of choice for the 
anaemia at the dose level of 200mg/kg. 
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 The open clinical trial results revealed that 76% of patients were having 
improvement in the clinical futures and biochemical reports. The study validates the 
effectiveness of herb in improving hemoglobin level and also helps for curing certain 
causes like worm infestation etc. 
 
 The drug is easily available and preparation is very simple. The trial medicine is 
cost effective. No adverse effects were produced during the entire course of treatment.  
Conclusively, that the drug “Echuramooli ilai chooranam” (Aristolochia indica) gives a 
new hope in the field of Anaemia treatment.  
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7. SUMMARY 
“Echuramooli ilai chooranam” were collected from Idappadi, Salem district and 
powdered then purified and stored. This drug was subjected for various studies by the 
author. 
Echuramooli ilai chooranam was selected by the author for this study to establish 
the Haematinic activity. 
To collect the information about the drug, various text books, literature were 
referred. From them, the author came to an idea about the drug and its efficacy on 
Anaemia. 
A brief description about botanical aspect of the Echuramooli ilai chooranam and 
its identifying characters and Phyto chemical data were given. 
The wide use of Echuramooli according to Gunapadam aspect as well as in 
various Siddha literatures were discussed with much importance to that of preparation 
related to Paandu noi. 
The Phyto chemical analysis of the drug showed that it contains Iron, Calcium, 
Chloride, Sulphate, Reducing sugar, Zinc and Magnesium. It is related in treatment of 
Anaemia. 
The preclinical study showed that the drug has got safety and significant 
haematinic activity. 
The patients were responding well from the beginning of the treatment and no 
adverse effects were reported. 
The clinical result revealed that 76% of patients were having improvement in the 
clinical futures and biochemical reports. 
This present study confirmed that Echuramooli ilai chooranam has the remarkable 
Haematinic activity and high therapeutically value against the clinical symptom of 
Anaemia.  
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1. INTRODUCTION 
Siddha system of medicine, being the oldest traditional system in the world has a 
strong significance in detoxification, anti-oxidation, immune modulation and metabolic 
balance. It is a carefully guarded medical system given away incredible and rapid 
outcomes in various unremitting ailments. During the period of Siddhars there was not 
even a microscope, but were able to identify,  as many as 3500 herbs, their properties, 
purification process, also administered plant based and mineral-based medicine with 
suitable adjuvant and they documented all these things. The therapeutic effect has been 
proved for thousands of year that were never changed for centuries. Like other medical 
systems based on the foundations of logic and scientific methods, Siddha medicine had 
theoretical foundations as well as deserves to be called a medical science. 
Since, Siddha medicine, based an individualistic medicine, on patients constitution 
and syndrome differentiation that we cannot make use of modern medical system as a 
standard to explain in all levels. Our Siddha medicine  not only pay attention to the 
preventive and curative methods, but also focused on the physical, mental, spiritual and 
psychological well-being thus giving a total perfection in life.  
Ancient India is the creator of sexual education. The sex is considered as a part of 
life. It was wide-open in all kind of arts, like literatures, sculptures etc. An American 
professor Wendy Downier states that, “For Hindus, the phallus in the back ground, the 
archetype of which their own penises are manifestations, is the phallus (called the lingam) 
of the god Siva”. 
The term infertility has traditionally been used to describe the inability to make 
off-spring. For life to continue, an organism must reproduce itself before it dies. A male 
cannot make his off-spring is known as male infertility. 
 A fall in the sperm count in the reproductive years is now a serious global 
problem and public health warning and unfortunately the crisis is equally acute in India. 
According to specialists, the sperm count of a normal adult in India has plunged to around 
20 million per ml, one-third of what it was three decades ago. This trend could be linked 
to diet, lifestyle modification (The Times of India, Health & Fitness, Dec 26, 2012). 
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The World Health Organization‟s guidelines specify the normal, healthy sperm 
count to be 20 million sperm per milliliter in a total semen volume of two ml. This 
indicates that how overtime, sperm counts have gone down across the world. "A decade 
or two ago, 40-50 million was the normal sperm count. However, WHO has changed the 
definition of what's 'normal' and has brought it down to 20 million. Urban-influenced 
lifestyles along with food, water and milk contamination have adversely affected sperm 
health over the years (WHO, 2011). 
Several factors can interfere with the process of spermatogenesis and reduce 
sperm quality and quantity. The alterations in motility, viability and morphology of 
spermatozoa in treated rats are likely the result of adverse effect of the treatment on 
epididymal functions. Inadequate concentration, sluggishly motile or immotile 
spermatozoa could not penetrate the cervical mucus and thus failed to fertilize the ova. 
Some diseases such as coronary heart diseases; diabetes mellitus and chronic liver 
diseases have been reported to cause deleterious effects on spermatogenesis.  
So, there is an urgent need to establish the causes of male infertility so measures 
can be taken to prevent further damage. 
In this present scenario, male infertility can be managed by the use of 
Spermatogenesis activity drug. This can also be viewed as any food, drug, scent or device 
that can increase Sperm quality. 
Research during past two decades has an unfolded focus on male infertility, 
impotence (erectile dysfunction), and pre mature ejaculation. There are a number of 
prescription drugs which may act as increasing sperm count, the use of medicines have 
not shown significant improvement in treating infertility, at the same time there are large 
number of side effects. These include arrhythmias, suicide tendency, mental confusions 
and tremors etc… 
A recent study estimated that 152 million men worldwide experience some degree 
of infertility. In addition, based on population projections, it is likely that the prevalence 
of the condition will more than double over the next 25 years. Today, the development of 
numerous treatments has allowed the social stigma to subside and both the patient and the 
physician some choice in how to manage the condition.  
Successful treatment of infertility may improve not only sexual relationships, but 
also the overall quality of life. This is very important because of the side effect associated 
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with other treatment options and the readily available drugs. The increasing incidence of 
male infertility is necessitating more and rapid search into drugs with spermatogenesis 
potentials with negligible side effects.    
There are many spermatogenic medicines in Siddha which is given for many 
years. Except few, most of the drugs were not yet validated scientifically. Among them 
Anda odu is one of the known Spermatogenesis, mentioned in classical Siddha literature. 
By the literature evidence and the scientific background all parts of the eggs are 
medicinally useful, in that the Anda odu are particularly mentioned for male infertility in 
Anuboga Vaidhiya Navaneedham- Part 3 written by Hakeem Mohammed Abdhulla 
Shahibu. So I have chosen the Anda odu Parpam (Egg shell of Gallus domesticus) in my 
present study for Vindhu kuraivu (Oligospermia). This study is intended to provide 
adequate information on the screening of Anda odu Parpam with sperm enhancing 
potentials since attention is now being focused on the use of Siddha drugs as Indian 
traditional medical practice in the management of this high rising incidence of infertility. 
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2. AIM AND OBJECTIVES 
Aim 
Infertility, Sexual dysfunction and other related problems are eluding scientific 
community and medical practitioners since time memorial. There has been constant 
exploration for newer medicines or herbs to overcome these age-old problems of 
infertility. A variety of plants, herbo-minerals and animal origins have been used as fertile 
drugs in Siddha medicines. There is no scientific evaluation on Anda odu Parpam 
substantiating its usage as sexual stimulant. 
The main aim of this dissertation is to do a scientific review, to validate the safety 
and efficacy of the Anda odu Parpam for Vindhu kuraivu (Oligospermia). 
Objectives 
 Besides the scientific study of Siddha science and medicine also our aim, the 
following methodology was adopted to evaluate the safety and efficacy of the test 
drug. 
 Identification of the Anda odu (Egg shell of  Gallus domesticus) 
 Collection of various Siddha and modern scientific literature 
 Preparation of drug according to the text 
 Physio chemical analysis of Anda odu Parpam  
 Phyto chemicals analysis test drug 
 Evaluation of the toxicity of test drug 
 Evaluation of  Spermatogenesis activity of test drug  
 Evaluation of Spermatogenic activity of test drug in experimental animal 
model 
 Clinical assessment of  Anda odu Parpam on Oligospermia 
 Statistical analysis 
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3. REVIEW OF LITERATURE 
 
3.1. Gunapadam Aspect: 
A) •møh Kk 
(Hen’s Egg Shell) 
120 E£µŒ ŒµUSPÎÀ JßÓõÚ •møh Kk, ]zu©¸zxÁzvÀ ”sn®, 
£Ø£® @£õßÓ ©¸¢xPÍõP öŒ#¯¨£mk, CµŒÁõuz öuõÈ¾US®, ©¸zxÁ 
öuõÈ¾US® ªS¢u £¯øÚ u¸QßÓx.  ]zu ©¸zxÁzvÀ •møh Kk £» 
@|õ#PøÍ }UP £¯ß£mhõ¾®, ]Ó¨£õP Â¢xøÁ AvP›¨£uØS |À» ©¸¢uõP 
APzv¯º uÚx APzv¯º £ßÛ¸ Põsh® 200 ¡¼À SÔ¨¤kQßÓõº. 
@ÁÖ ö£¯ºPÒ  : 
 “•møh²h @£ºuøÚ@¯ ö©õÈ¯U @PÐ 
  •®‰ºzv, ©gŒÒ öÁÒøÍP¸Ä©õS® 
 {møh¯õ[ Pk[Põµ }Ö ©õ@Úõß 
  }ØÖsøh ³ø©¯õ •¸øÍ¯õS® 
 Smøh ¯õg”snzxUS E°¸©õ@Úõß 
  öPõk Ásh® ö©ÊSUS Tºø©¯õ@Úõß 
 Pmøh¯õ® @»õP[PÒ uPº¢x Œõk[ 
  Põµzvß Œzx¸Áõ® •møhuõ@Ú 
 “Fø© ²ÖÁ Ð¯º¢u }ØÖsøhuõß47 
 x©¯ Ásh •ÖÁõÚ •®‰ºzv 
 uõ©¯ ©gŒØ ÓÛöÁÒøÍ ¯õ[P¸ 
 Põ©¯ ÂzøuU SøPPsh Ásn@©” 
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•®‰ºzv             ”snzvØS E°¸©õ@Úõß 
©gŒÒ öÁÒøÍP¸   Ash® 
Pk[Põµ }Ö©õ@Úõß
  
ö©ÊSUS Tºø©¯õ@Úõß
 
}ØÖsøh    @»õP[PÒ 
Fø©     Œõµzvß Œzx¸ 
E¸øÍ    SøP 
Põ©¯Âzøu    bõo¯sh® 
•UP¸Ä    ø©¯sh® 
 
•møh Kk : 
 Ash@Áõk 
 AshSøP 
 Ash@uõÀ 
 ]zusk 
 |¢v› 
 £gŒ ”sk 
•møh & •møh@uõk, öÁsP¸, ©gŒÒP¸ 
 ö£õxÁõP •møh AÀ»x ]ØÓsh® Gß£x @©ØTÔ¯ ‰ßøÓ²® 
SÔ¨¤h¨£kQßÓx. 
•møh ö£õxUSn® : 
 ö£ØÓUP¸ÄUS P¸Áõ#¨ @£uª»õ |Øö£õ¸Íõ# 
 ÁØÓ ©¸¢xU SÓÁõQ¨ & £ØÖ 
 ªÚ©õ ¯ÂÌu Â¸¨£õ °¸USg 
 ]øÚ •møh ¯sh ö©Ýg ^º. 
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 ]øÚ, Ash® GÚ¨£kQßÓ •møh P¸ÄUS P¸Áõ²®, ©¸¢xUS 
@£uª»õ EÓÁõ²®, ö£õ¸¢v¯ CÚ©õ²®, AÂÌuzvß C¸¨¤h©õ²® ^º ö£Ó 
Aø©¢v¸US®. 
£gŒ§u E£µŒ ŒµUS :  
 A¨¦ §u® 
•møh Kk ”zv•øÓPÒ : 
 AÊUPPØÖ® §PØ”sn® @|µõ°mk 
  Aøu¯Í¢x Œmi°mk £õoöµmi 
 ÂÊUP¸zu bõÛ]øÚ £zx@© uõß 
  Âmk } öPõvUPøÁUP ö¯sön# PUS® 
 (AÊUPPØÖ® § & §}Ö, PØ”sn®, bõÛ ]øÚ & @PõÈ•møh) 
PØ”snõ®¦, §}Ö P»¢u P»øÁ°À öPõvUP øÁzx ŒÆÄ }UQU öPõÒÐuÀ
 
A•›}º AÀ»x A¨£ÍPõµzvÀ öPõvUP øÁzx PÊÂ GkzxU öPõÒÐuÀ. 
£øPaŒµUSPÒ : 
 “C¸®¦US Œzx¸ HØÔÚß GßÚ¢v 
 A¸®¤@¯ Ashzvs öÁõk A¨¤µP® 
  
& C¸®¦ •møh KmiØS Œzx¸Áõ®. 
Ash@uõÀ Œzx¸UPÒ &  Põµ®  öÁ[Põµ® 
     Œõµ®  ^Ú® 
     u[P®  @PõÈ•møhöÁsP¸  
PõŸ¯®  |õP® 
     Põ¢u®  öÁsP»® 
     ¤zuøÍ uµõ 
     
x¸”  öÁi²¨¦ 
•møh°À EÒÍ
   
PõµŒµUS & Ash Kk, |õP® 
     ŒõµŒµUS & ©gŒÒ P¸, öP¢v 
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@PõÈ•møh°À |õP®, µŒ®, öP¢v EÒÍx 
 “Kmizu KhxÄ |õP©õa” 
 ²zu©@Ú öÁsP¸uõß‹u©õa” 
 ”mizu ©gŒÒ P¸ öP¢v¯õa” 
 A¨£@Ú Ashzvß ¤ÓÂ uõ@Ú  
@©ØPsh £õh¼À •møh KmiÀ |õP® EÒÍx GÚU TÓ¨£kQÓx. 
C¢|õP® C¯ØøP |õPzøu Âh E¯ºÄøh¯uõS® Gß£øu 
 “Bö©Ú °ßÚ® öŒõÀ¼ AøÓQ@Ó Û¢u ©mk® 
 uõö©Ú Ashz xÒ@Í uÛzu öÁsP¸@Á E¨¦ 
 Áõö©Ú ©gŒÒ ©õºUP® ÁÇ[Q¯ ¦Î@¯ ¯õa” 
 Kö©Ú @©¼@Úõk ÄŒ¢vk® |õP©õ@© 
    
GßÓ £õh¼ß ‰»® AÔ¯»õ®. 
•møh KmiÀ 2 ŒÆÄPÒ EÒÍx 
1. @Põøµ 
2. áÆÄ 
 
”zv öŒ#²®@£õx 2 ŒÆÂøÚ²® }USuÀ @Ásk® 
£gŒ ”sn SøP°À •møh Kk @Œ¸QÓx. 
 “S°Ý©õ® @PõÈ•møh ŒµUSUöPÀ»õ® ”sn©õ®. 
 
@PõÈ •møh ŒµUSPøÍ ”sn©õUS® ußø© Eøh¯x. 
•møh Kk @Œº¢u ©¸¢xPÎÀ ]» 
”sn ©¸¢xPÒ : 
 Ash”sn®   & £Ø£» Âu©õÚ Áõ²UPÒ 
(G¾ªaøŒŒõÖ+Cg]ŒõÖ)  @©P[PÒ w¸® 
 Ash”sn®   & £»@|õ#PÒ wºUS® 
 ]ØÓsh ”sn®  & wµõu @|õ# GÀ»õ® w¸®. 
 ]ØÓsh ”sn®  & Áõ#ÄPÒ w¸®. 
 Ash ”sn®  & £Ø£» öPõi¯@µõP[PÒ 
(|gŒÖ¨£õß)    Ash @|õ# w¸®. 
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 ]ØÓsh ”¯ ”sn®  & Áõ#ÄPÒ w¸®. 
(£õøÁŒõÖ) 
 Ash”sn®(G¸UP®£õÀ) & CµŒÁõu öuõÈÀ öŒ#¯Ä® 
      @|õ# wºUPÄ® EuÄ® 
 uÛ Ash ”sn®  & CµŒÁõu öuõÈÀ öŒ#¯Ä® 
      @|õ# wºUPÄ® EuÄ® 
 PØ§µ Ash”sn®  & CµŒÁõu öuõÈÀ öŒ#¯Ä® 
      @|õ# wºUPÄ® EuÄ® 
 AshS¸ ”sn®  & CµŒÁõu öuõÈÀ öŒ#¯Ä® 
      @|õ# wºUPÄ® EuÄ® 
 Ash”sn®   & ¤zuÁõ²øÁ Sn¨£kzx® 
      AvÂ¯ºøÁø¯ {Özx® 
 Á[P ”sn®   & @©P ‹ø» w¸® 
 öÁÒÎ ”sn®  & £» @|õ#PøÍ wºUS®. 
 
£Ø£ ÁøPPÒ 
 •møh Kmk £Ø£®  & Â¢x SøÓÄ, Azv”µ®, ‰ºaøŒ@£õS® 
 öÁÒÎ£Ø£®   & @©P® @£õS® 
 uõªµ£Ø£®   & @©P®, Sß©® @£õS® 
 u[P£Ø£®   & uõx@ŒõºÄ }US® 
 Ash£Ø£®   & PÀ»øh¨¦, }µøh¨¦,}ºPmk w¸® 
 Á[P uõ®£µ £Ø£®  & @©PFÓÀ,Ck¨¦ Áõu®, 
      ŒºÁõ[P |kUP® w¸® 
 öÁÒÎ£Ø£®   & |µ®¦ uÍºa] }[Q uõx Á¾US® 
 öÁÒÁ[P£Ø£®  & @©Pµn®, øPPõÀ ¤i¨¦, 
      SøhaŒÀ, öÁÒøÍ w¸® 
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 ]ØÓsh PÀ|õº£Ø£®  & }ºPmk, }º G›aŒÀ, öÁÒøÍ, öÁmøh 
      w¸® 
 BÓõuõµ£Ø£®   & }µøh¨¦, PÀ»øh¨¦, }ºPmk, 
      }º G›aŒÀ @£õS® 
 ©Põ uõ®£µ £Ø£®  & @©P® 20, ¤µ@©P® 21, Áõu® 80, 
      ¤zu® 40,]@»zx©® 20 @£õS®. 
 Cµõá uõ®¤µ £Ø£®  & @©P®, ŒP» Euµ @µõP[PÒ @£õUS® 
 P¸Á[P £Ø£®   & }›ÈÄUS ]Ó¢ux 
 uõªµ £Ø£®   & @©P® 20, ¤µ@©P® 21, ©Põ £¯[Pµ©õÚ 
      @µõP[PÒ w¸®. 
 
B)G¾ªaøŒ 
@ÁÖö£¯ºPÒ : 
 Œ®¥µ® 
 @u]¨£Ç® 
£¯ß£k® EÖ¨¦ :   
 
       Cø», Põ#, £Ç®, £ÇµŒ®, Gsön# 
”øÁ : 
         Cø» : ¦Î¨¦ 
         ußø© : öÁ¨£® 
         ¤›Ä : Põº¨¦ 
öŒ#øP: 
             SÎºa]²shõUQ 
Põ#, £Ç® : 
            ”øÁ   :  ¦Î¨¦ 
 ußø© :  öÁ¨£® 
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 ¤›Ä  :  Põº¨¦ 
 öŒ#øP  :   SÎºa]²shõUQ 
  £Ç® :  
ö£õxSn® : 
         “uõP® Su@|õ# uõÇõa ]¼£u@|õ# 
 @ÁP[öPõÒ Eß©õu® ÃÖ¤zu® & ©õ PsÚõ# 
 Ps@nõ# Áõ¢v²®@£õ[ PmkÁõ vzöuõÈ¼À 
 ©ßöÚ¾ªa Œ[PÛø¯ ÁõÌzx” 
uõP®, Su@|õ#, ]¼£u®, Eß©õu®, ¤zu®, Ps@nõ#, Áõ¢v, 
Á°ØÖ¨@£õUS. 
      ŒP» @©P@µõP[PÐUS® ö|# : 
AÍÄ  :        2 @uõ»õ, 2 @ÁøÍ 
w¸® @|õ# :  ¤µª¯®, u¢v¤µª¯®, øP PõÀ G›Ä 
      P¸Á[P £Ø£®: 
G¾ªaøŒ ŒõÖ, P¸Á[P® 
AÍÄ  :  1 £nöÁøh,  2 @ÁøÍ 
AÝ£õÚ® :      @uß 
         10 |õÒ Á°ØÖ Á¼ w¸®. 
                           Av©xµ®, •ÒÍ[QŒõÖ, £Ø£® & 21 Âu @©P® w¸®. 
     
   ö£õx•øÓ :  
    öÁÒÍõmk¨£õÀ, G¾ªaøŒŒõÖ, ©õ®£møh ŒõÖ 
         1.  {øÓ 3 |õÒ 
 2. G¾ªaŒ® ŒõÖ,  D¸ÒÎaŒõÖ, £Ú[P¸¨¦UPmi, 1 {øÓ 
  CµÂÀ £Û°À øÁzxU Põø»°À 3 |õÒ Œõ¨¤hz w¸® 
¤µ@©P®, ”µ¨¤µ@©P® w¸®. 
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1. G¾ªaøŒ Gsön# :  
2. |Àö»sön# 
3. G¾ªaøŒŒõÖ Œ© AÍÄ 
AÍÄ  :  1&2 @uUPµsi 
AÝ£õÚ®     :  }µõPõµ® 
w¸® @|õ#    : öÁÒøÍ 
‹k, Pk¨¦ wµ HÓsh Gsön# 
 B©nUöPsön# 
 @u[Põ# £õÀ 
 G¾ªaŒ® £ÇaŒõÖ 
 öÁ[Põ¯a ŒõÖ 
 Cµsk @ÁøÍ 
ö|À¼ P¢uP® 
£”®£õÀ 
G¾ªaøŒ£ÇaŒõÖ 
PØ”snöuÎ}º 
PØÓõøÇaŒõÖ Œ© AÍÄ ¤µ@©P® w¸® 
G¾ªaøŒ @»Q¯® & ¤zu® w¸® 
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3.2 Modern Aspect 
A) •møh Kk 
Zoological Aspect 
Egg Shell (Or) Ovi Testa of Gallus Domesticus 
Economy of Gallus Domesticus
 
Gallus domesticus is a domestic cock and hen. Taxonomy followed Howard & 
Moure (1994) species name updated according to peters and sciccessors (1931-1987) 
Kingdom  : Animal kingdom 
Class   : Aves 
Order   : Galliformis 
Family   : Phasianidae 
Genus   : Gallus 
Species  : Domesticus 
Synonyms  :  Gallus & Gallus  
    Gallus Gallus domesticus 
Vernacular Names:
   
English  : Egg 
Sanskrit  : Anda 
Hindi   : Anda 
Bengali  : Anta 
Tamil   : Muttai 
Canada  : Mottey 
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Maharashtra  : Ande 
Telugu   : Gadda 
Malayalam  : Mutta 
 
Structure:
 
 
Egg consists of a shell, membrane, white and yolk. Hen and duck egg of average 
size are made up of, 
Albumin : 57% 
Yolk  : 32% 
Shell  : 11% 
The shell of an egg has a rigid yet porous structure and is composed mainly of 
organic salts (Chiefly calcium carbonate). It has great resistance to the entry of 
microorganism. The surface of egg shell is covered by a thin cuticle. 
Inside the shells are two tough and fibrous membranes are present. One attached 
to the shell and the other to the thick white at the small end of the egg. 
Egg Shell Layers
 
There are several layers in egg shell each with a different function. Different egg 
shells are made from slightly different materials. A chicken egg is much more rigid than 
other eggs. 
5 layers morphologically differentiated from the inner to outer layer are, in consecutive 
order. 
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Inner egg membrane (innermost) 
 
Outer egg membrane 
 
The mammillae 
 
Matrix 
 
Finally cuticle (Outer most) 
 The porous white finally surrounds the calcined egg shell on the outside the CO3 
ion as well as calcium is equal significance in the calcification process of egg 
shell. 
 Surrounding the egg white was two shell membranes each composed of a network 
of fibres. Outer membrane consists of 3 layers. Outer must keratin fibres & 2 
mucin fibres & inner membrane consist of keratin & mucinfibres. 
 The cuticle to be mainly mucin the presence of protein containing many 
disulphide links and free sulphydryl groups and some evidence for the presence of 
phospholipids was shown by Simkiss (1958). 
 
Chemical Constituents:
 
The shell of egg consists of predominately of calcium carbonate-96%. It has 
following composition. 
Ca  –  38% 
Mg  –  0.6%  
CO3  –  55% 
Protein –  1.5% & Reminder with water, trace minerals. 
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 Carbonate of lime  
 Phosphate of lime  
 Trace amount of Sulphur  
 Iron  
 Some Organic matters 
 Salts like Chlorides, Iodides, Sulphates and Phosphate of  K, Mg, Ca  
 CaCo3 – 88- 97%  
 Ca and Mg, Phosphate (0.5 to 5%)  
 MgCo3 – (0.2%) 
 
 
 Organic substance – 2 – 5%  
Action & Uses:  
 Useful in Oligospermia 
 The carbonate of calcium renders the shell absorbent and antacid  
 Shell sometimes used as antacid  
 Bhasma of the shell is antacid and styptic, useful in diabetes, stops excessive 
urination and strengthen the kidney.  
 
Egg Shell Proteins  
 
Protein contain egg shell membrane and it contains several bactericidal enzymes 
and other membrane component, which may alter the thermal resistance of gram +ve, 
gram –ve bacterial pathogens in the thermal resistance of microorganisms might lead to 
the use of more moderate process. 
 
Egg Shell Collagen 
 
Egg Shell membrane comprises about 10% collagen, it is used in the bio-medical 
field, research to produce skin and tissue replacement Egg shell collagen economical 
acceptable than bovine collagen and protected from allergy of bovine collagen. 
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Egg Shell Minerals  
 
 It is considered as a good source of highly bio available calcium. 
 Also contains significant quantities of strontium, which increases bone 
density in humans. 
 A lower level of lead, aluminium, cadmium and mercury that normally occurs 
in egg shell may be advantage of egg shell powder over other natural calcium 
sources. 
 Calcium – used as an oral phosphate binder. Patient suffering from renal 
failure often require oral phosphate binder to supplement other treatments to 
prevent hyper phosphatemia  
 Egg shell calcium was shown to be more efficient as an oral phosphate binder 
than calcium carbonate. 
Egg Shell Carbohydrates  
Glycosaminoglycons, have a wide range of applications in the pharmaceutical, 
cosmetics and food industries, including moisturizers in cosmetics treatment of 
osteoarthritis and as an emulsifying agent in mayonnaise and dressings. 
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B) G¾ªaøŒ 
Lemon 
(Citrus Limon) 
Scientific classification:
  
Kingdom        : Plantae 
Division         : Magnoliophyta 
Class              : Magnoliopsida 
Subclass         : Rosidae 
Order             : Sapindales 
Family           : Rutaceae 
Genus             : Citrus limon 
Binomial name : Citrus limon 
Other names: 
English : Lime 
Malayalam : Cheru-Naranga 
Hindi  : Ninbu Limu 
Telugu  : Nimma 
Kannada : Nimbe 
Sanskrit : Jambira 
 
Plant description: 
1. Grow up to 10mt but usually smaller. 
2. Leaves are green shining and elliptical acuminate 
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3. Flowers are white violet streaked interior with strong fragrance. 
4. On a Lemon tree, flowers and ripe fruits can be found at the same time. 
Fruits raw without peel: 
Nutritional value per 100gm 
Energy  :  30 Kilo Calories (120KJ) 
Carbohydrates :  9 g 
Sugars  :  2.5 g 
Dietary fibers :  2.8 g 
Fat  :  0.3 g 
Protein  :  1.1 g 
Water  :  89 g 
Vitamin C :  53 mg (88%) 
Citric acid :  5 g 
pH  :  2-3 
Medicinal uses of lemon: 
Lemon has been used for centuries for its protective and therapeutic qualities. 
Fresh lemon juice squeezed into water is often promoted to aid fertility health – plus it's 
refreshing. 
A very common and easy to find fruit.Lemons are packed full of vitamin C which 
is an important antioxidant. They also contain the B vitamins, potassium, calcium, iron, 
magnesium, bioflavonoids, and phytochemicals, among other beneficial nutrients for 
spermatogenesis. 
Antioxidants in lemon help protect our cells from free radical damage. This is 
important for the health of sperm cells and the female ovum (egg cell) including the DNA 
within. 
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The high vitamin C content in lemon juice helps ward off and relieve the 
symptoms of infections such as colds, sore throats, and influenza. Sickness if bad enough 
can upset the body's natural rhythms, including ovulation or sperm production. In fact a 
bout of flu/fever can lower a man‟s sperm count for up to three - four months after the 
ailment has passed! 
Getting adequate amounts of vitamin C through lemon juice and other foods in 
diet may improve male fertility. A study published in the July 2011 issue of 
"Reproductive Biology and Endocrinology" investigated the effect of vitamin C on 
hyperglycemic rats and found it decreased the amount of abnormal sperm and boosted 
testosterone levels, both of which may contribute to male infertility.  
Consume a serving of lemon juice have 3 percent of the thiamin for each day. This 
thiamin may contribute to a protective effect when it comes to testicular injury. Research 
featured in the February 2009 "Journal of Huazhong University of Science and 
Technology" indicates that thiamin consumption -- in conjunction with vitamin C -- 
benefits sperm count and motility in male rats with impaired fertility triggered by lead 
exposure. 
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C) Ghee 
Ghee is a class of clarified butter. It is composed almost entirely saturated fat. 
Ghee is rich with antioxidants and acts an aid in the absorbtion of vitamins and 
minerals from other foods, serving ti strengthen the immune system. 
Ghee is a an oil that offers important nutritive benefits, even for lacto-vegetarian 
diets, helping cell membranes maintain a low state of oxidation by replacing oxidized 
fats. 
 
Calories and Fat 
Ghee contains 112 calories per tbsp. and 33 mg of cholesterol. The total fat 
content is 12.7 g, of which almost 8 g are saturated fat, 3.7 g monounsaturated fat and .5 g 
polyunsaturated fat. Ghee provides many essential fatty acids, such as omega-3 and 
omega-6 that provide anti-oxidant  properties, regulate DNA production and assist with 
cellular communication. 
Nutrition 
The protein content of ghee is .04 g per tbsp., which includes 17 amino acids, 
essential for good health. Ghee contains 3 percent linoleic acid, an antioxidant. Ghee 
provides 393 IU of vitamin A per tbsp., including 105 mcg of retinal and 25 mcg of beta-
carotene. Other vitamins include .36 mg vitamin E per tbsp., 1.1 mcg of vitamin K, and 
small amounts of riboflavin and pantothenic acid. Minerals in ghee include 1 mg of 
calcium and potassium per tbsp. 
 
Health Benefits 
Ghee is a good choice for the lactose intolerant because all the milk proteins are 
removed during the clarifying process, making it lactose free. Although ghee contains a 
high amount of fat -- about 65 percent saturated, 25 percent monounsaturated and about 5 
percent polyunsaturated -- fats are essential to life and are needed to assimilate vitamins 
A, D, E and K, and help nourish the skin, hair,cell membranes and help to increase the 
sperm production.Fats promote a healthy body temperature, help nourish and protect 
internal organs and the brain and store energy.  
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3.3 Siddha Aspects of the disease (Vindhu kuraivu) 
Evolution Theory 
 £µõ£µ ©õQ¯ £µ@©ìÁµß 
 uµõuõ® £øhUPz uõÛøÚ¢ u¸Î 
-Jeevorpathi Chintamani(A compendium of Siddha Doctreine) Pg.42. 
According to the work Jeevorpathi Chintamani the paraparam (the God Supreme) 
the Sivam emerges from Para, the Sakthi from Siva, then Nandha from Sakthi, the Vindhu 
from Nandha, the Sadasivam from Vindhu the Maheswara from Sadasiva, the Rudra 
from Maheswara, the Vishnu from Rudra, the Brahma from Vishnu, then the Akash 
(Space) comes out from Brahma, Vayu (Air) from Akash, Agni (Fire) from Vayu, Appu 
(Water) from Agni, then Prithivi (Earth) from Appu, then the Food (Annam) emerges 
from Prithivi then the Food gives rise to Sangama objects like Human, Animal, Birds 
And Vegetation. 
Athuva tathuvam: 
From the Food, Saaram (Chyle) is produced, from Saaram Senneer (Blood) is 
formed, from that Oon (Muscle), Kozhuppu (Fat), Enbu (Bone), Moolai (Bone marrow), 
Sukkilam (or) Suronitham [Semen (or) Ovum] are formed in that order. The fusion of 
these sukkila and Suronitha constitutes the human body. 
Â¢x (Semen) 
 
 Cµu •u»õÚ HÌ uõx ‰ßÔß 
 E›¯ vÚzvß J¸ ¦Ø £Û @£õÀ 
 A›¯ xÎ Â¢x ÁõS @©Ì ‰ßÔß 
 ©¸Â¯ Â¢x ÁÍ¸[Põ ¯zv@» 
&v¸©¢vµ®&1897 
Cµu©õQ¯ Œõµ® •u»õP öŒõÀ»¨£k® HÊ •uØ ö£õ¸ÒPÍõÀ 
BUP¨£mhvÆ ÄhÀ CÆ@ÁÊ EhØPmkPÐÒ Œõµ®, öŒ¢}º, öÁspº BQ¯ 
‰ßÖ® Jº |õÒ J¸ ¦Ø£Û@£õÀ vµÐ®. 
 
Czvµm]@¯ Â¢x GÚ¨£k®. CÆ Â¢x HÌ ‰ßÓõQ¯ C¸£zv JßÖ 
|õmPÒ Áøµ ÁÍ¸® GÚ v¸‰»º TÖQßÓõº. 
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 “AÈQßÓ Â¢x AÍøÁ¯Ô¯õº 
 ”ÈQßÓ ußøÚ²m PõUP¾¢ @uµõº 
 AÈQßÓ Põ¯z uª¢u¯º ÄØ@Óõº 
 AÈQßÓ ußø© ¯Ô¢ öuõÈ¯õ@µ” 
&v¸©¢vµ®&1899 
As per the Thirumoolar Thirumandiram it has been described that 6400 drops of 
Blood Cells make one drop of Vindhu (Example: 80 drops of red cell make one drop of 
white corpuscle and 80 drops of white corpuscle make one drop of vindhu) 
Thus 80 x 80 = 6400 drops of blood cells makes one drop of vindhu. 
If extensive loss of vindhu occurs in one human body naturally it will reflect on 
blood cells. 
 
Siddhar Therayar: also mentioned about the importance of vindhu 
  
 “öÁÀ¾® ¦Â°À ÂÍ[Q¯ uõ£µ® 
 ¦À¼kg Œ[P©® ö£õÔ°k® Â¢@u 
 Â¢vÚõ»À@µõ @©vÛ ¯õa”x 
 öŒ¢xUPöÍg»õºg ]Á©¯©õa”x (@©vÛ& E»P®) 
 Á¢vk® |õu® ö©ÍÚ® P»¢vx 
 ]¢øu°¾ÒÍz öuÎÁõPa öŒ¨¦@©” 
 
&@|õ# |õhÀ @|õ# •uÚõhÀ vµmk 1 &£UP® 94, 
 
 Â¢xÂÚõÀuõß E»P® (@©vÛ) Eshõa” GßÖ ]zuº @uøµ¯º TÖQÓõº. 
 
Agathiyar Vaidya Valladhi -600: 
 “Bsø©ö¯ßÖ ©[øP¯ºPÒ §US[Põ»® 
 AßÖ •uÀ £vÚõ¾ |õÐ® A¢uz  
 uõßø©¯ßÔ¨ £vÚõÖ Cu©õ# {ßÓ 
 uõ©øµ@£õÀ ©»º¢v¸USg ŒõØÓU @PÐ 
 Põsø©¯ßÔ vÚö©õßÖ CuÌ uõöÚßÖ 
 P¸ÁõÚ P¸USÈuõß C¢ |õmkUSÒ@Í 
 £õßø©ö¯ßÓ Â¢u[@P ³Ö®@£õx 
 £õ²©¨£õ  ÁßÛ@¯õk Áõ²uõ@Ú !  
&]zu ©¸zxÁõ[P ”¸UP® & £UP® 36. 
 According to Agathiyar Vaidya Valladi – 600 – The vindhu (Semen) is chiefly 
constituted by the Fire (Vanni) and Air (Vayu) elements. 
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Siddhar Kaya Karpam-300: 
  
 “@¯õQ²® bõÛ²® Ezu© ]zuÝ® 
 @¯õQ²® bõÚ ¦µ¢uµ Úõ@ÁõÝ® 
 @©õP •ÔÝ •øµ¯ªº xs@£õÝ® 
 BQ¯ Â¢x AÈ¯õu Asn@» 
 JÈ¯õu Â¢xÄhß {ØS® 
 AÈ¯õ¨ ¤µõnß Bv £»g Œzv 
 JÈ¯õu ¦zv u£göŒ£ @©õÚ® 
 AÈ¯õ ]zv²shõ® Â¢x ÁØÔ@»”  
 &]zuº Põ¯ PØ£® 300&£UP® 8&9 
 
In this poem Siddhars emphasized the need to control, the vindhu through siva 
bhogam, for a healthy and long life. Thirumoolar, Therayar and Agathiyar, Bhogar 
recommended the Kayakarpam  theraphy to rejuvenate vindhu. 
 
Saint Yoogi said: 
 •øÚ¯ÖS ~Û£Û@£õÀ Œ@µõouzvÀ @Œº¢x 
 uõUP@Á ”@µõou¢ vµsk uß¹£©õQz 
 u©ºÁõŒÀ uøÚ‰k® Áõ² uõÝ® 
 
The Semen and Ovum are like dew on the sharp tip of a grass. (•øÚ¯ÖS 
~Û£Û@£õÀ) which means the Semen and Ovum merges and that the Sperms in the 
Semen moves in almost swiftness and the Spermatozoa enters by penetrating the wall of 
the Ovum and merges with in it.  
 
 “@ÁºUP@Á @Á¼@£õÀ ÁøÍ¢x PõUS® 
 Â¢xÄhß ¤µõnÁõ² ÂÍUP »õ@©” 
&]zu ©¸zxÁõ[P ”¸UP® & £UP®&3.9 
According to Saint Yoogi, just as the Fence guards the garden the air surrounds 
the zygote and guards and prevents other sperms entering it. 
According to Thiruvalluvanayanar  Gnanavettiyan – 1500 
 Thiruvalluva  Nayanar clearly explained that the hormonal influence and Brain 
stem is charactgerized with the following features. 
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 “Â¢x Si°¸¢u v¸|õmøh Âm@hß 
 ©õÖQßÓ Pzu›U@PõÀ £mh¢ußÛÀ 
 Â¢x {ßÖ ÂÍ[S |v ø©¯zxÒ@Í 
 ÂÍ[S ”ÁõvèhõÚ öÁÎ°@»uõß” 
 
In this poem we may understand that; 
 Spermatogenesis is stimulated by commands from the cerebral cortex. 
Decussating of the fibers in the brain stem explains this. Spermatogenesis is controlled by 
pituitary gland and Hypothalamus. 
 
Thiruvalluva Nayanar – Navarathina Chinthamani – 800 
 
 v¸ÁÒÐÁ |õ¯Úõº u¢øu Â¢vÚõÀ ¤Ó¨¦ EshõQÓx Gß£øu RÌ Á¸® 
£õhÀ ‰»® öŒõÀQÓõº. 
  
 u¢øu Â¢uv Œõµzv»µÁ©õ ²vzx 
 I¢x §u© uõP Ä¨£x ÄÁº £hº¢x 
 Â¢x @©»¤ Á¸uÀøu ©õ] £[SÛ²® 
 Â¢x Áõ¾vz v»Q¯ |õu •ªx@Á 
 
&v¸ÁÒÐÁ |õ¯Úõº |ÁµzvÚ øÁzv¯ ]¢uõ©o& 800 £UP® &3 
 
 
 u¢øu°ß Â¢xÂß ŒõµzvÚõÀ E°ºPÒ E¸ÁõQ E°º 5 §u[PÎÚõÀ 
ÁÍº¢x Á¸® GÚÄ®, SÇ¢øu øu ©õuzvÀ ¤ÓUP Â¢xÁõÚx ©õ], £[SÛ°À 
|õu•hß @Œµ @Ásk® GÚ v¸ÁÒÐÁº |õ¯Úõº |ÁµzvÚ ]¢uõ©o & 800 °À 
TÖQÓõº. 
  
“¤ßÝ©õ® ”UQ»zvØ ¤µõnÁõ² uõß öŒßÖ 
 ¤ßÝ©õ® Cµzu® ‹Ì¢x EuõÚÁõ² ÁÍºUS®” 
 &uß Á¢v› |õi& ]zu ©¸zxÁõ[P ”¸UP®& £UP®&39 
 
C¢v›¯¨ £›møŒ 
 “I¯©øÍ £õÀ @©õº@u Úõa]¯[PÒ P®ª øÁø¯  
 ø¯¯©øÍ ¯õuÔ¢x öPõÒÐÁõ& ø¯¯©øÍ  
 ²zu ©zøu •ß@Ú Sn›¢v›  ¯¨£›møŒ 
 ²zu©zøu¡»uøµ @¯õº 
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 uspøµ¨ @£õ¼¸¨¤ß Œõµ® •u¼¯ 
 EhÀ uõxUPÎ¾® ŒØÖ® Œõµ©ØÓÁöÚßÖ® 
 E°¸hß C¸¢uõ¾®, ¤nzxUS J¨£õÚÁß 
 GßÖ® EnµUPhÁõ# 
&@uøµ¯º ¯©P öÁs£õ& £UP® &65 £õP®&1 
 
 C¢v›¯¨ £›møŒ Auß £USÁ©õÚ {ø»ø¯, B²Ò@Áu ö©ßQÓ ÁõPh 
Œõzvµ¨£i@¯ TÓ @Ásk® GßÖ TÖQÓõº. 
 
”UQ»zußø© 
¤o¯õÍÛß ”UQ»® 
  
 öÁsø©²® öÁsønUS {Pµõ²ª¸¨¤ß 
 Ezu@©õzu©ö©ßÖ® 
 
 öÁsø©²® u°¸US {Pµõ²ª¸¨¤ß 
 Ezu©zvÀ Cµshõ® uµ Ezu©ö©ßÖ® 
 
 öÁsø©²® £õ¾US J¨£õPÄª¸¨¤ß 
 ©zv @©õzu© ö©ßÖ® 
 
 @uøÚ²® Auß {Ózøu²®  PÚzøu²® 
 Jzv¸¢uõÀ Au© ©zv©ö©ßÖ® 
 
ö|#ø¯²® Auß {Ózøu²® PÚzøu²® 
Jzv¸¢uõÀ Au© ©zv©ö©ßÖ® 
 
PÒøÍ¨ @£õßÓ {Ó•® ui¨¦ª¸¨¤ß 
Au©õu @©õzu©® GßÖ® 
 
& @|õ# |õhÀ @|õ# •uÚõhÀ vµmk &1&£UP® &197 
uspøµ¨ @£õ¼¸¨¤ß Œõµ® •u¼¯ EhØuõxUPÎ¾® ŒØÖ® Œõµ©ØÓøÁ 
GßÖ®, E°¸hÛ¸¢uõ¾® ¤nzxUS J¨£õÚÁöÚßÖ® GÚ @uøµ¯º TÖQÓõº. 
 
1. It is good if semen is white and resembles like butter or curd. 
2. If it is thin like honey and ghee in its colour and densities, it is not considered as 
good quality semen. 
3. It is suppose to be worst if the semen resembles like toddy or water in its colour. 
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 The disease “Aan Maladu” (Male Infertility) is well described in Yoogi Vaidya 
Chindamani as  
 
 “£õºUP@Á Bs©PÛß Â¢x uõÝ®  
  £u©õÚ vzv¨¦°À»õu uõ¾® 
 GØP@Á Œ»ªvÀ ªu¢uuõ¾® 
  GÈ»õP E°º¨£ØÖ C¸¨£uõ¾® 
 @ŒºUP@Á ‰zvµzvÀ ~øµuõß @£õ¾® 
  öŒ¯»õÚ P¸ÁxÄ® u›UP ©õmhõ 
 wºUP@Á ³Q •Û ]QaŒõŒõµ® 
  öuÎÁõP £õi øÁzuõº vÓªuõ@Ú” 
& ©PÎº ©¸zxÁ®& £UP® &45 
The characteristics of “Aan maladu” (Male infertility) as for as the Semen is 
concerned are  
1) Lack  of Sweetness 
2) lacking of motility of the semen 
3) lack of virility and frothy micturition 
4) buoyancy on water  
BsPÎß Â¢xøÁ }›¼hªu¢uõ¾®, CÛ¨¦ ”øÁ°À»õ©À C¸¢uõ¾®, 
E°º¤À»õ©À C¸¢uõ¾®, ¦nºa]²›Ý® P¸zu›UPõ©À C¸UQßÓ  
SÔSn[PøÍ öPõsh öŒ#øPUS Bs©»k GßÖ ³Q•ÛÁº öuÎÁõP 
TÔ²ÒÍõº. 
                                       -   -- -APzv¯º øÁzv¯ ]¢uõ©o öÁs£õ & 4000 
”UQ» Áõu®: 
 “Áõ² Áõu® PõØÔÛøh Á¢uõÀ AÁ¯[PÒ 
 £õ²[PõÀ Á¼US® £sqSn®& Põ¯zvß 
 ”UQ»U Põ»¢vµzvØ xßÝ x›uªßÚ® 
 ¦UQ {Óz uõx öPmk¨@£õ®” 
 
& APzv¯º øÁzv¯ ]¢uõ©o öÁs£õ& 4000 & £UP® &60&£õP®&1  
 
 ¤ß Ck¨¤À PÀø» Pmi¯x @£õßÓ £õµ® EshõQ Ck¨¦ Á¼US®. 
EhÀ Á¼ ,@ŒõºÄ  EshõS®. 
 
 ”UQ»® ÂøµÂÀ öÁÎ¯õuÀ,  uõx öPhÀ @£õßÓ SÔSn[PÒ ”UQ» 
ÁõuzvÀ Á¸®. Bs©»k uõx öPhÀ & BÀ Á¸® GÚ APzv¯º øÁzv¯ 
]¢uõ©o öÁs£õ ¡À TÖQÓx. 
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”UQ» ]@»zx©®: 
 “@©ß ‰a” @|õÂ¸©À ö©# ‹®£À Ps@¯õuÀ 
  DÚz öuõÛ²® ^µn©õ® & @©ß PÊzx 
 ”mQzx ©õº¦ @|µ® ^öµ›aŒÀ uõP•©õ® 
  ”UQ» ]@»zx© ö©Úa öŒõÀ” 
&APzv¯º øÁzv¯ ]¢uõ©o öÁs£õ& 4000 £UP® & 76& £õP®&1 
  
£vÚõUS @ÁP[PÎÀ JßÓõÚ ”UQ»zøu AhUQÚõÀ EshõS® @|õ#PÒ:  
 “”UQ»¢ uøÚ¯hUQß 
  ”µ•hÜºU PmhõS® 
 £UP©õ[ øP PõÀ Œ¢x 
  £õµ@|õ# ÁÈ°Ó[S® 
 ªUP ©õº @|õ²shõS® 
  ªS¢vk® ¤µ@©P¢uõß 
 uUP@uõº @£õx©õQß 
  u›zvk® Áõ²U T@Ó” 
&EhÀ uzxÁ®& £UP® &337 
If semen is controlled by man against nature, it may lead to fever, oliguria, joint 
pain, urinary infection, spermatorrhoea, leucorrhoea and chest pain. 
 
v¸‰»º v¸©¢vµ®: 
 “£õ#¢u ¤ß Ag@ŒõiÀ B²Ð® ¡ÓõS® 
 £õ#¢u ¤ß |õ@µõiÀ £õ›ÛÀ Gs£uõ® 
 £õ#¢vk® Áõ²® £SzuÔ¢ vÆÁøP  
 £õ#¢vk® @¯õQUS® £õ#aŒ¾©õ@©” 
&v¸©¢vµ®& 463 £UP® & 290, £õP® &2. 
 Bohª¸¢x öÁÎ¨£k® Â¢x I¢x ÂµØQøh £õ#¢@uõiÀ ¤ÓUS® 
SÇ¢øuUS B²Ò ¡Ö.  |õ¾ÂµØQøh £õ#¢@uõiÚõÀ B²Ò Gs£x. CÆÁõÖ 
”UQ»® ÂÊ® @ÁPzvØS uS¢uÁõÖ ]”Âß B²Ò {ºn¯® öŒ#¯¨£kQÓx GÚ 
Â¢xÂß •UQ¯zxÁzøu v¸‰»º TÖQÓõº. 
  
uõÌÄ ©Ú¨£õßø©¯õÀ ©»hÚõÁx £ØÔ v¸‰»º, 
 
 BsªQÀ BnõS® ö£sªQÀ ö£snõS® 
  §Ûµs öhõzx¨ ö£õ¸¢vÀ A¼¯õS¢ 
 uõsªS ©õQÀ uµo •ÊuõÐ®  
  £õnÁ ªUQiÀ £õ#¢ux® CÀø»@¯ 
& v¸©¢vµ® & 462, £UP® 290, £õP® &2. 
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Boß ŒUv ªS¢v¸¢uõÀ Bs SÇ¢øu ¤ÓUS®. ö£soß ŒUv 
ªS¢v¸¢uõÀ ö£s SÇ¢øu ¤ÓUS®. Cµsk® Œ©©õP  Jß@Óõk JßÖ @£õmi 
@£õmk AÈUP •Ø£k® {ø»°À ¤ÓUS®  SÇ¢øu A¼¯õS®. 
 
 P»Â°ß@£õx Boß ŒUv }izx {ßÓõÀ ¤ÓUS® SÇ¢øu E»øP@¯ 
BÍUTi¯ BØÓÀ EÒÍÁÚõP C¸¨£õß. 
Bs uõÌÄ ©Ú¨£õßø© HØ£mk xÁsk @£õÁõÚõÚõÀ ”UQ»® 
öÁÎ¨£kÁx® {ßÖÂk® GÚ v¸‰»º TÖQÓõº. 
 
APzv¯º øÁ‹› ¡¼À & APzv¯º 
 “AÔ¢u ¤ß CÁºPÐh Sn¢uõÚ¨£õ 
 A¢u¢u ŒŸµzvØ PkUu Áõµõ# 
 öu›¢u öuõ¸ SnUSÔPÒ @uõßÖ©¨£õ 
 vÓ©õÚ P¸®¤ÛøŒ Â¢øuU öPõÀ¾® 
 ¤›¢uöuõ¸ öPº¨£zøu ¯È¯¨ £sq® 
 £s£õP ¯ÁºPÐUS¨ ¤ÒøÍ°Àø» 
 •›¢u öuõ¸°ÁºPÐh Sn•g öŒõß@Úß 
 •øÓø©²hß ©¸¢x ÁøP öŒõÀ»U @P@Í”  
 
&@|õ# |õhÀ @|õ# •uÚõhÀ vµmk II £UP®&66. 
  
 APzv¯º uÚx APzv¯º øÁ‹› GßÓ ¡¼À P¸®£oøŒ A®ø© @|õ# 
£õvzuÁºPÒ BsPÍõP C¸¢uõÀ Â¢x AÈ²® GÚÄ®, ö£sPÐUS  Pº¨£•® 
AÈ²® GÚÄ® C¢@|õ°À Á¸¢v¯ÁºPÒ ö£¸®£õ¾® ©»hõP@Á C¸¨£õºPÒ GÚ 
TÖQÓõº. 
 
 A®ø© @|õ°À CßöÚõ¸ ÁøP¯õÚ ¦mhõ»®ø© (Mumps) @|õ# 
£õvzuÁºPÐ® ö£¸®£õ¾® ©»hõP C¸¨£õºPÒ GÚ ]zu ©¸zxÁ® TÖQÓx. 
 
T.V. Œõ®£]Á®¤ÒøÍ AÁºPÎß TØÖ 
Bs ©»k:  
  
 Bs ¤ÒøÍUS C¯ØøP¯õP@Á Aø©¢u ©»mkzußø©, CuÚõÀ 
AÁºPÎß Â¢x vzv¨¦  CÀ»õ©À usp›À ÂmhõÀ Pøµ¢x ªu¨£x®, 
E°º¨£ØÓx®, ‰zvµzvÀ  ~øµ PmkÁx©õP C¸US®. CÆÂ¢xÂÚõÀ  
ö£sPÐUS J¸ Põ¾® P¸¨£¢u›UP ©õmhõx. 
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 Want of fertility of fecundation in a man‟s Semen. The semen in such cases will 
be devoid of sweetness, immotile and will float on the surface of water and the urine also 
will be frothy. Such man will be in capable to impregnate women. 
 
 
The variations of the Sukkilam – physical constituents 
 Sukkilam  excess: 
Excess sukkilam causes love and lust towards women and also urinary calculi. 
 
Sukkilam decreased: 
 Decreased sukkilam causes failure in reproduction, pain in the genitalia etc. 
 
Diagnosis (¤o-¯ -Ô-•-øÓø©): 
 
 Diagnostic methods in Siddha medicine are very unique and are mainly based on 
the clinical aspect.  
 £¼ -¨£-uØS Â¯õ-v-²Ò@Íõº @uPU TÖ® 
  £¸z-u-Ä-hÀ ö©¼¢-u-Ä-hÀ @|õ-°ß TÖ® 
 Œ¼ -¨¤À-»õ ©»U-T-Ö® Œ»z-vß TÖ® 
  Œõz-v-¯ ® AŒõz-v-¯ -•® uz-x-ÁU TÖ® 
 Á¼ -¨¤À-»õz uõx {z-v-øµ-°ß TÖ® 
  ©[-øP-¯ º-PÒ BøŒ -°ß @©À ©¯UP TÖ® 
 £¼ -¨¤À-»õU Pß-©-ußø© |õm-hU TÖ® 
  £õºz-u-Ô¢u ¤Ó-S £õº ©¸¢-vß T@Ó! 
                         ]zu ©¸z-x-Áõ-[P ”¸U-P® 
.£U.309. 
 
 According to this the constitution of body types of disease, examination of stools 
and urine, whether it is curable or not, sleep nature of the patient, Sexual indulgence and 
karma should be analyzed and then only treatment should be given to the patient. 
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3.4 Modern aspects of the disease 
Infertility 
The WHO defines infertility as a disease if the reproductive system that impairs 
the body‟s ability to perform the basic function of reproduction. Although conceiving a 
child may seem to be simple and natural, the physiological process is quite complicated 
and depends on the proper function of many factors, including the following, 
 Production of healthy sperm by the man 
 Production of healthy ovum by the woman 
 Unblocked fallopian tubes that allow the sperm to reach the ovum 
 The sperm‟s ability to fertilize the ovum 
 The ability of the fertilized ovum to become implanted in the uterus 
 Adequate embryo quality 
 
Male Infertility 
Definition 
Male factor infertility is said to be present when a couple fails to achieve 
pregnancy after one year of unprotected coitus and a problem is identified in the male 
partner. 
Causes of infertility in men can be explained by deficiencies in ejaculate volume 
causing low sperm production (Oligospermia), poor sperm motility (asthenospermia), 
abnormal morphology (teratospermia), and abnormal sperm function or by preventing 
sperm transport to vagina. 
 
Classification 
Primary Infertility 
This is when the man has never impregnated women. 
Secondary Infertility 
This is when the man has impregnated women, irrespective of whether she is the 
present partner and irrespective of the outcome of the pregnancy. Men with secondary 
infertility in general have a better chance of future fertility. 
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Structures of Male Genital Organ 
Male reproductive system 
The male reproductive system consists of the primary reproductive organs, the testis 
and the secondary reproductive organs, which include the, 
 Scrotum 
 Epididymis 
 Ductus deferens 
 Seminal vesicles 
 Prostate gland 
 Urethra 
 Bulbo-urethral glands and 
 Penis 
The tests in which the sperm cells develop are located outside the body cavity in the 
scrotum where the temperature is lower. 
Sperm cells are transported from the testes to the epididymis, which lies on the 
external surface of each testis and then through the ductus deferens into the prostate. 
Just before the ductus deferens enters the prostate gland, the ductus deferens increases in 
diameter to become the ampulla of the ductus deferens. A short duct of the seminal 
vesicle joins the ampulla of the ductus deferens to form the ejaculatory duct at the 
prostate, which then projects through the prostate gland and empties into the urethra, with 
in the prostate gland. The urethra exists from the pelvis and passes through the penis to 
the outside of the body. 
 
Physiology 
 Spermatogenesis 
 Performance of the male sexual act 
 Regulation of male reproductive functions by the various hormones. 
Spermatogenesis 
Spermatogenesis occurs in all the seminiferous tubules during active sexual life as 
the result of stimulation by anterior pituitary gonadotropic hormones, beginning at an 
average age of 11-13 years and continuing throughout the remainder of life. 
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Stages of Spermatogenesis 
Primordial germ cells 
Spermatogenesis 
Primary spermatocytes 
Secondary spermatocytes 
Spermatids 
Spermatozoa 
Stages in Spermatogenesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spermatids                                
transformed 
into 
Secondary                                
Spermatocytes 
Spermatogenium            
Type B 
Spermatogenium            
Type A 
First meiotic            
division 
 
  22+X 
 
  22+X 
 
   
22+Y 
 
   
22+Y 
Second meiotic            
division 
Primary                                
Spermatocyte 
 
44+X+
Y 
 
44+X+
Y 
 
   
22+X 
 
   
22+Y 
 
44+X+
Y 
 
44+X+
Y 
Spermatoza Spermatoza Spermatoza 
Spermatoza 
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The process of spermatogenesis takes approximately 60-70 days from the 
beginning of the differentiation of the spermatocyte to a completion of the motile sperm. 
When the sperm leave the testis they are relatively immature and have a poor capacity to 
fertilize. The transport of the sperm through the epididymis to the ejaculatory duct 
requires an additional 12 to 21 days. 
Secretary products of the cells in the testis 
Sl.No Cell Products Proposaed Function 
A. 
Leydig Cells 
1. Androgens 
2. Proopiomelanocortin 
3. Inhibin 
4. IGF – I 
5. IL - 1β 
1. Endocrine, paracrine, 
autocrine control 
2. Opioids, α-MSH, ACTH 
3. Endocrine, paracrine 
activity 
4. Growth, differentiation 
5. Kinin activity 
B. 
Sertoli Cells 
1. ABP 
2. Transferrin 
3. Ceruloplasmin 
4. Estrogen/Aromatase 
5. Laminin, Collagen 
6. Proteoglycans 
7. TFG-α, TFG-β, IGF-I, IL-I 
1. Binding of androgens 
2. Iron Transport 
3. Copper Transport 
4. Endocrine, paracrine 
regulation 
5. Extracellular matrix 
6. Growth factors which 
inhibit or stimulate cell 
physiology and 
proliferation  
C. 
SC-EGF 
1. Inhibin, Activin 
2. Mullerian, inhibitory factor 
3. LHRH-Like substance 
4. Lactate / Pyruvate 
1. Endocrine, paracine 
2. Fetal Sertoli cell 
development 
3. Binds of leydig cells in 
rats 
4. Metabolites, nutrients for 
gem cells. 
D. 
Peritubular Cells 
1. P-Mod-S 
2. Fibronectin 
3. Proteoglycans 
4. TFG-α, TFG-β, IGF-I 
1. Paracine regulation od\f 
Sertoli cells 
2. Extra cellular matrix 
3. Growth factors 
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During passage through the epididymis the spermatozoa has the following features, 
o Maturation takes place 
o Sustained motility 
o Modification of nuclear chromatin and tail organelles 
o Loaf of spermatid cytoplasm 
 
Hormonal factors that stimulate Spermatogenesis 
 
1. Testosterone 
It secreted by the leydig cells. Located in the interstitium of the testis, is essential 
for growth and division of the germinal cells in forming sperm. 
 
2. Luteinizing Hormone 
Secreted by the anterior pituitary gland, stimulates the leydig cells to secrete 
testosterone. 
 
3. Follicle – Stimulating Hormone 
FSH is also secreted by the anterior pituitary gland, stimulates the sertoli cells. 
Without this stimulation the conversion of the spermatids to sperm will not occur. 
 
4. Estrogens 
It formed from testosterone by the sertoli cells, when FSH stimulates them. It is 
probably also essential for spermatogenesis. 
The sertoli cells also secrete an androgen-binding protein that binds both 
testosterone and estrogens and carries these into the fluid in the seminiferous tubular 
lumen thus making both these hormones available for maturing the sperm. 
 
5. Growth Hormone 
It is necessary for controlling the back ground metabolic functions of the testes. 
Growth hormone especially promotes early division of the spermatogonia themselves. 
In its absence as in pituitary dwarfs, spermatogenesis is severally deficient or absent. 
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The Hypothalamic – Pituitary – Testicular Axis 
The hypothalamic – pituitary – testicular axis is physiologically a closely integrated 
system. 
Testicular function is regulated by a series of closed-loop feedback systems 
involving the higher centre in the central nervous systems (CNS), the hypothalamus, the 
pituitary and the testicular, endocrine and germinal compartments. 
The hypothalamus is the site of production of gonado-tropin-releasing hormone 
(GnRH). GnRH binds to GnRH receptors in the pituitary gland and stimulates the 
synthesis and release of the Gonadotropic Hormones, Luteinizing Hormone (LH) and 
Follicle stimulating Hormone (FSH). LH and FSH are secreted by the pituitary gland into 
the general circulation and carried to the testes. In the testis they stimulate gonadal 
secretion of steroid hormones (testosterone and estradiol) that are important in the 
maturation and maintenance of spermatogenesis. 
Testosterone is the major steroid hormone produced by the testis. 98% of 
testosterone circulates bound either to sex hormone – binding globulin (SHBG) or to 
albumin. The testis secretes only 25% of circulating estradiol. Dihydro testosterone 
(DHT) another potent androgen is derived from the peripheral conversion of testosterone. 
This DHT is necessary for external virilization during embryogenesis and androgen 
action during puberty and adulthood. 
The testis also produces non-steroid substance inhibin, secreted by the sertoli 
cells. Inhibin may also exert local regulatory effects on spermatogenesis. 
Prolactin a polypeptide hormone is synthesized and secreted from the pituitary 
gland. Prolactin stimulates lactation in women. Elevated levels of prolactin suppress 
testosterone synthesis in man. Control and coordination of testicular function occur via 
feedback signals both positive and negative exerted by the hormones secreted at each 
level of the hypothalamic-pituitary-testicular axis. 
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Infertility History 
1. History of Infertility 
 Duration    
 Prior Pregnancies 
 Previous treatments   
 Evaluation and treatment of wife 
 Present partner   
 Another partner 
 
2. Sexual History of the Man 
 Frequency of masturbation      
 Frequency of intercourse, 
 Timing of intercourse   
 Potency 
 Lubricants 
 
3. Childhood and Development 
 Undescended testicles    
 Herniorraphy 
 Testicular trauma   
  Testicular torsion 
 Y-U plasty of bladder    
 Onset of puberty-early, normal of delayed 
 
4. Family History 
 History of infertility in his family members 
 Cystic fibrosis 
 Androgen receptor deficiency 
 
5. Infections 
 Viral infections    
 Febrile 
 Sexually transmitted disease  
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 Tuberculosis 
 Chicken pox   
 small pox   
 Mumps   
 Orchitis 
6. Surgical History 
 Pelvic injury     
 Orchitectomy 
 Herniorraphy     
 Pelvic injury or scrotal swelling 
 Y-V plasty, Transulatal   
 Retro peritoneal surgery 
7. Gonadotoxins 
 Thermal exposure    
 radiation 
 Smoking     
 Chemicals – Pesticides 
 Drugs, Chemotheraputic, Marijuana, Sulfasalazine, nitro furantoin, 
androgentic steroids. 
Causes of Infertility     
Varicocele 
A varicocele is defined as a dilation of the veins of the pampiniform plexus of the 
scrotum. Varicocele is present in 15% of the male population. Dilated spermatic vein 
leads to the reflux of toxins (impure blood-increased CO
2
 concentration produces 
excessive heat) down through the spermatic vein to the testis. That increases scrotal 
temperature caused by varicocele. 
High Fever: 
A high fever exceeding 38
0
C may suppress spermatogenesis over a period of 6 months. 
Example: Influenza, malaria. 
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 Testicular trauma 
Testicular trauma is the second most common acquired cause of infertility the 
testes are at risk far both thermal and physical trauma because of their exposed position. 
Orchitis 
The most common cause of acquired testicular failure in adults is viral orchitis 
usually caused by the mumps virus, echovirus or group B arbovirus. 
Down syndrome 
These patients have mild testicular dysfunction with varying degrees of reduction 
in germ cell number. LH and FSH are usually elevated. 
Sertoli – cell only syndrome (Germinal cell aplasia) 
Patients with germinal cell aplasia have LH and testosterone levels within the 
reference range but have an increased FSH level. The etiology is unknown but is probably 
multi-factorial patients present with small to normal sized testes and azoospermia. 
Secondary sex characteristics are normal. Histology reveals seminiferous tubules 
lined by sertoli cells and a normal interstitum although no germ cells are present. 
Commoner Abnormalities of Genital Organs 
 Local infection        
 Idiopathic 
 Testicular trauma of Torsion       
 Varicocele 
 Obstruction of epididymis, 
  Obstruction of vas deferens    
 Cryptorchidism 
Chronic Diseases 
 Mumps    
 Tuberculosis 
 Leprosy    
 Epididymitis 
104 
 
 Prostatitis    
 Diabetes mellitus 
 Hypertension     
 Sexual transmitted diseases 
Impaired Sperm Production and Function 
1. Hypothalamic pituitary disorders 
Congenital hypo-gonadotropic hypogonadism kalimann‟s syndrome due to 
deficiency of gonadotrophin releasing hormone (GnRH). In the X-linked form of this 
disease, deletion of a gene kalig-2 has been found. This gene encodes for neurons 
involved in production of GnRH. Acquired hypogonadotrophic hypogonadism pituitary 
adenoma (including prolactinomas) cranio-pharingiomas other brain tumours, intracranial 
radiation therapy. 
 
2. Genetic Factors 
Sex chromosome abnormalities 
a) 47-xxy karyotype (Klinefelter syndrome) is almost always associated with 
azospermia (destruction of seminiferous tubules at puberty leading to shrinkage of 
testes). 
b) Extra Y chromosome results in various degrees of impairment of spermatogenesis. 
Characteristic decreased sexual function, gynaecomazia, decreased length of penis 
and testis and decreased testosterone level. 
Other chromosomal abnormalities 
a) Translocations cause more severe impairment in male than female. 
b) Impaired chromosome pairing in melosis leads to azoospermia. 
c) Deletions corresponding to AZF (Human azoospermia factor) region on long arm 
of chromosome. This genetic region controls spermatogenesis in human beings. 
 
3. Undescended Tetsis ( Cryptorchidism) 
Extent of impairment of spermatogenesis is variable from a complete sertoli-cell 
only pattern to only a slight reduction in the number of germ cells. Spermatogenesis is 
also impaired in contra lateral testis in patients with unilateral mal-descent. Early 
treatment before age of two years is advocated. 
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4. Testicular Cancer 
This is associated with increased risk of impaired spermatogenesis oligospermia is 
observed in more than 40% of patients at the time of Diagnosis of testicular cancer. 
  
5. Germ cell Aplasia 
Seminiferous tubules contain only sertoli cells. Absence of germ cells may be due 
to factor present during fetal life. Leydig cell insuffiency may also be associated. 
This cytological appearance can also result from cryptorchidism, cytotoxic drugs 
or irradiation. 
 
6.  Drugs 
Sulphasalazine, used to treat inflammatory bowel disease can markedly reduce 
semen quality. The effect is reversible if smaller doses are used for limited time else it 
may be permanent, B-Blockers may cause importance Anabolic steroids may cause 
oligo (or) azoospermia and cytotoxic drugs especially the alkylating agents 
(Cyclophosphamide, cisplatin and procarbazine) also cause gonadal failure. 
 
7. Environmental Factors 
Exogenous heat can impair spermatogenesis, Pesticides (Chlorinated nematocide 
dibromochloropropane – DBCP, Chlordane, carboxyl and ethylenedibromide) glycol 
ethers (used in paintings, painting and adhesives) and metals (lead, calcium and 
mercury) have adverse effect on sperm production. Male metal welders may be at 
increased risk of sub-fecundity. Several other environmental toxins can also have an 
adverse effect on male reproductive organs. Various hormonal metabolic and neural 
signals like stress, under nutrition, emotional upset and drugs can affect 
hypothalamic-GnRH pulse generator and thus, spermatogenesis. 
 
Impaired sperm transport 
1. Autoimmune Infertility 
Spermatozoal antigens are shielded inside the testes and are not recognized 
by the immune system. Autoimmune reaction against sperms is manifested as 
circulating sperm antibodies. These antibodies may be associated with vasectomy, 
unilateral or bilateral obstruction of genital tract, Epididymis and varicocele. 
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2. Obstructive Azoospermia 
Sexually transmitted diseases may cause epididymitis and block the ductal 
system. Agenesis of epididymis and other parts of ductal system, congenital 
bilateral agenesis of vas deferens is found in many patients with cystic fibrosis. 
 
3. An Ejaculation / Retrograde Ejaculation 
 Diabetic patients 
 Retroperitoneal lymph-node dissection causing neural damage. 
 Spinal card injury 
 Bladder neck surgery 
 Other sexual dysfunction-including impotence 
 Kartagener‟s syndrome (immotile cilia syndrome) sperms are immotile 
due to missing dyne in arms. 
 
4. Disturbance in sperm Oocyte Function 
Complementary adhesion molecules are present on surface of oocytes and 
spermatozoa. These molecules interact and cause fusion of gametes. 
Abnormalities in these molecules may potentially contribute to infertility. 
 
5. Unexplained Infertility 
Semen quality is normal and no effect can be found in the female partner. 
 
Evaluation of the infertile man 
I. This includes, 
 A comprehensive history, 
 Physical examination 
 Multiple semen analysis and  
 Endocrine evaluation 
 
II. In special circumstances, further specific investigations may also be indicated. 
 Bacterial examination 
 Genetic assessment 
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 Testicular biopsy 
 Sperm function tests 
 Ultrasound 
 Other parameters 
 
a) History 
Sexual history 
About 5 percent of all couples are barren due to sexual dysfunction. 
 
Smoking 
Reduces sperm density, reduces the proportion of motile sperms and increase level 
of abnormal morphology. 
Alcohol 
Excess intake impairs liver function leading to increased estrogen levels, 
decreased sexual performance and depressed spermatogenesis. 
 
Drug abuse 
Marijuana can lead to impotence and infertility marijuana inhibits the secretion of 
GnRH and can suppress reproductive functions in both men and women and cocaine 
use is known to reduce – spermatogenesis. 
 
Medical treatment 
Psychiatric drugs like phenothiazines, anti-hypertensives like B-blockers, epileptic 
drugs like diphenyl hydantoin, anti-bacterials like Sulphasalazine and nitrofurantion, 
H2 antagonist‟s cimetidine and ranitidine, erythromycin tetracycilne‟s anabolic 
steroids and chemotherapeutic agents can depress sperm quantity and quality. 
 
Past history of surgery 
For hernia, hydrocele may lead to vassal damage. Orchidopexy for undescended 
testis (If done late in life) and surgery far varicocele, may all affect the semen quality. 
Past history of mumps, orchitis,  epididymitis, prostatitis, sexual transmitted disease 
and testicular injury. 
 
 
108 
 
Exposure to excessive heat 
A small rise in scrotal temperature can adversely affect spermatogenesis and a 
febrile illness can produce striking changes in sperm court and motility. The effect of 
the illness can be seen in the sperm count and motility even 2-3 months later. 
Environmental sources of heat such as the use of khaki shorts instead of boxes shorts 
excessively hot baths hot tubes or occupation that require long hours of sitting e.g. 
Drivers may all decrease fertility potential. Severe allergic reactions and exposure to 
radiation or to industrial or environmental toxins- 
 
A study from Scandinavia did show lower sperm courts in males from an urban 
area compared to males in rural areas, suggesting an affect of urban pollutants. In any 
case the clinician should determine it a male with an abnormal semen specimen had 
exposure to industrial or environmental. 
 
Exposure to diethyl stillbestrol in utero has been suggested (but not proven) as a 
cause of male infertility. Indeed in the largest follow-up of men born to the women 
treated with diethylstilbestrol, no impairment of fertility of sexual function was 
detected. 
 
Coital frequency 
Counts at the lower levels of the normal range may be depressed to below normal 
levels by ejaculations occurring daily or more frequently. Most couple‟s every 36 
hours around the time of ovulation will give the optimal chance far pregnancy. 
However studies in men with Oligospermia fail to detect a decline in sperm-numbers 
with sequential ejaculations suggesting that in limitations on coital frequency are not 
necessary. 
 
B. Examination 
 
Bodily habitus 
 
 Size of testes estimated by comparing with Orchidometer normal volume is – 
150-200ml. 
 Scrotal palpation for vas deferens and varicocele. 
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 Presence of penis abnormalities like hypospadias, scar and induration. 
 Shrunken testis (5ml) with infantile genitalia sparse body hair, gynaecomazia 
and low testicular volume are seen in congenital gonadotrophin deficiency. 
 Eunuchoid habits with infantile genitalia sparse body hair, gynaecomazia and 
low testicular volume are seen in congenital gonadotrophin deficiency. 
 Androgenized man with normal sized testis and distended epididymis may 
indicate obstructive azoospermia. 
 Androgenized man small sized testes may have seminiferous tubular failure. 
 Absence of cord like feel of vas of the neck of the scrotum indicates vassal 
aplasia. 
 
Endocrine Evaluation 
Serum follicle-stimulating hormone (FSH) helps to distinguish patients with 
azoospermia who have obstruction (normal FSH) from those with seminiferous tubule 
destruction(Raised FSH),Low levels of FSH, LH and testosterone suggest acquired 
hypo gonadotrophin hypogonadism. 
 
C. Semen Analysis: 
 
The Semen analysis is the corner stone of the male infertility work up should be 
performed according to the WHO recommended procedure. Computer assisted semen 
analysis (CASA) is considered mainly a research tool and is not used routinely. If 
abnormal results are obtained semen analysis is repeated after 6-12 weeks. 
 
Semen volume  : Normal ejaculate volume is 1.5-5ml. 
Colour   : Grey, yellow or opalescent 
Ph    : 7.2 – 8 
Liquefaction : Coagulation occurs soon after ejaculation but semen 
liquefies            within 5-20 minutes failure to liquefy after 
30 min is abnormal. 
Sperm concentration : Sperm per ml of semen 
    Normal  - 20 x 10
6
 sperms/ml 
    Oligozoospermia - 20 x 10
6
/ml 
    Polyzoospermia - 350 x 10
6
/min 
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Total sperm count : Sperm concentration  x volume of semen Normal) 40 x 
10
6       
sperms ejaculate. 
Sperm Motility : At least 100 sperms are evaluated. Normal is 50% with 
forward progression within 60min of ejaculation. 
Morphology : Assessed by light microscopy (hematoxylin, eosin, geimsa 
or   papanicoloau stain) or electron microscopy. At least 
100 sperms are examined. Normal is 30% with normal 
forms. 
White blood cells : have to be differentiated from immature germ cells. 
Normal (1 x 10
6
 / ml peroxidase staining technique). If 
excessive, semen culture should be performed. 
Sperm antibodies : Detected by immunobead or mixed antiglobulin reaction 
which localizes IgG or IgA specific regions of spermatozoa. 
Normal for immunobead test for antiglobulin reaction test – 
10% spermatozoa with adherent particle. 
Accessory gland functions: Assessed by measuring seminal fructose for seminal 
vesicles (Normal 13µmol/ejaculate) and acid phosphatase, 
zinc citrate for prostate.Post ejaculatory urine should be 
examined for presence of sperms if retrograde ejaculation is 
suspected. 
Collection of semen: 
 The sample should be obtained atleast in three occasions. 
 With an interval of atleast two months of each specimen. 
 Atleast 4 days abstinence from sexual activity. 
 A sample to be collected by masturbation into a clean, dry, sterile container. 
 The specimen (semen) should be examined should not be missed since it 
contains the highest concentration of spermatozoa. 
 
Other Investigations 
Bacteriological examination 
Bacterial examination of semen in patients with leukocytospermia. 
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Chromosomal and genetic assessment 
Chromosomal analysis is essential in men with azoospermia with raised FSH 
levels and small testicular volume, in order to diagnose klinefelter syndrome. Screening 
for cystic fibrosis-by-cystic fibrosis transmembrane conductance regulating (CFTR) gene 
analysis is done in men with congenital absence of vas deferens. 
Testicular biopsy 
Can confirm the diagnosis of obstructive azoospermia (Normal testis size with 
azoospermia) before reconstructive surgery. 
h) Sperm function 
 Strict morphology evaluation 
 Acrosomal assessment 
 Sperm – zone binding tests 
 Production of reactive oxygen species by sperms. 
Ultrasound 
Transrectal and scrotal ultrasound can be used to assess prostate and seminal 
vesicle and diagnose ejaculatory duct obstruction. Testicular ultrasound can locate 
impalpable testes or those with hydrocele. 
Other Parameters 
Although all of the major elements of the semen analysis have some bearing on 
fertility, especially when markedly deficient the lack of precise correlations have led to a 
search for tests of the functional capacity of sperm. Despite enthusiasms generated by a 
variety of assays over the past four decades, no test has emerged as a reliable standard for 
the fertilizing ability of sperm. 
Measurement of sperm velocity 
The CASA systems are best at supplying information on sperm velocity and 
specific movements such as lateral head displacement however; it is unlikely that these 
measurements provide information that cannot be obtained with less expensive methods. 
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Hypo-osmotic swelling test 
When sperm are placed in a hypo-osmotic solution of sodium citrate and fructose, 
a sperm tail with normal membrane function will swell and coil as fluid is transported 
across the membrane. Conversely, if there is a functional disturbance of the tail 
membrane the tail will appear unaffected. 
Measurement of acrosin 
Acrosin is a proteolytic enzyme associated with the acrosome that may be 
important far aiding sperm to traverse the zona. Low acrosin concentrations could be 
associated with infertility. Although theoretically appealing, the test has little application 
in clinical practice. 
Measurement of the acrosome reaction 
The acrosome reaction that allows the release of enzymes from the acrosome 
occurs on or near the zona pellucida. However a low percentage of sperm will also 
become reactive while in media or following treatment with calcium, innophore that 
includes capacitation. Although the artificial initiation of the acrosome reaction has been 
correlated with IVF results the relatively small difference in an acrosome reactive sperm 
in the different groups indicates that this approach is not clinically important. 
Sperm penetration assay (SPA) 
The zona pellucida of most mammalian species presents not only a block to 
polyspermia but also a barrier to fertilization of an ovum by sperm of a different species. 
However, foreign sperm can fuse with and penetrate an ovum if the zona is removed by 
gentle enzyme digestion. In the sperm penetration assay, ovum are collected from super 
ovulated golden hamsters the zona are removed by enzyme digestion, and the denuded 
ovum are cultured for 2-3 hours with human sperm that have been washed and incubated 
over night in culture media. Presence of a swollen sperm head in the ovum cytoplasm is 
evidence of successful penetration. Most laboratories report the percentage of ovum 
penetrated and compare this figure to the percent penetrated by a known fertile sperm 
specimen. 
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Human zona binding assay 
Whereas the SPA tests the ability of sperm to penetrate or to be engulfed by the 
ovum it does not test the critical ability to pass through the zona pellucida. 
The zona is of course, removed in preparation for the SPA because it is, with rare 
exceptions, impervious to foreign sperm. Thus, to test zona penetrating or zona binding 
ability of human sperm requires the use of human zona. 
One approach is to use zona obtained from surgically removed ovarian tissue and 
slit them in half so that both patient sperm and donor sperm can be tested in parallel on 
different portions of the same zona. 
The ratio of the number of sperm bound for the test subject to the number of 
sperm bound for fertile control sperm bound for fertile control sperm has been labeled the 
hemizona assay index (HZ1) a break point at on HZI value of 36 has provided a good 
correlation with results in human IVF. 
The limited availability of the zona and the technical requirements of the assay 
will always restrict its application to a small number of committed laboratories. 
In the future, development of materials that mimic the properties of the zona could 
lead to simple tests. 
However the widespread use of ICSI, which by passes the zona, renders such, 
tests superfluous, unless they can determine with certainty which couples require ICSI. 
Measurement of the adenosine triphosphate (ATP) 
ATP is an important component of sperm metabolism related to tail movement. In 
one reports levels of ATP in semen were a strong discriminator between populations of 
fertile and infertile males. A multicentre study sponsored by the world health organization 
concluded. However, those levels of semen ATP could not predict the occurrence of 
pregnancy when the female was normal and the male partner had a sperm concentration 
greater than 20million/ml. 
Immunological factors: Anti sperm antibodies 
Immunological factors have been impacted in the causation of human infertility. 
In men, this may present as anti-sperm antibodies in the semen, serum or on the surface of 
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the sperm. Anti-sperm antibodies have also been demonstrated in the cervical mucus and 
the serum of the female partner. 
Though there are several tests to detect anti-sperm antibodies the exact 
significance of these tests is not known. Besides there is no satisfactory way to treat these 
couples, though immunosuppressive therapy with corticosteroids, testosterone therapy, 
intrauterine artificial insemination with husbands sperms (IUAID) and have all been 
suggested as appropriate therapy. The pregnancy rate has been variable. 
The role of anti-sperm antibody is significant since the sperm is not recognized, as 
self-antigen in our body immunologically speaking the spermatogenesis does not occur, 
when the ontogeny of the „T‟ lymphocytes happens.At this time of ontogeny of the „T‟ 
lymphocytes our body proteins are started to recognize as self-antigens. It any antibody 
arises against our own protein it will be destroyed by clonal energy. 
The sequestered sperm protein also causes the immune response, especially 
vasectomy like surgeries. 
 
Non-surgical factors related to male infertility 
Gonado-toxine   Ejaculatory dysfunction 
Genital tract infection   Hormonal imbalances 
Coital timing    Testicular hyperthermia 
 
Retrograde ejaculation 
 Disruption of the innervations of the vasa deferentia and bladder neck can result in 
retrograde ejaculation. Diabetes mellitus complicated by peripheral neuropathy, multiple 
sclerosis, medical therapies interfering with sympathetic tone, Tran urethral resection of 
the prostate bladder neck surgery retroperitoneal lymph node dissections and extensive 
pelvic surgery also can lead to retrograde ejaculation. 
The diagnosis is confirmed by identification of large numbers of sperm in a post ejaculate 
urine specimen. 
  
Microbiology 
The presence of white blood cells (WBC‟s) in the patient‟s semen may indicate an 
infection. Accordingly the semen should be evaluated for bacterial growth, mycoplasma 
and chalmydia. 
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Distribution of final diagnostic categories 
Found in male fertility clinic 
 
Diagnosis 
Varicocele      Endocrine 
Testicular failure     Cryptorchidism 
Ejaculatory Failure Agglutination   Low Volume 
Sexual Dysfunction Viscosity   Idiopathic 
 
Necrospermia 
Relative frequency of causes and associated conditions in men who present with 
infertility. 
 
Conditions 
Varicocele   Viral Orchitis    immotile sperm 
Coital disorders  Abdrogen resistance  
 Radiation/chemotherapy 
Obstruction of epididymis or of vas deferens    Klinefelters syndrome 
 
Surgical operations in the male possibility associated with male infertility 
1. Hydrocele    6.   Sympathectomy 
2. Varicocele    7.   Testicular torsion 
3. Inguinal hernia   8.   Hypospadias 
4. Vasectomy    9.   Urethral strictures or diverticula 
5. Prostatectomy    10. Bladder neck operation 
WHO manual – semen analysis – nomenclature’s 
1. Normozoospermia   -  Normal semen 
2. Aspermia    - Absence of ejaculation 
3. Azoospermia    - Absence of sperms in the semen 
4. Oligo zoospermia   - Less than 20 millions count / ml 
5. Astheno zoospermia   - Less than 5.0% spermatozoa with  
forward Progression 
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6. Terato zoospermia   - Less than 30% spermatozoa with    
                                                                        normal head morphology 
7. Oligoastheno teratozoosperima - Signifies the disturbance of all the      
                                                                        above variables 
 
Sub fertility options – Abbreviations 
For infertility disorders there are so many latest and advanced techniques are 
available and some of them are listed below, 
IVF  : In Vitro Fertilization 
GIFT  : Gamete Intra Fallopian Transfer 
TET  : Tubal Embryo Transfer 
TUFT  : Trans-Uterine Fallopian Transfer 
ICSI  : Intra-Cytoplasmic Sperm Injection 
SUZI  : Sub Zonal Sperm Injection (Directly into Ovum) 
ZIFT  : Zygote Intra-Fallopian Transfer 
POST  : Peritoneal Oozyte Sperm Transfer 
PESA  : Percutaneous Epididymal Sperm Aspiration 
MESA  : Micro Epididymal Sperm Aspiration –from testis  
 
Sperm Function Tests 
Sperm migration test  : More than 150 million in 250 micl-fertile 
Hypo osmotic test  : More than 60% with HOS positive - Fertile 
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Acrosomal intactness 
Test nuclear chromatin : More than 60% with halo 30micm – Fertile 
Decondensation test  : More than 70% NCD – Fertile 
 
Sperm mitochondrial 
Activity Index   : More than 50 SMAI – Fertile 
 
In vitro cervical mucus 
Penetration test  : Score:  0-Negative,  3-Poor,  6-Good,   9-Excellent 
Post coital test   : More than 10 rapid forward progressing  
sperms/HPF 
Post ejaculatory urine  : No spermatozoa in urine 
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4. MATERIALS AND METHODS 
Drug selection: 
In this dissertation the stamens of Anda odu Parpam (Egg shells of Gallus domesticus) 
was taken as a compound drug for Vindhu kuraivu (Oligospermia) from the literature of 
the preparation was collected from Anuboga vaidhya navaneedham-Third part written by 
Hakeem Mohamed Abdhulla Shahib, Page no.106 Incredients of the test drug are Egg 
shells of Gallus domesticus and Lemon juice. 
Source of collection: 
The hen egg shells (Ovitesta of Gallus Domesticus) were collected from the 
hatchery at Namakkal and the lemon were collected from a form house at Idappadi, 
Salem District. 
 
4.1 Preparation of the drug 
Purification of egg shell:
  
The egg shells were boiled with Appalakaram water (Sodium Carbonate) for 
20minutes. Then the membranous layer is peeled out and then washed with water for two 
times. 
Preparation of parpam and strorage:
 
The purified dried egg shells were powdered and sieved in clean white cloth 
(Vastharakayam). This fine powder about 320gms is kept in a vessel and 500ml of lemon 
juice is poured into the powder and kept in sunlight. It is repeated for seven times. After 
then the product was made into Villai and dried in sunlight and kept in an Agal (mud pan) 
with suitable cover. Make 10 mud smeared cloths around the Agal and kept for pudam 
(calcinations process) in 20 varatties (cow dung cakes). After calcination it was powdered 
and kept in dry clean air tight container (Anuboga Vaidhaya Navaneetham Part III). 
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Fig No.1 Anda odu (Egg Shell of Gallus domesticus) 
 
 
Fig No.2 Elumichai Pazham (Lemon - Citrus Limon) 
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Fig No.3 Anda odu parpam 
 
 
Administration of the Drug: 
 Form of the medicine  : Parpam (Powder) 
 Route of Administration : Enteral 
 Dose    :  130 mg 
 Anubanam (Vehicle)  :  Ghee 
 Time of Administration :  Twice in a day; before food 
 Duration   :  48 days 
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4.2 Standardization of the drug 
Standardization is the first step for the establishment of a consistent biological 
activity, a consistent chemical profile standardized herbal products of consistent quality 
and containing well-defined constituents are required for reliable clinical trials and to 
provide consistent beneficial therapeutic effects.  
4.2.1. Physio-chemical analysis of test drug 
Quantitative analysis 
Ash and acid insoluble ash: 
 To the ash add 1:5 Hcl: Distilled water 15 ml boil, cooled and then filtered using 
whatman filter paper (No.41) repeat 3 to 4 times till the yellow colour disappear or 
colourless, then remove the filter paper and add to the filter to the original dish and keep 
it in the muffle furnace at 600
o
 C and take constant weight and calculate the acid 
insoluble ash value. 
Acid insoluble residue = Acid insoluble ash value – Empty weight of the dish 
Loss on drying: 
 3gm of the drug is heated in a hot oven at 105
0
 c to constant weight. The % of 
weight was calculated. 
Loss on drying value at 105
0
 c – 9.485 %w/w 
Potential of hydrogen (pH): 
 The pH scale is logarithmic and runs from 0.0 to 14.0 with 7.0 being neutral. 
Readings less than 7.0 indicate acidic solutions, while higher readings indicate alkaline or 
base solutions. pH of Anda odu Parpam – 13. 
 
 Weight of acid insoluble residue x 100 
Acid insoluble ash (%) 
= 
 
                   Weight of  the sample 
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4.2.2 Chemical analysis 
Methodology for chemical analysis 
Preparation of extract 
5gm of sample is weighed accurately and placed in a 250ml clean beaker and 
added with 50ml of distilled water. Then it is boiled well for about 20 minutes. Then it is 
cooled and filtered in a 1000ml volumetric flask and made up to 100ml distilled water. 
S.No Experiment Observation Inference 
1. 
Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract& 
boil for 2  min. 
Green / Yellow / 
Red Precipitation 
Presence of 
Reducing Sugar 
2. 
Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of N/50 
Iodine Solution. 
Blue Colour 
Presence of 
Starch 
3. 
Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Violet or Purple 
Colour 
Presence of 
Proteins 
4. 
Test for amino Acid : 
Place 2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin and allow 
drying. 
Violet Colour 
Presence of 
Amino Acid 
5. 
Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch‟s reagent. 
Yellow Precipitation 
Presence of 
Albumin 
6. 
Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Yellow Precipitation 
Presence of 
Phosphate 
7. 
Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
White Precipitation 
Presence of 
Sulphate 
 
8. 
 
Test for Chloride : 
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Cloudy White 
Precipitation 
Presence of 
Chloride 
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S.No Experiment Observation Inference 
9. 
Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric Acid. 
Red Colour Presence of Iron 
10. 
Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
White Precipitation 
Presence of 
Calcium 
11. 
Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it 
into the blue flame. 
Yellow Flame 
Presence of 
Sodium 
12. 
Test for Potassium : 
Add a pinch of the sample to 2 ml of 
Sodium Nitrate Solution. Then add 
2ml of Cobalt Nitrate in 20% acetic 
acid. 
Yellow Precipitation 
Presence of 
Potassium 
13. 
Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
White Precipitation Presence of Zinc 
14. 
Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution. 
White Precipitation 
Presence of 
Magnesium 
15. 
Test for Alkaloids : 
a. To 2ml of extract, add 2ml 
of Potassium Iodide Solution 
b. To 2ml of extract add 2ml of 
Picric Acid. 
c. To 2 ml of extract add 2ml 
of Phospho tungstic Acid. 
 
Red Colour 
 
Yellow Colour 
 
White Precipitation 
 
Presence of 
Alkaloids 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. 
Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Black Precipitation 
Presence of 
Tannic Acid 
 
Results are discussed in table 1.1 
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4.2.3 Instrumental analysis 
 
 
Fig No. 4 Fourier Transform Infrared Spectroscopy (FTIR) 
 
Instrument details: 
Model   :  Spectrum one: FT-IR Spectrometer  
Scan Range   :  MIR 450-4000 cm-1  
Resolution   :  1.0 cm-1  
Sample required :  50 mg, solid or liquid. 
 Fourier Transform Infrared Spectroscopy (FTIR) is an analytical technique used to 
identify mainly organic materials. FTIR analysis results in absorption spectra which 
provide information about the chemical bonds and molecular structure of a material. The 
FTIR spectrum is equivalent to the "fingerprint" of the material and can be compared with 
cataloged FTIR spectra to identify the material. 
Applications: 
Infrared spectrum is useful in identifying the functional groups like -OH, -CN, -
CO, -CH, -NH2, etc. Also quantitative estimation is possible in certain cases for 
chemicals, pharmaceuticals, petroleum products, etc. Resins from industries, water and 
rubber samples can be analyzed.  
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Fig No. 5 Mechanism of FTIR analyzer 
 
Fourier Transforms Infrared Spectroscopy analytical capabilities: 
 Identifies chemical bond functional groups by the absorption of infrared radiation 
which excites vibrational modes in the bond 
 Especially capable of identifying the chemical bonds of organic materials  
 Detects and Identifies organic contaminants  
 Identifies water, phosphates, sulphates, nitrates, nitrites, and ammonium ions  
 Detection limits vary greatly, but are sometimes <10
13
 bonds/cm
3
 or sometimes 
sub monolayer  
 Useful with solids, liquids, or gases 
Results are shown in Graph no: 1 
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4.2.4. Toxicological study 
Acute and sub acute toxicity study on Anda odu parpam  
Animals  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-28
0
C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group.  
 
Acute toxicity study 
 Acute oral toxicity test for the Anda Odu Parpam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavages using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight. After the substance has been administered, food 
was withheld for a further 2 hours in mice. The animals were observed continuously for 
the first 4 h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or changes in 
general behaviour and other physiological activities. Single animals are dosed in sequence 
usually at 48 hr intervals. However, the time interval between dosing is determined by the 
onset, duration, and severity of toxic signs. Treatment of an animal at the next dose was 
delayed until one is confident of survival of the previously dosed animal.  
Observation of toxicity signs:  
General behavior, respiratory pattern, cardiovascular signs, motor activities, 
reflexes, change in skin and fur, mortality and the body weight changes were monitored 
daily. The time of onset, intensity, and duration of these signs, if any, was recorded.  
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Sub-acute toxicity  
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the Anda 
Odu Parpam (p.o.) for 28 days at a dose of 50, 100 and 200mg/kg respectively. The 
animals were then observed daily for gross behavioural changes and any other signs of 
sub acute toxicity. The weight of each rat was recorded on day 0 and weekly throughout 
the course of the study, food and water consumption per rat was calculated. At the end of 
the 28 days they were fasted overnight, each animal was anaesthetized with diethylether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4
o
C for 10 min to separate the serum and used for the 
biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (glucose, creatinine, total 
protein, albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, sizes and 
colors of internal organs were evaluated. The Spleen, Testes, Pancrea, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs‟ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
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embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analyzed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparison Test using Graph Pad Instat-V3 software. P values < 0.05 were 
considered significant. 
 
4.2.5. Pharmacological study 
Spermatogenic activity of Anda odu parpam against 2, 3, 7, 8 -Tetrachlorodibenzo-p-
dioxin induced Oligospermic Rats 
Introduction 
Increasing concern expressed about the declining sperm counts of humans in the 
last few decades. This is hypothesized to be as a result of the rising incidence of both 
testicular cancers and subfertility caused by exposure of the developing male embryo to 
certain potential environmental estrogenic agents that disrupt normal hormonal balance in 
the body. Male reproductive function seems to have deteriorated considerably in the past 
4 to 5 decades. It was  observed that the significant decline in mean sperm concentrations 
from 113 × 10
6
/ml in 1940 to 66 × 10
6
/ml in 1990; a fall of 0.94 × 10
6
/ml/year.  
 Infertility is one of the major health problems in life and approximately 30% of 
this problem is due to male factors. Several factors can interfere with the process of 
spermatogenesis and reduce sperm quality and quantity. The alterations in motility, 
viability and morphology of spermatozoa in treated rats are likely the result of adverse 
effect of the treatment on epididymal functions. Inadequate concentration, sluggishly 
motile or immotile spermatozoa could not penetrate the cervical mucus and thus failed to 
fertilize the ova. Some diseases such as coronary heart diseases; diabetes mellitus and 
chronic liver diseases have been reported to cause deleterious effects on spermatogenesis. 
The present study was conducted to evaluate the possibility of using Anda Odu Parpam 
as a therapeutic agent to treat spermatogenic disorders in the animal models. 
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Materials and methods 
Chemicals  
 
 The 2, 3, 7, 8-Tetrachloro dibenzo-p-dioxin (tcdd) and necessary chemicals and 
reagents were obtained from Sigma chemicals. All other solvents and Analytical Kits 
were of analytical grade and obtained from Qualigen fine chemicals and Artek 
laboratories.  
Animals  
 Adults male rats weighing between 140-160g and albino mice weighing between 
28-32g (For acute toxicity study) were maintained in a well ventilated animal house under 
standard condition of humidity, temperature and a constant 12 hour light:12 hour dark 
lighting schedule. The animals were housed in clear polypropylene cages. The animals 
were maintained with standard pellet feed (Sai Durga Feeds and Foods, Bangalore, India) 
and water ad libitum. The health, normal behaviour and reproductive status of the animals 
were assessed and only healthy animals were selected for the experiment. All 
experimental procedures described were reviewed and approved by the Institutional 
Animal Ethical Committee (IAEC). IAEC approval no: 
(XIII/VELS/PCOL/65/2000/CPCSEA/IAEC/08.08.2012). 
Drug Stock solution  
 The powdered form of Anda Odu Parpam was mixed uniformly in 2% CMC and 
made into uniform suspension to achieve 200mg/ml as main stock solution and used in 
this study. 
Animal grouping and Treatment 
 Twenty four adult male rats were randomly divided into four groups of six 
animals each. Group 1 (control) was administered with the vehicle (2% CMC suspension) 
while groups 2 and 3 were given suspension of Anda Odu Parpam at 50mg/kg and 
100mg/kg. One rat was sacrificed to ensure the oligospermic induction at the beginning of 
the experiment i.e. after one week of TCDD injection. Two rats from each treatment 
group were randomly sacrificed after 14 days of Anda Odu Parpam administration while 
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the remaining rats treatment were continued up to 28 days. Treatment was done daily 
using oral dosing needle and twenty four hours after the last dose, blood was collected 
and the animals were sacrificed. All procedures regarding handling of the test animals 
were in accordance with the existing CPCSEA and IAEC guidelines. 
Induction of Oligospermia by TCDD in rats 
 
 Initially, rats were injected with 40μg TCDD/kg i.p. At one week after TCDD 
exposure, a rat from each group was selected and tested for induction of Oligospermia 
and after ensuring the Oligospermic conditions the study was proceeded further.  
 
Blood sample and organ collection 
 
 After the last dosing of Anda Odu Parpam, all the animals were sacrificed by 
employing euthenesia procedure and the testes, epididymis, vas deferens, seminal vesicles 
and ventral prostates were identified, dissected out, blotted free of blood and cleared of 
connective tissue or fat. The organs were weighed immediately using an electronic digital 
balance. Blood samples were collected by retro-orbital puncture into anticoagulant pre-
coated and also in plain sterile eppendorff tubes and allowed to clot at room temperature. 
Serum samples were separated by centrifugation at 3000 rpm for 10 min and stored at -
20°C until testosterone assay. Anticoagulant added blood samples were used for the 
studying haematological parameters 
 
Sperm collection and Measurement of sperm parameters 
 
 The rats were anaesthetized with anesthetic ether and sacrificed after the last day 
of administration and weighed for the essential reproductive organs, such as testis, caudal 
epididymis, seminal vesicle and prostate glands. A scrotal incision was made to 
exteriorize the testis and epididymides. The epididymides were carefully dissected out of 
the testes and blotted free of blood. To prepare sperm suspension, epididymal sperm were 
obtained by mincing cauda epididymis of each rat in pre-warmed beaker containing 2 ml 
of physiological saline (maintained at 37°C). Several incisions were made on it to allow 
sperm swim out.  
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 Sperm characteristics were determined according to the standard protocols derived 
by the previous investigators in this research area. Sperm motility was also assessed 
immediately by counting both motile and immotile spermatozoa per unit area at the 40x 
magnification. Sperm count was done using the improved Neubauer‟s haemocytometer 
under the light microscope at 100x magnification. The count was expressed as million/ml 
of suspension. Sperm viability was assessed using eosin-nigrosin test. The percentages of 
unstained (alive) and stained (dead) spermatozoa were calculated by counting 100 
spermatozoa randomly per sample. Morphological appearance of normal and abnormal 
spermatozoa was determined by examining stained smears under the oil immersion 
(100x) and their percentages were calculated. 
Testosterone Assay  
 Blood samples were spun at 2500rpm for 10 minutes in a table top centrifuge. The 
serum samples obtained were analyzed to determine the concentration of testosterone. 
The analysis was carried via the tube-based enzyme immunoassay method as described in 
the kit. 
Collection of tissues and histological analysis 
 
 The testes were collected and immediately fixed in Bouins fluid for 6 h and 
transferred to 70% alcohol for histological processing. And following fixation of the 
testes from both control and test animals, tissue sections were processed by dehydration 
in 95% and absolute alcohol, cleared in xylene and embedded in pure clean molten 
paraffin wax from which blocks of tissues were made for sectioning. Ribbon slices of 
about 5.0μm in thickness were made with the aid of a microtome and the sections picked 
with slides which were dried in oven. The slices were then stained with Haemotoxylin 
and Eosin, and then mounted using DPX onto a light microscope (magnification 40x) for 
histopathological and morphological changes. The changes observed were recorded and 
photomicrographs of the most prominent pathological alterations. 
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Statistical Analysis 
 The results were analyzed by one-way analysis of variance using INSTAT version 
3 for Windows. Significant differences within group variables were determined by 
Tukey's multiple comparison tests. Results were considered significant at 5% level of 
probability (P < 0.05). The data were presented as mean ± SEM.  
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4.3 Clinical assessment 
Aim 
Male factor infertility is said to be present when a couple fails to achieve 
pregnancy after one year of unprotected coitus and a problem is identified in the male 
partner. 
Causes of infertility in men can be explained by deficiencies in ejaculate volume 
causing low sperm production (oligospermia), poor sperm motility (asthenospermia), 
abnormal morphology (teratospermia), and abnormal sperm function or by preventing 
sperm transport to vagina. 
The increasing incidence of male infertility is necessitating more and rapid search 
into drugs with spermatogenic potentials with negligible side effects. This study is 
intended to provide adequate information on the Clinical trial of Anda odu Parpam with 
sex enhancing potentials. 
Objectives:  
 
 To evaluate the spermatogenic effect of Anda odu Parpam 
 To explore the efficacy of Anda odu Parpam in patients with infertility. 
 
Design of the Study:  
 
The Open clinical trial phase-2B 
Study period was 1-3 months (according to prognosis) 
 
Study Centre:  
 
Govt.Siddha Medical College Hospital, Arumbakkam, Chennai – 106.  
 
Study Participants:  
 
Male patients in all races and ethnic groups were eligible for this trial. The 
patients will be selected from the Out-patient department of Govt Siddha Medical College 
Hospital, Chennai.  
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Number of Subjects:  
Number of participants were 50. 
 
Registration Process:  
 
To register a patient, the following documents should be completed by the investigator.  
 Copy of required laboratory tests  
 Signed patient consent form  
 Other appropriate forms (e.g., Trial profoma).  
This Clinical trial is an ethical and scientific quality standard for designing, 
conducting and recording trials that involve the participation of human subjects. 
Compliance with this standard provides assurance to public that the rights, safety and well 
being of trial subjects are protected, consistent with the principles enshrined in the 
Declaration of Helsinki and ensures that clinical trial data are credible. 
 
Selection of patients 
The patients were selected for clinical trial, those who had the following clinical features, 
 Decreased fertility 
 Presence of nocturnal emission 
 Premature ejaculation 
 Decreased sexual desireness 
 
Consent form 
Patients were included in this clinical study only after getting the consent form 
(both English and Tamil). The confirmation is sought only after information about the 
trial including an explanation of its status as research, its objectives, potential benefits, 
risks and inconveniences, alternative treatment that may be available and of the subject‟s 
rights and responsibilities has been provided to the potential subject.   
The patients were selected for clinical trials as per the following criteria, which 
are listed below. 
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Inclusion criteria 
 Age-25-50 
 Low sperm count 
 Willing to give semen for the investigation 
Exclusion criteria 
 Age below 25yrs and above 50yrs 
 Azoospermia 
 Cardiac diseases 
 Diabetic mellitus 
 Hypertension 
 Mumps 
 Orchitis 
 Varicocele 
 Hydrocele 
Withdrawal criteria 
 Irregular visit 
 Uncooperative patient 
 Drug abuse 
 Detoriation of vital signs 
 Any adverse effects during the treatment period 
Investigation criteria: 
 Complete blood count 
 Lipid profile 
 Blood glucose level 
 Semen analysis 
Diagnosing of infertility Patient history 
 Is the patient has oligospermic or from loss of libido or disorder of ejaculation 
 No child birth 
 Prior  history of smoking, heart attacks, strokes 
 Is the patient taking medications that can contribute to infertility 
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Laboratory tests: 
 Complete blood counts 
 Blood glucose level 
 Semen analysis 
Semen analysis: 
 Volume 
 Colour  
 Appearance 
 Viscosity 
 Liquefaction time 
 Motility 
 Sperm count 
  Management:   The aim of the Noineekkam (Treatment) is based on  
 To bring the three Thathus in equilibrium 
 Treatment of the disease 
 Paththiyam (diet restriction) 
 
Drug and Dosage: 
 The test drug Anda odu Parpam was given to the patients at the dose level of 130 
mg once in a day with ghee before food. 
 The duration of the treatment varies according to the severity and response of the 
treatment. 
 It had been given minimum of 1-3 months. 
 
Dietary advice  
The patients are advised to take nuts (Walnuts & Pine nuts), fruits (Bananas, 
Dates, Figs, Grapes, Pomegranate, Strawberry, Peach and Mango) and Vegetables 
(Carrots, Fennel, Onions, Garlic, Cardamom, Asafoetida & pepper). 
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Criteria for assessment of response to therapy: 
1) Marked response : 76%-90% relief in the presenting symptoms and 
marked normality in semen analysis. 
2) Mild response : 50%-75% relief in the presenting symptoms and mild 
normality in semen analysis. 
3) Fair response :    Below 50% relief in the presenting symptoms and fair 
normality in semen analysis. 
 
Observation: 
 The duration of the treatment ranged between 30-90 days. 
 At the time of treatment, no adverse effects were observed. 
 The drug was well accepted by all the patients. 
 
Statistical analysis:  
  The data were subjected to paired student „t‟ test to determine the significance of 
changes followed by comparisons to analyze the significance of difference between pre 
and post treatment.  P value of <0.05 was considered as significant. The results are shown 
in page no. 168 and 169. 
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5. RESULTS AND DISCUSSIONS 
Various studies have been carried out in this trial drug Anda odu parpam. The 
study includes literary collections, physio and bio chemical analysis, toxicological study, 
pharmacological study and clinical study. Anda odu parpam was taken for the treatment 
of Oligospermia. The drug has been selected for the treatment of Oligospermia in 
reference with Anuboga vaidhya navaneedham-Third part written by Hakeem Mohamed 
Abdhulla Shahib. 
 Literary collections about the drug from various text books were done. It 
indicates the efficacy of the drug in the treatment of Oligospermia. Zoological aspect 
deals with the identification, description, cultivation and ethno medicinal importance of 
egg shell. Gunapadam aspect expressed that the drug possess good Spermatogenic 
property. 
Since the trial drug, Anda odu parpam is very easy to prepare, the drug was 
prepared according to the classical methods. This method helps to vitalize the drug. 
The trial drug was studied for its clinical importance in the management of Vindhu 
kuraivu (Oligospermia). 
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Physio chemical report of Anda odu parpam  
 
 
 
Table No.1 Results of Physio chemical report of Anda odu parpam  
S.No Parameter Mean Value 
1.  Loss on Drying at 105°C 0.38 % 
2.  Total Ash  91.47 % 
3.  Acid insoluble Ash   2.3 % 
4.  Particle size Completely passes through sieve no.44 
5.  pH 13.0 
 
By the above results, the trial drug has very low foreign matter and acid insoluble 
ash, indicates that trial drug will digest completely in human GI tract. The analytical 
parameters like total Ash value, Acid insoluble ash value, Loss on drying values are 
helping us to interpret the digestion and solubility capacity of the crude extract. As per the 
result the tested sample contains good percentage of solubility as well as digestive 
capacity. 
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Proximate Chemical Analysis of a Drug 
Department of Bio-Chemistry 
Govt. Siddha Medical College, Chennai – 600 106. 
Preparation of Extract: 
Add 5 gm of the Anda odu parpam to 50ml of distilled water. Boil the solution for 
20 minutes, cool and then filter. Use the Extract for the following tests. 
Table No: 1.1 Chemical analysis of Anda odu parpam 
S.No Experiment Observation Inference 
1. 
Test for reducing 
Sugar 
Absence of Green / Yellow / Red 
precipitation 
Absence of Reducing 
Sugar 
2. Test for Starch  Absence of Blue Colour Absence of Starch 
3. Test for Proteins  Violet  Colour Presence of Proteins 
4. Test for amino Acid  Violet Colour Presence of Amino Acid 
5. Test for Albumin  Absence of Yellow precipitation Absence of Albumin 
6. Test for Phosphate  Yellow precipitation Presence of Phosphate 
7. Test for Sulphate White precipitation Presence of Sulphate 
8. Test for Chloride  Cloudy White precipitation Presence of Chloride 
9. Test for Iron  Red Colour Presence of Iron 
10. Test for Calcium White precipitation Presence of Calcium 
11. Test for Sodium  Absence of Yellow Flame Absence of Sodium 
12. Test for Potassium  Yellow precipitation Presence of Potassium 
13. Test for Zinc  White precipitation Presence of Zinc 
14. Test for Magnesium  White precipitation Presence of Magnesium 
15. Test for Alkaloids  
Absence of Red Colour 
Absence of Yellow Colour 
Absence of White precipitation 
Absence of Alkaloids 
Absence of Alkaloids 
Absence of Alkaloids 
16. Test for Tannic Acid  Absence of Black precipitation Absence of Tannic Acid 
 
Results: From the preliminary chemical analysis of Anda odu parpam contained Zn, Mg, 
K, S, Cl, Ca, Iron, Protein and Amino acid. The above result, the major ions are 
performing an important role in the spermatogenesis and promotes sperm count.  
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Physio chemical result – FTIR 
Graph No. 1 Physio chemical result (FTIR) 
 
AOP 26.09.12.pk 
SP  3601  4000.0  400.0  3.1  100.0  4.0  %T  4  2.0 
REF 4000 100.0 2000 74.2 600 
3879.5  92.6   3644.6  3.1    3586.3  67.5   3446.1  60.4   2981.7  86.7    
2874.1  79.9   2513.6  63.8   1799.2  40.8   1423.5  4.0    1159.0  53.6    
951.5   68.4   875.2   36.4   712.7   79.2   577.4   85.9    
END 14 PEAK(S) FOUND 
Interpretation 
The above result shows the Anda odu parpam contained amines, phenols, 
alcohols, alkanes, carboxylic acid, Esters (C-O stretch), aromatic and bromoalkanes 
compounds. All these compounds help the spermatogenesis activity. 
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Fig. No: 6 Image of scanning electron microscope (SEM) for AOP at 10um 
Fig. No: 7 Image of scanning electron microscope (SEM) for AOP at 2um 
 
Results: 
The particle size of Anda odu parpam 113nm, 116nm, 123nm & 188nm. Because 
of these smaller size of the particles, it absorbs easily in the digestive system  
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Toxicological Study 
Results 
Table 2: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 500 + - - + - + + - - - - - - - - - - - - - 
2 1000 + - - + - + + + - - - - - - - + - - + + 
3 2000 + - - + - + + + + + + - + - - + + + + + 
 
 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming 5. Gripping 6. Touch 
Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle 
Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 
15.Lacrimation 16. Exophthalmos       17. Diarrhoea 18. Writhing 19. Respiration 
20. Mortality 
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Table 3. Effect of Anda Odu Parpam on Hematological and Biochemical blood 
parameters of rats after 28 days oral administration. 
 
Parameter 
Treatment and Dose 
Control 
Anda Odu 
Parpam 
(50mg/kg) 
Anda Odu 
Parpam 
(100mg/kg) 
Anda Odu 
Parpam 
(200g/kg) 
WBC(X10
3
/µL) 11.1±3.0 12.0±1.4 11.5±0.8 11.0±0.6 
RBC(X10
12
/l) 7.0±0.15 6.66±0.14 6.25±0.19* 6.72±0.22 
Hemoglobin(g/dl) 14.0±0.42 12.25±0.30 12.59±0.28 12.11±0.82* 
Hematocrit (%) 0.42±0.02 0.35±0.02 0.35±0.02 0.37±0.04 
MCV (fl) 54.2±0.3 52.4±0.4* 52.1±0.5** 52.2±0.5* 
MCHC (g/dl) 35±0.1 36.2±0.5 35.4±1.2 34.1±1.2 
MCH (pg) 20±0.2 20±0.1 20±0.2 20±0.3 
Platelet count (X10
9
/l) 868.0±102 862.1±120 848.8±136 838.4±166 
Bilirubin 1.60±0.5 0.48±0.04 1.00±1.2 1.23±1.4 
ALT (µ/l) 70.2±2.4 78.0±5.2 75 ± 4.0 68.5±3.5 
AST (µ/l) 90.2±3.4 98.17±2.5 127.4±2.8** 126.10± 3.0** 
Creatinine (µ/l) 28.11±2.0 28.14±2.4 29.00 ± 4.0 28.19 ± 4.3 
Cholesterol (mmol/l) 40.22±1.2 47.15±1.4* 45.92±2.6 42.12±2.0 
Alkaline 
Phosphate(µ/l) 
72.24±2.2 82.8±3.9 90.44±2.1** 91.35±3.2** 
Triglyceride (µ/l) 25.5±4.0 26.11±4.2 23.88±4.1 24.10±3.4 
 
Values are mean of 6 animals  S.E.M. (Dunnett's test). *P<0.05; **P<0.01. Vs. control  
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Table 4: Effect of Anda Odu Parpam on vital organ weight in 28 day sub-acute 
toxicity study 
 
  
Values are mean of 6 animals  S.E.M. (Dunnett's test). *P<0.05; **P<0.01. Vs. control  
 
 
 
 
 
 
 
Organs Control 
Anda Odu 
Parpam 
(50mg/kg) 
Anda Odu 
Parpam 
(100mg/kg) 
Anda Odu 
Parpam 
(200mg/kg) 
Lung 1.24 ± 0.05 1.21 ± 0.05 1.20 ± 0.03 1.12 ± 0.04 
Heart 0.80 ± 0.04 0.81 ± 0.02 0.85 ±0.05 0.84 ± 0.02 
Liver 6.25 ± 0.20 6.45 ± 0.17 6.82 ± 0.31 6.22 ± 0.23 
Pancreas 0.84 ±0.05 0.86 ±0.05 0.84 ± 0.04 0.81 ± 0.03 
Spleen 0.61 ± 0.02 0.59 ± 0.02 0.60 ± 0.04 0.58 ± 0.04 
Testis 0.50 ± 0.03 0.49 ± 0.03 0.51± 0.04 0.48 ± 0.04 
Kidney 0.78 ±0.02 0.76 ± 0.02 0.77 ± 0.02 0.76 ± 0.02 
Ovary 0.08 ± 0.00 0.07 ± 0.01 0.08 ± 0.04 0.08 ± 0.02 
Brain 0.47 ±0.05 0.44 ± 0.03 0.45 ± 0.05 0.44 ±0.04 
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Table 5- Urine Analysis 
 
Parameters 
Control Anda Odu 
Parpam 
(50mg/kg) 
Anda Odu 
Parpam 
(100mg/kg) 
Anda Odu 
Parpam 
(200g/kg) 
Colour Yellow Yellow Yellow
 
Yellow 
Transparency Clear Slightly turbid cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen 
Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
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Fig No: 8 Histopathological images of animals treated with Anda odu parpam 
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Animals were shown significant toxic clinical signs during the dosing period of 28 
days. All animals from treated dose groups not survived throughout the dosing period of 
28 days and it was found two animal dead after 12days of treatment in mid and high dose. 
Results of body weight determination of animals of control and different dose groups 
exhibited comparable body weight gain throughout the dosing period of 28 days. During 
dosing period, the quantity of food consumed by animals from different dose groups was 
found to be comparable and normal with that of control animals. Ophthalmoscope 
examination of animals in control and Anda Odu Parpam treated group revealed minor 
abnormality.  
 The results of haematological investigations conducted on day 28, revealed 
following significant changes in the values of different parameters investigated when 
compared with those of respective controls and, the increase or decrease in the values 
obtained was within normal biological and laboratory limits. A slight fall in total 
Heamatocrit, Hb and RBC count values were obtained for animals in the dose group of 
100 and 200 mg/kg (P<0.05). Results of Biochemical investigations conducted on days 28 
revealed the significant changes in the values of different parameters studied when 
compared with those of respective controls; however, the values obtained were within 
normal biological and laboratory limits. Cholesterol level is elevated in animals of 50 and 
100 mg/kg dose group (P<0.05). AST and ALP levels slightly increased in animals of 100 
and 200mg/kg group (P<0.01). Urine analysis data of control group and treated group of 
animals determined in week 4 did not reveal any abnormalities.  Comparison of organ 
weights of treated animals with respective control animals on day 28 was found to be 
comparable but the testis and kidney weight was increased. Gross pathological 
examination of animals in control as well as the treated groups did not reveal any 
abnormalities.  
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Pharmacological Study - Results and discussion  
Table 6. Effect of Anda Odu Parpam on body weight of male albino rats. 
Parameter Control 50 mg/kg 100 mg/kg 
Initial Body Weight (g)  164.12 ± 1.30 160.10 ± 2.02 158.88 ± 1.29 
Final Body Weight (g))  191.41 ± 1.22 180.35 ± 1.74** 174.20 ± 2.25** 
*P<0.05, values expressed as Mean±SEM, n=6 
Table 7. Effect of Anda Odu Parpam on reproductive organ weights of male albino 
rats 
Organs Control 50 mg/kg 100 mg/kg 
Testes (g) 1. 90 ± 0.02 2.18 ± 0.02** 2.26 ± 0.02** 
Epididymis (g) 0.35 ± 0.01 0.42 ± 0.01** 0.45 ± 0.01** 
Ventral prostate (g) 0.29 ± 0.02 0.34 ± 0.03 0.36 ± 0.02 
Seminal vesicle (g) 0.47 ± 0.01 0.54 ± 0.01** 0.58 ± 0.01** 
Vas deferens (g) 0.12 ± 0.01 0.12 ± 0.01 0.13 ± 0.01 
 
 
 
0
0.5
1
1.5
2
2.5
Testes (g) Epididymis (g) Ventral prostate (g) Seminal vesicle (g) Vas deferens (g) 
W
e
ig
h
t 
in
 g
m
s
Organs
Control 50 mg/kg 100 mg/kg
Graph No. 2 Effect of Anda Odu Parpam on reproductive organ weights of male 
albino rats  
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Table 8. Effect of Anda Odu Parpam on hematological and biochemical parameters 
in male rats after 28days of treatment. 
 
Parameters Control AOP 50mg/kg AOP 100mg/kg 
Hemoglobin (gm %) 12.57± 0.22 13.24±0.18  13.66±0.20**  
RBC (million/cu.mm) 5.50± 0.03 5.62± 0.03  5.70± 0.03  
WBC (X10
3
/cu.mm) 4.38± 0.50 4.36±0.42  4.34± 0.65  
Blood sugar (mg/dL) 72.12± 1.25 68.30± 2.65  64.13± 3.12  
Blood urea (mg/dL) 31.46± 2.42 30.41±3.14  33.58± 3.11  
S.Cholesterol (mg/dL) 72.32± 0.45 68.10± 1.00**  66.24± 1.12**  
S.phospholipids (mg/L) 72.41± 0.42 70.28± 0.40** 72.40± 0.45  
S. protein (mg/dL) 7.99± 0.62 8.10±0.64  8.36± 0.48  
*P<0.05, values expressed as Mean±SEM, n=6 
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Graph No. 3 Effect of Anda Odu Parpam on hematological and biochemical 
parameters  
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Table 9: Effects of Anda Odu Parpam on sperm count, motility, viability and 
abnormal morphology after 14 days treatment. 
Groups 
Count 
(10
6
/ml) 
Motility (%) 
Viability 
(%) 
Abnormal 
Morphology 
Control 8.72 ±0.44 87.48±1.20 94.07 ±1.28 2.12 ±0.30 
AOP 50mg/kg 8.90±0.70 89.52±2.18 95.24 ±1.52 2.27 ±0.28 
AOP 100mg/kg 9.02±0.64 90.55±1.56 95.66 ±1.30 2.14 ±0.42 
*P<0.05, values expressed as Mean±SEM, n=6  
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Graph No. 4 Effects of Anda Odu Parpam on Semen quality after 14 days 
treatment  
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Table 10: Effects of Anda Odu Parpam on sperm count, motility, viability and 
abnormal morphology after 28 days treatment 
Groups 
Count 
(10
6
/ml) 
Motility (%) 
Viability 
(%) 
Abnormal 
Morphology 
Control 8.10±0.24 85.10±1.77 90.02 ±1.79 2.60 ±0.30 
AOP 50mg/kg 9.22±0.25* 87.54±2.28 95.26 ±2.17 2.55 ±0.35 
AOP 100mg/kg 9.25±0.34* 90.50±1.62 95.80 ±1.74 2.62 ±0.34 
*P<0.05, values expressed as Mean±SEM, n=6 
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    Fig No: 9 Histo pathology study on AOP treated in animals at various dosages 
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  In the acute and sub acute toxicity study, Mortality and sign of toxicity, such as 
weight loss, abnormal grooming, reflex response and other behavioral manifestations was 
seen in the limit test dose at 2000 and 5000mg/kg. The mild behavioural change like 
lethargy was observed in the 500mg/kg treated animals. From the maximum tolerable 
dose 500mg/kg of Anda Odu Parpam one-fifth and one tenth of the dose was taken as the 
therapeutic dose levels for the further pharmacological study. The rats did not reveal 
observable signs of central nervous system and mortality during spermatogenic 
assessment. And also a significant increase in the average daily body weights indicating 
that the test animals were in healthy condition at the throughout the study. This indicates 
that the dosages administered were below toxic level.  
 TCDD and its related congeners have been shown to act as developmental and 
reproductive toxicants, which reduce testicular and accessory sex organ weights, alter 
testicular morphology, and decrease sperm production. Significant increase (P < 0.05) in 
weights of testes, epididymides, ventral prostrate, seminal vesicles and vas deferens were 
observed in the treated groups compared with the control. It is well established that 
androgens are the major regulators of the growth, structure and functions of accessory sex 
organs. In accessory sex organs it is not testosterone, but rather the 5α-reduced 
metabolites, dihydrotestosterone and 3α, 17β-androstiendiol are the primary regulatory 
hormones controlling their structure and functions. A decrease in such androgen 
metabolites might eventually result in decreased accessory sex organs weight.  
 High levels of intratesticular testosterone are necessary for the proliferation and 
differentiation of spermatogenic cells and spermatogenesis. While high circulating 
testosterone concentration is required for functional integrity of androgen dependent 
accessory sex organs. Testosterone is synthesized and released by the Leydig cells in 
response to LH. The Leydig cells are able to respond to changes in LH secretion within 
half an hour and influence the seminiferous tubules by maintaining a high concentration 
of testosterone in the peritubular compartments of the testis. Spermatogenesis involves a 
complex interplay between the structural elements of testis and the endocrine system.  
 Hypothalamic gonadotrophic releasing hormone induces pituitary gonadotrophin. 
Abundance of spermatozoa in seminiferous tubule clearly indicates spermatogenesis 
which is regulated by hormone. Hypertrophy of Leydigs cells is also suggestive of 
steroids synthesis. A significant decrease in the seminiferous tubular diameter, Leydig 
cell nuclear diameter and alterations in the Leydig cells differential counts probably 
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correspond to decrease in testosterone production and or inhibin of pituitary gonadotropin 
secretion, hence, disruption of spermatogenesis occurred. In the heamatological 
investigations, no significant differences were found in the total leukocyte count, level of 
hemoglobin and in hematocrit value in Anda Odu Parpam treated rats compared to 
control. But, significant changes were noted in the levels of blood sugar, serum 
cholesterol and increase in the serum testosterone level in the rats treated with Anda Odu 
Parpam at the both dose levels used in this study.  
 Histological effect of Anda Odu Parpam on gonadal tissues at dose 0.1g/kg body 
weight showed spermatogenic series of cells seen at the various stages of transformation 
and differentiation with central tubule showing marked spermatogenic transformation of 
spermatids into spermatozoa. The supporting Sertoli cells are intact and also the basal 
lamina placed spermatogonia are intact and spermatids at various stages of differentiation 
filled up the central lumen of the tubules.  
 The outcome of all point to an increased activity of spermatogenesis. Similarly 
Anda Odu Parpam 50mg/kg treated male albino rats showed spermatogenic cells with 
central tubule showing marked spermiogenic transformation. Photomicrographs of the 
untreated control showed normal histoarchitecture of these structures. There were no 
treatment related adverse effects on seminal vesicles, prostate gland and vas deferens. 
Photomicrograph of normal testis of rat showing well layered seminiferous tubules with 
different stages of spermatogenic cells  
 The current investigation reveals that the therapeutic dose of Anda Odu Parpam 
has no toxic effects on rats administered orally. This was particularly based on the 
observation of the daily body weight changes which are not significantly different with 
the control. Although there was a slight decline in the reproductive organ weight to body 
weight ratio, reproductive organs in general were unaffected by oral administration of the 
Anda Odu Parpam. Further tests, however, should be conducted to confirm the precised 
effects on spermatogenesis. It is suggested that histological analysis be conducted to 
determine the effects of the Anda Odu Parpam, spermatogonia, epithelialization of 
spermatogonial cells, and lumen diameter. Our results indicated that administration of 
Anda Odu Parpam creates marked improvement in the sperm counts and motilities 
compared with control.  
 A significant enhancement in the number and motility of sperm (p<0.05) was 
observed in experimental animals, which could be due to the influence of the Anda Odu 
Parpam on the cell cycle, cell division and expression of genes necessary for the 
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spermatogenesis and also that these changes might be resultant effect of changes in the 
microenvironment of epididymis and creation of a pleasant environment influencing for 
the improvement of sperm count and motility. Reduced numbers of spermatozoa, 
abnormal spermatozoa or their reduced or insufficient motility are the leading causes of 
disturbed fertility or infertility in patient.  
 
Clinical results and discussions of Anda odu parpam 
 
The clinical factors considered for the purpose of the study comprised as follows: 
 
Age Distribution 
Occupational status 
Socio economic Status 
Food habits 
Personal habits 
Symptoms 
Udal kattugal 
Enn vagai thervu 
Naadi   
Classification on the basis of Neikkuri 
Clinical progress 
Results after treatment. 
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Inference: 
 According to the above mentioned data 60% of patients were in age groups 25-35 
years, 40% of patients were in age group 36-50 years. 
 
Occupational Status: 
 
 
Inference 
32% of cases were drivers. 
20% of cases were labours. 
28% of cases were Business Man. 
20% of cases were professionals. 
 
 
 
Sl.No Age 
No. of 
patients/50 
Percentage 
 
1. 
 
25-35 
 
30 
 
60% 
 
2. 
 
36-50 
 
20 
 
40% 
 
Sl.No 
Occupational   
status 
No. of 
patients/50 
Percentage 
`  1 Drivers 16 32% 
2 Labours 10 20% 
3 Professionals 14 28% 
4 Businessman 10 20% 
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Table No. 11 Age Distribution  Graph No.6  Age Distribution  
Table No. 12 Occupational status  Graph No.7 Occupational status  
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Inference 
 38% of cases belong to Low income group and 32% of patients belong to lower 
income group. 30% of cases belong to high income group. 
 
 
   
  Inference 
  66% of cases were mixed diet and 34% of cases were Vegetarian. 
 
 
 
Sl.No 
Socio Economic 
Status 
No. of 
patients/50 
In % 
1 
Low income group 
(below 
10000/month) 
19 38% 
2 
Middle income 
group 
(below 
15000/month) 
16 32% 
3 
High income group 
(below 
20000/month) 
15 30% 
Sl.No 
Food 
Habit 
No. of 
patients/50 
Percentage 
1. 
Vegetarian 
Diet 
17 34% 
2. 
Mixed 
Diet 
33 66% 
38%
32%
30%
LOW INCOME GROUP
MIDDLE INCOME GROUP
HIGH INCOME GROUP
Table No. 13 Socio economic status  Graph No.8 Socio economic status  
Table No. 14 Food habits Graph No. 9 Food habits 
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Sl.No  Personal Habits No. of patients/50 Percentage 
  1 Smoker               15 30% 
  2 Alcoholic               13 26% 
  3 Tobacco chewing               12 24% 
  4 No bad Habits               10 20% 
     
 
 
                 
 
 
Inference 
 20% of patients had no bad habits, 30% of cases were smoker, 26% of cases were 
alcoholic and 24% were tobacco chewers. 
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Table No. 15 Personal habits 
Graph No.10 Personal habits 
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Sl.No Symptoms No. of patients/50 Percentage 
  1 Premature ejaculation 10 20% 
  2 Erectile Dysfunction 5 10% 
  3 Painful Coitus 5 10% 
  4 Nocturnal Emission 10 20% 
  5 Burning Micturation 5 10% 
  6 No symptoms 15 30% 
  
 
 
 
 
 
Inference 
 20% of cases came with complaints of premature ejaculation and 10% of cases 
with erectile dysfunction, 10% cases had painful coitus, 10% cases with burning 
micturation, 20% cases with nocturnal emission and 30% of cases had no symptoms. 
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Table No. 16 Symptoms 
Graph No.11 Symptoms 
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Sl.No  Udal Kattugal No. of patients/50 Percentage 
     1  Saaram               50  100% 
     2 Senner                0 0% 
     3 Oon                0 0% 
     4 Kozhuppu                0 0% 
     5 Enbu                6 12% 
     6 Moolai                0 0% 
     7 Sukkilam               50  100% 
 
 
                   
 
Inference: 
 Both Saaram and Sukkilam were affected in 100% of patients and Enbu was 
affected in 12% of patients 
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Table No: 17 Udal Kattugal 
Graph No: 12 Udal Kattugal 
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Table No: 18 Enn Vagai Thervu 
 
Sl.No Enn Vagai Thervu No. of patients/50 Percentage 
   1 Naa             0            0% 
   2 Niram             0            0% 
   3 Mozhi             0            0% 
   4 Vizhi             15          30% 
   5 Naadi            50        100% 
   6 Sparism             0            0% 
   7 Malam             0            0% 
   8 Moothiram             0            0% 
 
Graph No: 13 Envagai Thervugal 
                 
 
Inference 
 Naadi was affected in 100% of patients and 30% of patients vizhi was affected. 
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Table No: 19 Naadi: 
 
Sl.No Naadi No. of patients/50 Percentage 
   1 Vathapitham 20       40% 
   2 Pithavatham 30       60% 
 
 
 
Graph No: 14 Naadi 
                 
 
 
Inference 
  40% of patient‟s vatha pitha naadi was felt and 60% of cases Pitha vatha 
naadi was felt. 
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Table No: 20 Clinical progress 
 
Sl.No Symptoms 
No.of patients/50 Percentage 
BT AT BT AT 
  1 Premature ejaculation       10     6 20% 12% 
  2 Erectile Dysfunction        5     4 10% 8% 
  3 Painful Coitus        5     1 10% 2% 
  4 Nocturnal Emission      10     2 20% 4% 
  5 Burning Micturation        5     1 10% 2% 
     
 
 
Inference 
   Before treatment 50% of cases had premature ejaculation, 50% of cases 
had nocturnal emission & 25% having erectile dysfunction. 
  After treatment premature ejaculation, nocturnal emissions were 15% and 
10% of cases respectively & 10% having erectile dysfunction. 
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Table No: 21 Gradation of results 
 
Sl.No Gradation of results No. of patients/50 Percentage 
   1 Marked response                30        60% 
   2 Mild response                12        24% 
   3 Fair response                 8        16% 
 
 
Graph No: 16 Gradation of results 
 
                     
 
 
 
Inference 
  60% of Patients show good improvement, 24% of shows moderate 
improvement and 16% of cases shows poor improvement. 
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Biostatistical Analysis 
Effect of Anda odu parpam on Sperm Count in human subjects 
Sl.No 
Sperm Count 
(Million/Cumm)  Sl.No 
Sperm Count (Million/Cumm) 
BT AT 
 
BT AT 
1 6.2 12.6 
 
26 60 70 
2 8 42 
 
27 20 45 
3 17 26 
 
28 40 50 
4 18 60 
 
29 65 85 
5 10 50 
 
30 12 16 
6 62 70 
 
31 6 45 
7 16.2 49 
 
32 55 68 
8 34 52 
 
33 48 70 
9 53 86 
 
34 35 45 
10 10 14 
 
35 59 80 
11 6 40 
 
36 26 52 
12 49 67 
 
37 10 56 
13 46 71 
 
38 25 30 
14 14 44 
 
39 16 20 
15 50 76 
 
40 67 75 
16 25 50 
 
41 44 70 
17 19 56 
 
42 35 48 
18 25 30 
 
43 18 25 
19 17 20 
 
44 20 59 
20 65 75 
 
45 26 45 
21 44 72 
 
46 60 70 
22 37 48 
 
47 18 45 
23 20 25 
 
48 40 55 
24 29 59 
 
49 45 80 
25 15 45 
 
50 12 16 
Software: spss17 version 
Variables: Sperm Count (millions/cu mm) – before treatment, after treatment 
Number of cases: 50 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.797 
Before and after treatment mean difference: 20.04±12.44 (millions/cu mm). 
P Value (2 tailed): p<0.01. 
Inference:  The „p‟ value is significant (p<0.01).  So the treatment was significantly 
improving the Semen count (millions/cu mm). 
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Effect of Anda odu parpam on Sperm Motility in human subjects 
Sl.No 
Sperm Motility (%) 
 Sl.No 
Sperm Motility (%) 
BT AT 
 
BT AT 
1 10 40 
 
26 15 30 
2 50 58 
 
27 6 30 
3 8 10 
 
28 30 55 
4 22 45 
 
29 15 45 
5 4 10 
 
30 3 4 
6 20 30 
 
31 4 45 
7 6 27 
 
32 18 30 
8 35 55 
 
33 28 53 
9 25 45 
 
34 10 20 
10 2 4 
 
35 12 40 
11 9 40 
 
36 15 50 
12 20 30 
 
37 7 55 
13 30 54 
 
38 28 25 
14 10 20 
 
39 20 15 
15 15 40 
 
40 13 34 
16 10 50 
 
41 30 48 
17 10 55 
 
42 55 58 
18 28 25 
 
43 6 10 
19 20 15 
 
44 22 50 
20 12 34 
 
45 3 11 
21 30 48 
 
46 15 30 
22 50 58 
 
47 4 38 
23 7 10 
 
48 35 60 
24 22 50 
 
49 20 45 
25 3 30 
 
50 6 8 
Software: spss17 version 
Variables: Sperm motility (%) – before treatment, after treatment 
Number of cases: 50 
Test: Paired t test 
Confidence Interval: 95% 
Correlation coefficient (r): 0.617 
Before and after treatment mean difference: 17.88±13.40 (%). 
P Value (2 tailed): p<0.01. 
Inference:  
The p value is significant (p<0.01).  So the treatment was significantly improving 
the sperm motility (%). 
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6. CONCLUSION 
The trial drug Anda odu parpam (Egg shell of gallus domesticus) is selected from 
the classical Siddha text Anuboga Vaidhaya Navaneetham-Part III for the evaluation of 
safety and efficacy in the management of Male infertility. 
 The trial drug was duly identified and authenticated by the Gunapadam experts. 
 The presence of Zn ions indicates that they help improving the sperm count. The 
other components Mg, K, Ca, Protein, Amino acid, Phosphate, Sulphate, Chloride and 
Iron ions are also responsible for its spermatogenic property. 
 Toxic effect was observed at 100mg/kg of Anda Odu Parpam treated via oral 
route over a period of 28 days. So, it can be concluded that the Anda Odu Parpam can be 
prescribed for therapeutic use in human with the 30-40% dose reduction from median 
dose used in this study. 
Oral administration of Anda Odu Parpam at 50 and 100mg.kg dose level increase 
the weight of testes and seminal vesicles, improve semen quality, quantity and increase 
testosterone levels.Therefore, this study recommends that intake of Anda Odu Parpam 
may be useful for patients who suffer from male infertility. Thus, the drug Anda Odu 
Parpam may provide an alternative for management of infertility due to reduced 
spermatogenesis or oligospermic condition at the prescribed dose level. 
Single dose (100 mg/kg body weight, oral) treatment with the Siddha drug Anda 
odu parpam produced remarkable spermatogenic activity. Finally it can be concluded that 
Anda odu parpam was found to possess remarkable (P< 0.05) in male rats.  
 The open clinical trial results reveal that 84% of patients were having 
improvement in the clinical futures and biochemical reports. The study validates the 
effectiveness of Anda odu parpam in improving the sperm count. 
            The drug is easily available and preparation is very simple. The trial medicine is 
cost effective. No adverse effects were produced during the entire course of treatment.  
Conclusively, that the drug “Anda odu parpam” (Parpam of egg shell of Gallus 
domesticus) gives a new hope in the field of Infertility treatment. 
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7. SUMMARY 
 The hen egg shells (Ovitesta of Gallus Domesticus) were collected from the 
hatchery at Namakkal and the lemon were collected from a form house at Idappadi, 
Salem District and Anda odu parpam is prepared as quoted in the classical Siddha 
literature. 
Anda odu parpam was selected by the author for this study to establish the 
Spermatogenic activity. 
To collect the information about the drug, various text books, literature were 
referred. From them, the author came to an idea about the drug and its efficacy on 
Infertility. 
A brief description about zoological aspect of the Anda odu parpam and its 
identifying characters and physio chemical and bio chemical data were given. 
The wide use of according to Gunapadam aspect as well as in various Siddha 
literatures were discussed with much importance to that of preparation related to Vindhu 
kuraivu. 
The bio chemical analysis of the drug shows that it contains Zn ions indicates that 
they help in maintaining the sperm count. The other components Mg, K, Ca, Protein, 
Amino acid, Phosphate, Sulphate, Chloride and Iron ions are also responsible for its 
spermatogenic property. It is related in treatment of male infertility. 
The preclinical study showed that the drug has got safety and significant 
Spermatogenic activity. 
The patients were responding well from the beginning of the treatment and no 
adverse effects were reported. 
The clinical result reveals that 84% of patients were improvement in the clinical 
futures and biochemical reports. 
This present study confirms that Anda odu parpam has the remarkable 
Spermatogenic activity and high therapeutical value against the clinical symptom of 
Oligospermia. 
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CONSENT FORM 
 
 
          I certify that I have disclosed all the details about the study in the terms 
readily understood by the patient.  
 
 
DATE :                                                         SIGNATURE OF THE INVESTIGATOR 
PLACE:                                                        NAME: 
 
 
 
 
 
CONSENT BY THE PATIENT 
 
           I have been informed to my satisfaction by the attending physician for 
the purpose of the clinical trial and the nature of the drug treatment and 
follow up including the lab investigation to be performed to monitor and 
safeguard my body functions. 
 
           I am aware of my right to opt out of the trial at any time during  
 the course of the trial without having to give reasons for doing so. 
 
           I ,exercising my free power of choice, here by  give my consent to be 
included as a subject in the clinical trial of  Echuramooli ilai Chooranam  
for the treatment of  Paandu. 
 
 
 
 
 DATE:                                                                                       SIGNATURE   
 
PLACE:                                                                                                 NAME                     
1 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
CHENNAI – 600106. 
M.D.(siddha) – BRANCH – II. GUNAPADAM 
 
Name of the Disease : Paandu (Anaemia) 
Name of the Medicine : Echuramooli ilai Chooranam (Aristolochia indica) 
Dose   : 1g bd before food with honey 
 
O.p.No  Address 
Date   
Name  
Age & Sex  
Occupation  
Income  
Marital status  Religion  
Body weight: B.P: P.R: R.R: 
 
 
 
Sign/Symptoms/Day 3 6 9 12 15 18 21 24 27 30 33 36 39 42
Pallor of conjunctivae               
Pallor of Nail beds               
Angular stomatitis               
Glossitis               
Anorexia               
Palpitation               
Swelling of the Body               
Sign of MO               
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Lab 
investigation 
Particulars Before Treatment After treatment 
Blood TC   
 DC   
 ESR   
 Hb   
 Sugar   
 Urea   
 MCV   
 PCV   
 Serum Ferritin   
Urine Albumin 
 Sugar   
 Deposits   
Motion Ova 
 Cyst   
 Occult Blood   
 
 
Siddha Aspect Before treatment After treatment 
Na   
Niram   
Vizhi   
Parisam   
Malam   
Muthiram   
Nadi   
 
 
 
Signature of MO:       Signature of HOD 
 
                                                 CONSENT FORM 
 
 
          I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient.  
 
 
DATE:                                                         SIGNATURE OF THE INVESTIGATOR 
                                                                      NAME: 
 
 
 
 
 
CONSENT BY THE PATIENT 
 
           I have been informed to my satisfaction by the attending physician for the purpose 
of the clinical trial and the nature of the drug treatment and follow up including the lab 
investigation to be performed to monitor and safeguard my body functions. 
 
           I am aware of my right to opt out of the trial at any time during  the course of the 
trial without having to give reasons for doing so. 
 
           I, exercising my free power of choice, here by  give my consent to be included as a 
subject in the clinical trial of  ANDA ODU PARPAM  for the treatment of  
OLIGOSPERMIA. 
 
 
 
 DATE:                                                                                       SIGNATURE   
                                                                                                    NAME                    
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             GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL 
                                                CHENNAI-600 106.   
                                  M.D (siddha) - BRANCH- II. GUNAPADAM   
Name of the Disease     :      Aan maladu (Spermatogenesis activity) 
Name of the Medicine  :     Anda odu parpam                            
Dose     :     130mg bd with ghee before food 
O.p.No                              ADDRESS 
Date   
Name  
Age & sex  
Occupation  
Income  
Marital status  Religion  
Body weight: BP: PR: RR: 
 
 
Clinical features Before Treatment                       During Treatment every 7 days 
1st 2nd 3rd 4th 5th 6th 7th
Premature ejaculation         
Erectile dysfunction         
Painful coitus         
Nocturnal emission         
Burning micturation         
Sign. of M.O :        
 
Investigations 
Semen Analysis Before Treatment After Treatment 
Colour   
Volume (ml)   
Viscosity    
Liquification time (min)   
Sperm concentration(million/cc)   
Motility (%)   
Active motile(%)   
Sluggish motile (%)   
Nonmotile (%)   
 
 
2 
 
 
 
 
 
 
 
  
SIDDHA ASPECT             Before treatment              After treatment 
Naadi   
Papisam   
Naa   
Niram   
Vizhi   
Malam   
Muthiram   
 
 
  
 Signature of MO                                                                                           Signature of HOD                         
Lab investiga-
tion 
Particulars Before Treatment After treatment 
Blood  TC 
 DC   
 ESR   
 Hb 
 Sugar   
 Urea   
 
Urine Albumin   
 Sugar   
 Deposits   
Motion Ova   
 Cyst 
Ultra sonography 
of  Scrotum 
   
Haemoglobin level of OP & IP patients-before treatment and after treatment 
Sl.No O.P. No. Name Age Sex 
Hb level 
before treatment 
Hb level 
after treatemnt 
Total no. of 
days Result 
1. 636 Lakshmi 45 F 12.0 14.2 70 Days Good Improvement 
2. 304 Avudayappan 50 M 11.2 13.7 65 Days Moderate Improvement 
3. 6280 Raj 45 M 6.6 9.2 76 Days Poor Improvement 
4. 1110 Seetha 55 F 13.1 16.2 50 Days Good Improvement 
5. 7400 Maharajan 23 M 9.5 11.5 70 Days Good Improvement 
6. 7732 Nallasivam 30 M 10.0 11.6 50 Days Moderate Improvement 
7. 5341 Lakshmi 40 F 11.5 13.5 56 Days Good Improvement 
8. 1012 Balakrishnan 40 M 14.0 15.2 62 Days Moderate Improvement 
9. 6922 Natrajan 60 M 12.3 14.8 49 Days Good Improvement 
10. 219 Meeran 34 M 9.0 10.0 65 Days Mild Improvement 
11. 4207 Periyasamy 46 M 12.0 14.5 63 Days Good Improvement 
12. 386 Amutha 30 F 7.5 10.8 87 Days Moderate Improvement 
13. 1070 Chitra 28 F 11.0 13.7 76 Days Good Improvement 
14. 5865 Rajesh 29 M 8.0 11.1 92 Days Moderate Improvement 
15. 1983 Pappurani 23 F 10.0 12.9 75 Days Good Improvement 
16. 4216 Shanthy 28 F 12.4 15.2 58 Days Good Improvement 
17. 5320 Abaragam 30 M 12.5 15.9 95 Days Good Improvement 
18. 581 Beerbathu 54 F 12.0 13.0 49 Days Mild Improvement 
19. 7013 Muneyansamy 59 M 9.0 11.4 56 Days Poor Improvement 
20. 2809 Muthammal 63 F 12.6 14.3 45 Days Moderate Improvement 
21. 726 Nalini 39 F 10.2 12.9 105 Days Good Improvement 
22. 420 Gomathy 45 F 11.3 12.5 65 Days Moderate Improvement 
23. 8716 Rekha 42 F 11.6 13.7 78 Days Poor Improvement 
24. 2227 Maharajan 65 M 13.0 15.1 115 Days Good Improvement 
25. 7171 Sayedbeeve 50 F 9.5 11.9 75 Days Good Improvement 
S.No O.P. No. Name Age Sex 
Hb level 
before treatment 
Hb level 
after treatemnt 
Total no. of 
days Result 
26. 7722 Thenmozhi 51 F 10.2 12.7 90 Days Moderate Improvement 
27. 5199 Ponnammal 76 F 10.9 13.2 95 Days Good Improvement 
28. 1301 Parveen 36 F 10.8 12.2 110 Days Moderate Improvement 
29. 6464 Sudalai 75 M 12.0 14.2 85 Days Good Improvement 
30. 108 Cheenisamy 65 M 10.4 11.7 65 Days Poor Improvement 
31. 4827 Ilavarasi 59 F 12.0 14.1 62 Days Good Improvement 
32. 196 Pushpa 60 F 12.3 14.5 87 Days Moderate Improvement  
33. 1053 Sudha 60 F 11.0 12.8 76 Days Good Improvement 
34. 5865 Murugaiya 58 M 12.0 12.8 92 Days Moderate Improvement 
35. 1984 Mageswari 38 F 11.8 14.0 75 Days Good Improvement 
36. 4270 Devi 49 F 12.1 14.7 58 Days Good Improvement 
37. 5203 Juliet 23 F 12.4 15.1 95 Days Good Improvement 
38. 501 Gopalsamy 63 M 14.0 14.9 49 Days Mild Improvement 
39. 7310 Chellavalli 55 F 12.0 12.4 56 Days Poor Improvement 
40. 2408 Radhika 45 F 13.7 15.1 45 Days Moderate Improvement 
41. 711 Radha 36 F 11.0 13.2 105 Days Good Improvement 
42. 166 Gayathri 32 F 10.2 12.7 65 Days Moderate Improvement 
43. 6789 Latha 41 F 8.6 9.2 78 Days Mild Improvement 
44. 1100 Tamilarasi 43 F 13.1 16.2 115 Days Good Improvement 
45. 2406 Elizabeth 33 F 9.0 11.5 75 Days Good Improvement 
46. 5317 Thangaraj 44 M 9.0 10.6 90 Days Mild Improvement
47. 5474 Gobi 34 M 11.3 14.8 95 Days Good Improvement 
48. 1201 Sathya 34 F 13.0 14.2 110 Days Mild Improvement 
49. 5282 Sivakumar 42 M 13.0 16.5 85 Days Good Improvement 
50. 801 Maniraja 31 M 7.4 8.0 65 Days Mild  Improvement 
 
Laboratory investigation report (OP) 
 
 
 
 
 
Sl. 
No. 
O.P. 
No.  Name  Age  Sex 
Haematological report  Urine analysis  Stool examination 
Before treatment  After treatment  ESR (mm)  Hb(Gm)  BT AT BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC  BT  AT 
BT  AT  Alb  Sug  Dep  Alb  Sug  Dep  Ova  Cyst  Ova  Cyst 
P  L  E  P  L  E  1/2hr 
1 
hr 
½ 
hr  1hr 
1.  636  LAKSHMI  45  F  9000  53  41  6  9100  58  38  4  22  51  11  24  10.0  14.2  NIL  ++  Opc  NIL  ++  NIL  NIL  NIL  NIL  NIL 
2.  304  AVUDAYAPPAN  50  M  9800  59  36  5  9900  62  34  5  44  87  41  62  11.2  13.7  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
3.  6280  RAJ  45  M  6100  44  51  5  6300  51  44  5  36  73  21  41  12.0  9.2  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
4.  1110  SEETHA  55  F  9800  59  36  5  9800  59  37  4  20  35  18  32  13.1  16.2  NIL  NIL  Fpc  NIL  NIL  Fpc  NIL  NIL  NIL  NIL 
5.  7400  MAHARAJAN  23  M  9200  52  39  9  9200  58  38  4  22  40  20  25  9.5  11.5  NIL  NIL  Oec  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
6.  7732  NALLASIVAM  30  M  7600  49  46  5  8000  52  44  4  15  25  15  22  10.0  11.6  NIL  +  Opc  NIL  +  Opc  NIL  NIL  NIL  NIL 
7.  5341  LAKSHMI  40  F  9400  57  36  7  10100  60  36  4  12  18  7  12  11.5  12.5  NIL  +  Opc  NIL  +  NIL  NIL  NIL  NIL  NIL 
8.  1012  BALAKRISHNAN  40  M  8700  59  35  6  8800  58  56  6  5  10  8  18  14.0  15.2  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
9.  6922  NATRAJAN  60  M  10400  63  31  6  10400  62  33  5  44  79  24  44  13.3  14.8  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
10.  219  MEERAN  34  M  7600  48  46  6  7800  50  45  5  13  15  15  17  7.5  10.0  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
11.  4207  PERIYASAMY  46  M  9000  49  45  6  9200  50  45  5  16  24  16  21  13.0  14.5  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
12.  386  AMUTHA  30  F  7400  53  41  6  7600  52  40  8  57  78  37  67  7.5  10.8  NIL  ++  NIL  NIL  ++  NIL  NIL  NIL  NIL  NIL 
13.  1070  CHITRA  28  F  9400  57  38  5  9500  59  36  5  12  17  17  22  11.0  12.7  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
14.  5865  RAJESH  29  M  10100  60  34  6  10200  60  36  4  35  68  13  33  8.0  11.1  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
15.  1983  PAPPURANI  23  F  7800  55  38  7  7900  54  42  4  39  71  24  39  10.0  11.9  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
16.  4216  SHANTHY  28  F  9800  55  39  6  9800  55  41  4  19  25  18  20  14.4  15.2  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
17.  5320  ABARAGAM  30  M  9700  60  36  4  9800  60  35  5  3  10  4  12  14.5  15.9  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
18.  581  BEERBATHU  54  F  8600  55  39  6  8700  56  38  6  15  28  11  21  12.0  15.4  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
19.  7013  MUNEYANSAMY  59  M  8000  55  39  6  8000  57  37  6  34  61  19  39  9.0  11.4  NIL  +  NIL  NIL  +  NIL  NIL  NIL  NIL  NIL 
20.  2809  MUTHAMMAL  63  F  9200  61  36  3  9300  62  35  3  36  63  20  33  12.6  14.3  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
 TC – Total Count       Hb – Haemoglobin        OEC – Occasional Epithelial Cells 
Dc – Differential Count    ESR – Erythrocyte Sedimentation Rate  OPC – Occasional Pus Cells 
P – Polymorph       Alb – Albumin          FPC – Few Pus Cells 
L – Lymphocyte      Sug – Sugar          FEC – Few Epithelial Cells 
E – Eosinophil        Dep – Deposits   
Sl. 
No. 
O.P. 
No.  Name  Age  Sex 
Haematological report  Urine analysis  Stool examination 
Before treatment  After treatment  ESR (mm)  Hb(Gm) BT AT BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC  BT  AT 
BT  AT  Alb  Sug  Dep  Alb  Sug  Dep  Ova  Cyst  Ova  Cyst 
P  L  E  P  L  E  1/2hr 
1 
hr 
½ 
hr 
1hr 
21.  726  NALINI  39  F  9400  55  32  13  9500  57  33  10  16  29  13  19  10.2  12.1  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
22.  420  GOMATHY  45  F  7600  48  46  6  7800  52  43  5  14  16  16  18  11.3  12.5  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
23.  8716  REKHA  42  F  10400  66  29  5  10400  65  30  5  20  50  13  35  11.6  13.7  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
24.  2227  MAHARAJAN  65  M  9200  53  40  7  9200  53  42  5  24  49  19  34  13.0  15.1  NIL  NIL  Fpc  NIL  NIL  Fpc  NIL  NIL  NIL  NIL 
25.  7171  SAYEDBEEVE  50  F  9100  57  30  13  9400  55  33  12  5  10  6  12  10.5  11.9  NIL  ++  Opc  NIL  ++  NIL  NIL  NIL  NIL  NIL 
26.  7722  THENMOZHI  51  F  9800  59  37  4  9400  60  33  7  11  14  11  13  10.2  12.7  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
27.  5199  PONNAMMAL  76  F  10700  63  34  3  10700  62  33  5  35  61  15  31  10.9  13.2  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
28.  1301  PARVEEN  36  F  8000  49  47  4  8100  52  45  3  13  30  8  10  10.8  12.2  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
29.  6464  SUDALAI  75  M  9000  55  30  15  9100  58  38  4  15  23  13  15  12.0  14.2  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
30.  108  CHEENISAMY  65  M  8400  58  36  6  8400  58  38  4  21  70  11  28  10.4  11.7  NIL  NIL  1‐2PC  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
31.  4827  ILAVARASI  59  F  10000  62  34  4  10100  58  35  7  16  26  9  16  12.0  14.1  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
32.  196  PUSHPA  60  F  9700  57  38  5  9600  58  37  5  17  47  17  32  12.3  14.5  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
33.  1053  SUDHA  60  F  9600  59  36  5  9600  58  40  2  25  53  18  38  11.0  12.6  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
34.  5865  MURUGAIYA  58  M  9000  47  48  5  9100  50  45  5  16  26  16  24  12.0  12.8  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
35.  1984  MAGESWARI  38  F  9400  55  39  6  9500  58  36  6  27  43  25  37  11.8  14.0  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
36.  4270  DEVI  49  F  9000  55  42  3  9200  57  40  3  10  18  10  17  12.1  14.7  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
37.  5203  JULIET  23  F  9000  55  39  6  9100  54  40  6  13  32  12  27  12.4  15.1  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
38.  501  GOPALSAMY  63  M  9400  55  41  4  9500  55  42  3  14  26  16  16  13.0  14.7  NIL  NIL  Fec  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
39.  7310  CHELLAVALLI  55  F  8000  58  37  5  8100  59  37  4  17  33  16  22  10.0  12.4  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
40.  2408  RADHIKA  45  F  8800  59  38  3  8900  59  39  2  10  20  11  20  13.7  16.1  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
                 
 
Laboratory investigation report (IP) 
 
 
 
Sl. 
No. 
O.P. 
No. 
Name  Age  Sex 
Haematological report Urine analysis Stool examination 
Before treatment  After treatment  ESR (mm)  Hb(Gm)  BT  AT  BT  AT 
TC 
CU/mm 
DC  TC 
CU/m
m 
DC  BT  AT 
BT  AT  Alb  Sug  Dep  Alb  Sug  Dep  Ova  Cyst  Ova  Cyst 
P  L  E  P  L  E 
1/2
hr 
1 hr  ½ 
hr 
1hr 
1.  726  RADHA  36  F  9000  53  41  6  9100  58  38  4  23  52  12  25  11.0  13.2  NIL  ++  Opc  NIL  ++  NIL  NIL  NIL  NIL  NIL 
2.  420  GAYATHRI  32  F  9800  59  36  5  9900  62  34  5  45  88  40  62  10.2  12.7  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
3.  8716  LATHA  41  F  6100  44  51  5  6300  51  44  5  35  72  20  40  8.6  9.2  NIL  NIL  Opc  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
4.  2227  TAMILARASI  43  F  9800  59  36  5  9800  59  37  4  10  25  8  22  13.1  16.2  NIL  NIL  Fpc  NIL  NIL  Fpc  NIL  NIL  NIL  NIL 
5.  7171  ELIZABETH  33  F  9200  52  39  9  9200  58  38  4  12  30  10  15  9.0  11.5  NIL  NIL  Oec  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
6.  7722  THANGARAJ  44  M  7600  49  46  5  8000  52  44  4  10  20  10  22  9.0  10.6  NIL  +  Opc  NIL  +  Opc  NIL  NIL  NIL  NIL 
7.  5199  GOBI  34  M  9400  57  36  7  10100  60  36  4  10  16  5  10  11.3  14.8  NIL  +  Opc  NIL  +  NIL  NIL  NIL  NIL  NIL 
8.  1301  SATHYA  34  F  8700  59  35  6  8800  58  56  6  2  7  5  15  13.0  14.2  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
9.  6464  SIVAKUMAR  42  M  10400  63  31  6  10400  62  33  5  40  75  20  40  13.0  16.5  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL  NIL 
10.  108  MANIRAJA  31  M  7600  48  46 6 7800 50 45 5 8 10 10 12  7.4  8.0 NIL NIL NIL NIL NIL NIL NIL NIL NIL NIL 
NO .OF OP & IP PATIENTS-BEFORE TREATMENT AND AFTER TREATMENT 
S.No  O.P.NO.  NAME  AGE SEMEN ANALYSIS BT SEMEN ANALYSIS AT NO. OF DAYS RESULT
1.  636  Arul  29  TSC – 6.2 million/cu. mmSM ‐10 % 
TSC – 126 million/cu. Mm
SM – 40 %  105 Days  Marked response 
2.  304  Dhamodaran  26  TSC ‐08 million/cu. mmSM ‐ 50 % 
TSC – 42 million/cu. Mm
SM ‐ 58 %  65 Days  Mild response 
3.  6280  Thangavel  33  TSC –17 million/cu. mmSM ‐ 08 % 
TSC – 26 million/cu. Mm
SM ‐ 10 %  76 Days  Fair response 
4.  1110  Venkatesan  35  TSC – 18 million/cu. mmSM ‐ 22 % 
TSC – 60 million/cu. Mm
SM ‐ 45 %  50 Days  Marked response 
5.  7400  Sudharsanam  40  TSC – 10 million/cu. mmSM ‐ 04 % 
TSC –50 million/cu. Mm
SM ‐ 10 %  70 Days  Marked response 
6.  7732  Vijayakumar  27  TSC – 62 million/cu. mmSM ‐ 20 % 
TSC – 70 million/cu. Mm
SM ‐ 30 %  50 Days  Mild response 
7.  5341  Rajmohan  38  TSC – 16.2 million/cu mmSM ‐ 06 % 
TSC – 49 million/cu. Mm
SM ‐ 27 %  56 Days  Marked response 
8.  1012  Mohanasundaram  31  TSC – 34 million/cu. mmSM ‐ 35 % 
TSC – 52 million/cu. Mm
SM ‐ 55 %  62 Days  Mild response 
9.  6922  Saravananakumar  30  TSC – 53 million/cu. mmSM ‐ 25 % 
TSC – 86 million/cu. Mm
SM ‐ 45 %  49 Days  Marked response 
10.  219  Stalin  41  TSC – 10 million/cu. mmSM ‐ 02 % 
TSC – 14 million/cu. Mm
SM ‐ 04 %  65 Days  Fair response 
11.  4207  Shanmugam  27  TSC – 06 million/cu. mmSM ‐ 09 % 
TSC –40 million/cu. mm
SM ‐ 40 %  63 Days  Marked response 
12.  386  Aravindhan  27  TSC – 49 million/cu. mmSM ‐ 20 % 
TSC –67 million/cu. mm
SM ‐ 30 %  87 Days  Mild response 
13.  1070  Dhilipan  26  TSC –46 million/cu. mmSM ‐ 30 % 
TSC – 71 million/cu. mm
SM ‐ 54 %  76 Days  Marked response 
14.  5865  Dharanidaran  40  TSC – 14 million/cu. mmSM – 10 % 
TSC – 44 million/cu. mm
SM – 20%  90 Days  Mild response 
15.  1983  Sriganesan  30  TSC –50 million/cu. mmSM ‐ 15 % 
TSC –76 million/cu. mm
SM ‐ 40 %  75 Days  Marked response 
16. 
 
4216 
 
Sundara moorthy 
 
34 
 
TSC – 25 million/cu. mm
SM ‐ 10 % 
 
TSC – 50 million/cu. mm
SM ‐ 50 % 
 
58 Days 
 
Marked response 
 
S.No  O.P.NO.  NAME  AGE SEMEN ANALYSIS BT SEMEN ANALYSIS AT NO. OF DAYS RESULT
17.  5320  Balasubramanian  30  TSC – 19 million/cu. mmSM ‐ 10 % 
TSC – 56 million/cu. mm
SM ‐ 55 %  95 Days  Marked response 
18.  581  Mohammed maideen  42 
TSC – 25 million/cu. mm
SM ‐ 28 % 
TSC – 30 million/cu. mm
SM ‐ 25 %  49 Days  Fair response 
19.  7013  Vinayaga sundaram  44  TSC – 17 million/cu. mmSM ‐ 20 % 
TSC – 20 million/cu. mm
SM ‐ 15 %  56 Days  Fair response 
20.  2809  Balaganesan  47  TSC – 65 million/cu. mmSM ‐ 12 % 
TSC – 75 million/cu. mm
SM ‐ 34 %  45 Days  Mild response 
21.  726  Iyyanar  33 TSC – 44 million/cu. mm
SM ‐30 % 
TSC – 72 million/cu. Mm
SM – 48 % 
105 Days Marked response
22.  420  John pandian  40 TSC ‐37 million/cu. mm
SM ‐ 50 % 
TSC – 48 million/cu. Mm
SM ‐ 58 % 
65 Days Mild response
23.  8716  muthuraman  25 TSC –20 million/cu. mm
SM ‐ 07 % 
TSC – 25 million/cu. Mm
SM ‐ 10 % 
78 Days Fair response
24.  2227  kamarajar  30 TSC – 29 million/cu. mm
SM ‐ 22 % 
TSC – 59 million/cu. Mm
SM ‐ 50 % 
110 Days Marked response
25.  7171  Karthikaiyan  41 TSC – 15 million/cu. mm
SM ‐ 03 % 
TSC –45 million/cu. Mm
SM ‐ 30 % 
75 Days Marked response
26.  7722  Sandresekar  28 TSC – 60 million/cu. mm
SM ‐ 15 % 
TSC – 70 million/cu. Mm
SM ‐ 30 % 
90 Days Mild response
27.  5199  Rajkumar  31 TSC – 20 million/cu mm
SM ‐ 06 % 
TSC – 45 million/cu. Mm
SM ‐ 30 % 
95 Days Marked response
28.  1301  Jayaraj  34 TSC – 40 million/cu. mm
SM ‐ 30 % 
TSC – 50 million/cu. Mm
SM ‐ 55 % 
70 Days Mild response
29.  6464  Abdhul raafi  37 TSC – 65 million/cu. mm
SM ‐ 15 % 
TSC – 85 million/cu. Mm
SM ‐ 45 % 
85 Days Marked response
30.  108  Dhurai  35 TSC – 12 million/cu. mm
SM ‐ 03 % 
TSC – 16 million/cu. Mm
SM ‐ 04 % 
65 Days Fair response
31.  4827  Vadivelan  45 TSC – 06 million/cu. mm
SM ‐ 4 % 
TSC –45 million/cu. mm
SM ‐ 45 % 
60 Days Marked response
32.  196  Anbarasan  31 TSC – 55 million/cu. mm
SM ‐ 18 % 
TSC –68 million/cu. mm
SM ‐ 30 % 
87 Days Mild response
33. 
 
1053 
 
Kumar 
 
33 
 
TSC –48 million/cu. mm
SM ‐ 28 % 
 
TSC – 70 million/cu. mm 
SM ‐ 53 %  76 Days  Marked response 
S.No  O.P.NO.  NAME  AGE  SEMEN ANALYSIS BT  SEMEN ANALYSIS AT  NO. OF DAYS  RESULT 
34.  5865  Micheal  40 TSC – 35 million/cu. mm
SM – 10 % 
TSC – 45 million/cu. mm
SM – 20% 
92 Days Mild response
35.  1984  Maniraja  34 TSC –59 million/cu. mm
SM ‐ 12 % 
TSC –80 million/cu. mm
SM ‐ 40 % 
70 Days Marked response
 
36.  4270  Soundhar  25 TSC – 26 million/cu. mm
SM ‐ 15 % 
TSC – 52 million/cu. mm
SM ‐ 50 % 
58 Days Marked response
37.  5203  Gopal  36 TSC – 10 million/cu. mm
SM ‐ 7 % 
TSC – 56 million/cu. mm
SM ‐ 55 % 
88 Days Marked response
38.  501  Kannan  32 TSC – 25 million/cu. mm
SM ‐ 28 % 
TSC – 30 million/cu. mm
SM ‐ 25 % 
49 Days Fair response
39.  7310  Mahendren  29 TSC – 16 million/cu. mm
SM ‐ 20 % 
TSC – 20 million/cu. mm
SM ‐ 15 % 
56 Days Fair response
40.  2408  Venkatesan  37 TSC – 67 million/cu. mm
SM ‐ 13 % 
TSC – 75 million/cu. mm
SM ‐ 34 % 
45 Days Mild response
41.  711  Radhakrishnan  36 TSC – 44 million/cu. mm
SM ‐30 % 
TSC – 70 million/cu. Mm
SM – 48 % 
105 Days Marked response
42.  166  Chandran  32 TSC ‐35 million/cu. mm
SM ‐ 55 % 
TSC – 48 million/cu. Mm
SM ‐ 58 % 
65 Days Mild response
43.  6789  Senthilkumar  41 TSC –18 million/cu. mm
SM ‐ 06 % 
TSC – 25 million/cu. Mm
SM ‐ 10 % 
78 Days Fair response
44.  1100  Tamilarasan  43 TSC – 20 million/cu. mm
SM ‐ 22 % 
TSC – 59 million/cu. Mm
SM ‐ 50 % 
96 Days Marked response
45.  2406  Anbuvendhan  33 TSC – 26 million/cu. mm
SM ‐ 03 % 
TSC –45 million/cu. Mm
SM ‐ 11 % 
75 Days Marked response
46.  5317  Thangaraj  44 TSC – 60 million/cu. mm
SM ‐ 15 % 
TSC – 70 million/cu. Mm
SM ‐ 30 % 
90 Days Mild response
47.  5474  Gobikrishnan  34 TSC – 18 million/cu mm
SM ‐ 04 % 
TSC – 45 million/cu. Mm
SM ‐ 38 % 
95 Days Marked response
48.  1201  Sathyaprakash  34 TSC – 40 million/cu. mm
SM ‐ 35 % 
TSC – 55 million/cu. Mm
SM ‐ 60 % 
70 Days Mild response
49.  5282  Sivakumar  42 TSC – 45 million/cu. mm
SM ‐ 20 % 
TSC – 80 million/cu. Mm
SM ‐ 45 % 
85 Days Marked response
50.  801  Maniraja  31 TSC – 12 million/cu. mm
SM ‐ 06 % 
TSC – 16 million/cu. Mm
SM ‐ 08 % 
60 Days Fair response
 
  
 
 
 
 
 
 
 
 
SL. 
NO. 
OP. NO.   
 
NAME 
 
AGE 
 
HEAMOTOLOGICAL REPORT  URINE ANALYSIS  STOOL  EXAMINATION 
BEFORE TREATMENT  AFTER TREATMENT ESR(mm) HB(Gm)
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC  BT  AT 
BT  AT 
BT  AT  BT  AT 
P  L  E  P  L  E  ½ Hr  1 Hr  ½ Hr  1 Hr  Alb  Sug  Dep  Alb  Sug  Dep  Ova  Cyst  Ova  Cyst 
1  636  Arul  29  9600  45  32  3  9700  55  36  3  2  5  3  6  14  14.2  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
2  304  Dhamodaran  26  9400  57  38  5  9600  60  37  4  3  5  3  8  12.8  13  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
3  6280  Thangavel  33  9400  58  34  6  9200  55  32  5  2  5  4  10  13  12.8  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
4  1110  Venkatesan  35  9400  58  39  3  9000  60  38  2  10  22  9  18  12.4  12.5  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
5  7400  Sudharsanam  40  10600  62  34  4  10450  55  30  4  7  17  8  18  14  14.1  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
6  7732  Vijayakumar  27  9400  56  39  5  9600  60  35  6  12  24  10  15  13  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
7  5341  Rajmohan  38  9700  58  37  2  9700  55  35  3  10  18  15  20  12.5  12.1  Nil  Nil  FPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
8  1012  Mohanasundaram  31  10700  66  30  4  10800  65  30  5  2  3  4  6  14  14  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
9  6922  Saravananakumar  30  9300  57  38  5  9400  55  35  6  10  20  9  18  13.8  13.7  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
10  219  Stalin  41  9000  58  38  4  9200  56  35  4  2  4  3  6  14.8  15  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
11  4207  Shanmugam  27  9000  60  32  8  8800  62  30  6  6  12  5  10  12.6  12.5  Nil  Nil  FPC  Nil  Nil  FPC  Nil  Nil  Nil  Nil 
12  386  Aravindhan  27  9700  54  42  4  9600  58  40  5  10  22  8  18  14  13.5  Nil  Nil  FPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
13  1070  Dhilipan  26  10100  59  37  4  10300  60  36  3  15  25  10  13  13.2  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
14  5865  Dharanidaran  40  10700  62  31  7  10500  60  34  8  15  30  12  18  15  14.5  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
15  1983  Sriganesan  30  9800  55  42  3  9750  58  40  4  5  22  4  10  12.2  12.5  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
16  4216  Sundara moorthy  34  9200  56  38  6  9350  55  42  5  5  10  8  16  12.4  12.5  Nil  Nil  OEC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
17  5320  Balasubramanian  30  9400  58  39  3  9450  56  40  2  3  5  4  8  12  12  Nil  Nil  OEC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
18  581  Mohammed 
maideen 
42  9600  59  37  4  9550  60  35  3  7  12  10  14  13  12.5  Nil  Nil  OEC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
19  7013  Vinayaga sundaram  44  9600  58  36  6  9600  60  35  3  7  13  6  14  12.4  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
20  2809  Balaganesan  47  9000  59  35  6  9100  58  34  5  6  10  5  12  14.6  14.6  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
  
 
 
 
 
 
 
 
 
 
SL. 
NO. 
OP. NO.   
 
NAME 
 
AGE 
 
HEAMOTOLOGICAL REPORT  URINE ANALYSIS  STOOL  EXAMINATION 
BEFORE TREATMENT  AFTER TREATMENT ESR(mm) HB(Gm)
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC  BT  AT 
BT  AT 
BT  AT  BT  AT 
P  L  E  P  L  E  ½ Hr  1 Hr  ½ Hr  1 Hr  Alb  Sug  Dep  Alb  Sug  Dep  Ova  Cyst  Ova  Cyst 
21.  726  Iyyanar  33  7900 58 40 2 8000 50 47 3 2  5  3  6  14  14.2  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
22.  420  John pandian  40  9400 60 30 8 10000 64 32 4 3  5  3  8  12.8  13  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
23.  8716  muthuraman  25  8900 56 36 6 8900 58 34 8 2  5  4  10  13  12.8  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
24.  2227  kamarajar  30  8300 54 45 1 8800 60 39 1 10  22  9  18  12.4  12.5  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
25.  7171  Karthikaiyan  41  9000 62 34 4 9500 60 36 4 7  17  8  18  14  14.1  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
26.  7722  Sandresekar  28  8700 51 46 3 9200 50 47 3 12  24  10  15  13  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
27.  5199  Rajkumar  31  9500 60 34 6 9800 65 33 2 10  18  15  20  12.5  12.1  Nil  Nil  FPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
28.  1301  Jayaraj  34  8500 54 44 2 8700 51 47 2 2  3  4  6  14  14  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
29.  6464  Abdhul raafi  37  7900 54 43 3 8200 55 42 3 10  20  9  18  13.8  13.7  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
30.  108  Dhurai  35  6900 60 38 2 7100 60 40 - 2  4  3  6  14.8  15  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
31.  4827  Vadivelan  45  8100 60 39 1 8000 55 35 2 6  12  5  10  12.6  12.5  Nil  Nil  FPC  Nil  Nil  FPC  Nil  Nil  Nil  Nil 
32.  196  Anbarasan  31  7400 53 40 3 7400 55 43 2 10  22  8  18  14  13.5  Nil  Nil  FPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
33.  1053  Kumar  33  7900 55 40 3 7900 60 35 3 15  25  10  13  13.2  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
34.  5865  Micheal  40  7900 64 33 2 7900 60 37 3 15  30  12  18  15  14.5  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
35.  1984  Maniraja  34  8000 57 40 3 8100 60 37 3 5  22  4  10  12.2  12.5  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
36.  4270  Soundhar  25  8000 57 40 3 8100 60 37 2 5  10  8  16  12.4  12.5  Nil  Nil  OEC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
37.  5203  Gopal  36  7600 53 44 3 7700 57 40 3 3  5  4  8  12  12  Nil  Nil  OEC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
38.  501  Kannan  32  8000 57 40 3 8100 55 42 3 7  12  10  14  13  12.5  Nil  Nil  OEC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
39.  7310  Mahendren  29  6900 52 46 2 6900 55 42 2 7  13  6  14  12.4  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
40.  2408  Venkatesan  37  7800 57 37 4 7800 56 38 4 6  10  5  12  14.6  14.6  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
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NO. 
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NAME 
 
AGE 
 
HEAMOTOLOGICAL REPORT  URINE ANALYSIS  STOOL  EXAMINATION 
BEFORE TREATMENT  AFTER TREATMENT ESR(mm) HB(Gm)
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC  BT  AT 
BT  AT 
BT  AT  BT  AT 
P  L  E  P  L  E  ½ Hr  1 Hr  ½ Hr  1 Hr  Alb  Sug  Dep  Alb  Sug  Dep  Ova  Cyst  Ova  Cyst 
41.  711  Radhakrishnan  36  9,000 55 40 5 9000 60 36 4 2  5  3  6  14  14.2  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
42.  166  Chandran  32  8,700 67 27 5 9200 64 30 5 3  5  3  8  12.8  13  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
43.  6789  Senthilkumar  41  9,900 58 38 4 9500 58 38 4 2  5  4  10  13  12.8  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
44.  1100  Tamilarasan  43  10,100 73 22 5 9800 70 25 5 10  22  9  18  12.4  12.5  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
45.  2406  Anbuvendhan  33  9,100 66 30 4 9200 65 30 5 7  17  8  18  14  14.1  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
46.  5317  Thangaraj  44  8,900 55 40 5 9200 66 30 4 12  24  10  15  13  13  Nil  Nil  OPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
47.  5474  Gobikrishnan  34  9,800 50 40 8 9800 56 36 6 10  18  15  20  12.5  12.1  Nil  Nil  FPC  Nil  Nil  Nil  Nil  Nil  Nil  Nil 
48.  1201  Sathyaprakash  34  9,000 64 32 4 9200 64 32 4 2  3  4  6  14  14  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
49.  5282  Sivakumar  42  8,700 58 38 4 8800 60 36 34 10  20  9  18  13.8  13.7  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 
50.  801  Maniraja  31  9,300 69 26 5 9200 68 27 5 2  4  3  6  14.8  15  Nil  Nil  OPC  Nil  Nil  OPC  Nil  Nil  Nil  Nil 








